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Irrfitable bowel syndrome (IBS) fis a common gastrofintestfinal (GI) dfisorder, fin global terms 
afectfing more than every tenth person. Grafins are a staple food and an fintegral part of 
dafily dfiets al around the world. The FODMAPs (Fermentable Olfigo-, Dfi-, 
Monosaccharfides And Polyols), gluten and amylase trypsfin finhfibfitors (ATIs), whfich are 
present fin wheat, barley and rye, mfight be at least part of the reason why gluten-contafinfing 
grafins are often consfidered as trfiggers of functfional gastrofintestfinal symptoms. However, 
the relatfive contrfibutfions and comparatfive fimportance of these substances fin symptom 
aggravatfion remafin unclear. The mafin purpose of thfis thesfis was to determfine whether a 
reductfion fin the levels of FODMAPs and ATIs fin grafin products would fimprove 
gastrofintestfinal tolerabfilfity of rye and wheat fin IBS and non-coelfiac gluten sensfitfivfity 
(NCGS).  
 
The finterventfion grafin products used fin the studfies were produced by sourdough bakfing 
method whfich resulted fin a reduced FODMAP and ATI content fin the test breads. Four 
dfiferent randomfised studfies were performed among a female domfinant adult populatfion 
suferfing from IBS. 
 
In study I, subjects wfith IBS (n=87) consumed efither low FODMAP rye bread or regular 
rye bread for 4 weeks. Thfis cross-over trfial revealed that the low FODMAP rye bread 
reduced colonfic gas formatfion and alevfiated some IBS symptoms (flatulence, abdomfinal 
pafin, cramps and borgorygmfi) but that there was no dfiference between the breads fin 
overal symptom control or qualfity of lfife. 
 
In the second study, 26 IBS subjects wfith poor subjectfive tolerance for wheat were 
randomfised to efither wheat bread wfith yeast as a leavenfing agent or wheat bread made by 
a sourdough bakfing method whfich was free of addfitfives and had a lower content of ATIs 
and FODMAPs. No dfiference was detected fin the gastrofintestfinal tolerance of these two 
breads durfing the observatfion perfiod of seven days. 
 
In study III, the efects of low FODMAP rye bread and regular rye bread on fintestfinal 
events were evaluated wfith a wfireless motfilfity capsule (SmartPfil®, Gfiven Imagfing ltd, 
Israel) fin seven subjects wfith IBS. It was found that a low FODMAP content reduced 
colonfic fermentatfion as measured by breath hydrogen excretfion but there were no 
dfiferences between the bread perfiods fin fintestfinal pH, transfit tfime, pressure or 
contractfions. However, the overal symptom severfity and the total score of symptoms, 
evaluated wfith a vfisual analog scale, were assocfiated wfith colonfic pressure durfing the 
perfiod when the subjects consumed the regular bread. 
 
Study IV was performed as a sub-study of study I by examfinfing mficrobfial changes fin feces 
befing analysed fin 50 subjects. The low FODMAP rye bread reduced the abundance of the 





statfistficaly sfignfifficant changes fin fecal mficrobfiota were found between the perfiods when 
the test subjects ate the regular and low-FODMAP rye breads.  
 
The results emergfing from thfis thesfis demonstrated that the rye bread wfith the low 
FODMAP content reduced colonfic fermentatfion and therefore there was less gas formatfion 
when compared to the consumptfion of regular bread. It can be speculated that low 
FODMAP breads may represent a means of fimprovfing tolerabfilfity of breads among 
subjects wfith IBS but swfitchfing from regular to a low FODMAP versfion of bread fis lfikely to 
exert only modest efects on objectfively measured transfit tfimes, fintestfinal pH, fintralumfinal 
pressure and faecal mficrobfiota. Low FODMAP breads can be used as a part of a holfistfic 







Ärtyvän suolen ofireyhtymä (IBS) on ylefinen mahasuolfikanavan vafiva, sen esfifintyvyys on 
maafilmanlaajufisestfi nofin 11 %. Vfiljatuotteet ovat laajastfi käytettyjä elfintarvfikkefita ympärfi 
maafilman ja sfiten tärkeä osa ruokavalfiotamme. Rukfifin, vehnän ja ohran FODMAP-
hfifilfihydraatfit (Fermentable Olfigo-, Dfi-, Monosaccharfides And Polyols), gluteenfi ja 
amylaasfi-trypsfifinfi finhfibfittorfit (ATI:t) vofivat afiheuttaa ofirefita tofimfinnalfisfissa 
vatsavafivofissa kuten IBS:ssä. Efi ole kufitenkaan tarkkaa tfietoa sfifitä, mfikä on näfiden 
tekfijöfiden suhteelfinen tärkeys tofisfifinsa verrattuna ofirefiden afiheuttajana. Tämän 
väfitöskfirjan tavofitteena olfi tutkfia lfievfittääkö FODMAP-hfifilfihydraattfien ja ATI:n 
vähentämfinen rufis- ja vehnätuottefissa nfifiden sfiedettävyyttä henkfilöfilä, jofila on ärtyvän 
suolen ofireyhtymä tafi gluteenfiherkkyys.  
 
Tässä väfitöskfirjatutkfimuksessa tutkfittfifin erfityfisten hapatusmenetelmfien avula 
valmfistettuja rufis-ja vehnälefipfiä, jofiden FODMAP- ja ATI-pfitofisuudet olfivat vähäfisemmät 
kufin tavanomafisfissa rufis- tafi vehnälefivfissä. Väfitöstutkfimukseen sfisältyy neljä erfilfistä 
satunnafistettua tutkfimusta.  
 
Ensfimmäfiseen vafihtovuorotutkfimukseen osalfistufi 87 henkfilöä, jofile syötettfifin joko vafin 
vähän FODMAP-hfifilfihydraatteja sfisältävää tafi tavanomafista rufislefipää kumpaakfin 4 vfifikon 
ajan. Tutkfimuksessa havafittfifin, että vähemmän FODMAP-hfifilfihydraatteja sfisältävä lefipä 
afiheuttfi vähemmän kaasun kertymfistä suolfistoon ja samala vähensfi filmavafivojen 
tunnetta, vatsakfipua, vatsan kurfinaa ja kramppeja. Elämän laadussa tafi IBS-SSS mfittarfila 
mfitatussa kokonafisofirekuvassa efi kufitenkaan havafittu eroja lefipäjaksojen välfilä.  
 
Tofisessa tutkfimuksessa, johon osalfistufi 26 afikufista, tutkfittfifin hfifivala kohotetun, lfisättyä 
gluteenfia ja lfisäafinefita sfisältävän tavanomafisen vehnälefivän ja hapattamala tehdyn 
lfisäafineettoman lefivän sfiedettävyttä. Hapatetussa vehnälefivässä olfi vähemmän ATI:a ja 
FODMAP-hfifilfihydraatteja, mutta mahasuolfikanavan sfiedettävyydessä efi havafittu eroja 
ryhmfien välfilä vfifikon koejaksola.   
 
Kolmas tutkfimus vertafilfi vafin vähän FODMAP-hfifilfihydraatteja sfisältävän ja tavanomafisen 
rufislefivän suolfistovafikutuksfia yhden vuorokauden aterfiakokeessa, jossa ofirefiden lfisäksfi 
tutkfittavat myös nfielfivät erfityfisen langattoman suolfiston olosuhtefita mfittaavan 
kapselfilafitteen (SmartPfil®, Gfiven Imagfing ltd, Israel) mahasuolfikanavan tofimfintojen, 
erfityfisestfi pH:n, läpfikulkuajan, suolfiston sfisäfiseen pafineen ja supfistusten 
monfitorofimfiseksfi. Ofirefiden vafikeusaste lfifittyfi paksusuolen sfisäfiseen pafineeseen 
tavanomafista rufislefipää sfisältäneen koepäfivän afikana, mutta lefipäjaksojen välfilä efi 
havafittu eroja mfitatufissa suurefissa. Ofirefiden vafikeusastetta arvfiofitfifin IBS-ofirefiden 
summana ns. vfisual analog scale -mfittarfila. 
 
Neljännessä tutkfimuksessa analysofitfifin ensfimmäfiseen tutkfimukseen osalfistunefiden 50 
tutkfittavan mfikrobfisto ulostenäyttefistä ja ofirekehfitystä neljän vfifikon afikana seurattfifin. 





rufislefipäjakson afikana Klebsfiela bakteerfia esfifintyfi vähemmän ulostenäyttefissä kufin 
tavanomafista rufislefipää sfisältäneen koejakson afikana. Mufita eroja suolfiston mfikrobfistossa 
ryhmfien välfilä efi havafittu. 
 
Tämän tutkfimussarjan mukaan vafin vähän FODMAP-hfifilfihydraatteja sfisältävä rufislefipä 
vähentää paksusuolessa tapahtuvaa käymfisreaktfiota (fermentaatfiota) ja sfiten kaasun 
tuotto suolfistossa vähenee. Edeleen väfitöstutkfimuksen mukaan vähemmän FODMAP:ja 
sfisältävät lefivät vofivat ola paremmfin sfiedettyjä kufin tavanomafiset lefivät, mutta 
tavanomafisen lefivän vafihtamfinen vafin vähän FODMAP-hfifilfihydraatteja sfisältävään 
lefipään efi rfifitä yksfistään afiheuttamaan kovfin merkfittävfiä eroja mahasuolfikanavan pH:ssa, 
läpfikulkuajassa, pafineessa tafi mfikrobfistossa. Vafin vähän FODMAP-hfifilfihydraatteja 
sfisältävää lefipää vofidaan käyttää osana kokonafisvaltafista FODMAP-hfifilfihydraattfien 







































The consequences of defectfive dfigestfive processes are reflected fin many hfistorfical 
proverbs; Hfippocrates, the father of medficfine, fis quoted as sayfing, “Bad dfigestfion fis at the 
root of al evfil”, the French phfilosopher Voltafire, “The fate of a natfion has often depended 
upon the good or bad dfigestfion of a prfime mfinfister, and the poet Wfilfiam Shakespeare, 
“Thfings sweet to taste prove fin dfigestfion sour.” The scfientfifficaly documented hfistory of 
exfistence of firrfitable bowel syndrome dates back to at least the 17th century (Powel 1818).  
 
Irrfitable bowel syndrome (IBS) fis a common gastrofintestfinal (GI) dfisorder afectfing 
around 11% of the global populatfion (Canavan et al. 2014). Currently, IBS fis deffined as a 
dfisorder of gut-brafin finteractfion rather than a functfional dfisorder (Drossman and Hasler 
2016). In Ffinland, fits prevalence fis fin a range 5.1-16.2% dependfing on the dfiagnostfic 
crfiterfia fin use (Hfilfilä and Färkkfilä. 2004). IBS fis the largest dfiagnostfic group seen fin GI 
practfices (Drossman et al. 2002). The health related qualfity of lfife of patfients wfith IBS fis 
fimpafired to a degree comparable to that of other chronfic dfisorders such as depressfion, 
dfiabetes and finflammatory bowel dfisease (El-Serag et al. 2002). Furthermore, IBS related 
costs to the health care system are sfignfifficant and absence from work fis not uncommon 
because of IBS (Nelesen et al. 2014).  
 
Some 40 years ago, IBS was thought to be prfimarfily efither a psychologfical or gut motfilfity 
condfitfion. However, fit fis nowadays acknowledged that IBS fis lfikely characterfised by 
multfiple factors whfich finclude a lower than normal pafin threshold fin the gut and fin the 
central nervous system (vfisceral sensfitfivfity), dfisturbances fin the gut mficrobfiota (dysbfiosfis) 
and an altered actfivatfion of the gut fimmune system. The pathogenesfis of IBS, sfimfilar to fits 
clfinfical manfifestatfion, fis heterogeneous (Chey et al. 2015). It fis lfikely that there are 
dfiferent pathophysfiologfies behfind sfimfilar clfinfical symptoms (Chey et al. 2015). The 
clfinfical severfity of IBS varfies remarkably wfith some patfients suferfing agonfies whereas 
others consfider thefir symptoms as rather mfild and bearable even although they may fulffil 
the dfiagnostfic crfiterfia (Drossmann et al. 2011). 
 
The typfical symptoms fin IBS finclude abdomfinal pafin or dfiscomfort, bloatfing, flatulence, 
dfiarrhoea and/or constfipatfion, abdomfinal rumblfing and crampfing. Many other GI-
symptoms and extra-gastrofintestfinal symptoms such as tfiredness may also occur. The 
current officfial dfiagnostfic crfiterfia have been set and named by the not-for-proffit Rome 
foundatfion; the Rome IV crfiterfia are the currently valfid ones (Palsson et al. 2016). 
 
The therapeutfic modalfitfies fin IBS finclude dfiet, dfietary supplements, drugs, physfical 
exercfise and psychologfical finterventfions such as hypnotherapy and behavfioural therapy. 
The fincreased understandfing of FODMAPs (Fermentable Olfigo-, Dfi-, Monosaccharfides 
And Polyols) has led to therapeutfic applficatfions; a low FODMAP dfiet has become a 






Grafins, such as barley, buckwheat, oats, rfice, rye, sorghum and wheat, are staple foods and 
an fintegral part of the dafily dfiet al around the world. On the other hand, grafins can also be 
vfiewed as an example of a food group wfith potentfialy symptom-trfiggerfing substances for 
findfivfiduals wfith IBS. The FODMAPs, gluten and possfibly amylase trypsfin finhfibfitors (ATIs) 
present fin wheat, barley and rye seem to be one of the major reasons why these grafins are 
often consfidered as major trfiggers of the symptoms encountered fin IBS (De Gfiorgfio et al. 
2016). However, the role of the relatfive and comparatfive fimportance of these substances fin 
symptom aggravatfion fis uncertafin, nor fis fit known whfich other factors may contrfibute to 
the poor tolerance of gluten-contafinfing grafins fin IBS. 
 
So-caled non-coelfiac gluten sensfitfivfity (NCGS) belongs to the spectrum of functfional 
gastrofintestfinal dfisorders and fit fis clafimed to be caused solely by grafins (De Gfiorgfio et al. 
2016). It fis a new clfinfical entfity proposed by an finternatfionaly emfinent consensus group 
(Sapone et al. 2012). Thfis group have postulated that NCGS fis a totaly new clfinfical entfity 
characterfised by GI symptoms trfiggered by gluten-contafinfing grafins fin the absence of 
coelfiac dfisease, wheat alergy or gluten ataxfia. Thfis consensus statement has bot been 
unequfivocaly accepted, both the exfistence and the role of NCGS, or non-coelfiac wheat 
sensfitfivfity (NCWS), are stfil controversfial and questfioned (De Gfiorgfio et al. 2016). 
 
The mafin purpose of thfis thesfis was to examfine fif a reductfion fin the levels of FODMAPs 
and ATIs fin grafin products would fimprove thefir tolerabfilfity fin subjects wfith IBS and 
NCGS. The specfiffic afims were to study the efects of bfiotechnologficaly modfiffied grafin 
products on symptoms, colonfic fermentatfion and gut mficrobfiota, and fimmune actfivatfion 
fin findfivfiduals wfith IBS and NCGS. The grafin products used fin the studfies were findustrfialy 
modfiffied fin order to reduce thefir content of FODMAPs or amylase-trypsfin finhfibfitors. The 






2 REVIEW OF THE LITERATURE 
2.1  Deffinfitfion, severfity, prevalence and prognosfis of firrfitable 
bowel syndrome 
 
IBS fis tradfitfionaly descrfibed as a functfional gastrofintestfinal dfisorder. The term 
“functfional” refers to the absence of any organfic dfisease causfing the symptoms. The 
current dfiagnostfic crfiterfia for finvestfigatfional and clfinfical purposes were set by the Rome 
Foundatfion. The recent versfion of dfiagnostfic crfiterfia fis caled the Rome IV crfiterfia 
(Schmulsson and Drossman 2017). Accordfing to Rome IV crfiterfia, IBS fis deffined as a gut-
brafin dfisorder that fulffils the folowfing crfiterfia:  
 
• Recurrent abdomfinal pafin on average at least once a week fin the last 3 months 
assocfiated wfith 2 or more of the folowfing  
o Abdomfinal pafin fis assocfiated wfith defecatfion and/or 
o Abdomfinal pafin fis assocfiated wfith change fin frequency of stool and/or 
o Abdomfinal pafin fis assocfiated wfith the form (appearance) of stool 
 
At the tfime of finfitfiatfion of the studfies fincluded fin thfis thesfis, Rome III crfiterfia were the 
latest avafilable crfiterfia for IBS. Rome III crfiterfia dfifer mostly from Rome IV by havfing 
also “abdomfinal dfiscomfort” as a dfiagnostfic crfiterfion fin addfitfion to pafin. Other 
dfiferences, perhaps of mfinor fimportance, between Rome III and IV also exfist fin the terms 
related to defecatfion, stool form and frequency (Samuelsson and Drossman 2017). 
 
There has been a longstandfing debate centred around the term “functfional” as fit fis non-
specfiffic and potentfialy stfigmatfisfing (Schmulsson and Drossman 2017). Therefore, IBS and 
other functfional gastrofintestfinal dfisorders were recently re-deffined by the Rome IV 
consensus group as dfisorders of gut-brafin finteractfion (DGBI); these are “a group of 
dfisorders classfiffied by GI symptoms related to any combfinatfion of motfilfity dfisturbances, 
vfisceral hypersensfitfivfity, altered mucosal and fimmune functfion, gut mficrobfiota, and/or 
central nervous system processfing”. Consequently, the Rome IV group serfiously attempted 
to elfimfinate the term “functfional” from thefir thfinkfing and from clfinfical termfinology 
regardfing IBS. However, the group acknowledged the chalenge fin thfis attempt “The Rome 
Foundatfion understands that fit wfil take tfime untfil the term functfional fis completely 
elfimfinated from the health care language, and fin some clfinfical dfisorders the term 
functfional was retafined to dfistfingufish them from other sfimfilar dfisorders (for example 
Functfional Dfiarrhea) untfil a more approprfiate term can be used.” 
 
In addfitfion to abdomfinal pafin or dfiscomfort, the typfical symptoms experfienced by people 
wfith IBS finclude abdomfinal bloatfing/dfistensfion, cramps, flatulence, dyspepsfia, fincomplete 
felfing of evacuatfion, constfipatfion, or dfiarrhoea (Wfiklund 2003, Chey et al. 2015). These 
symptoms are typficaly evaluated fin clfinfical trfials and are a part of a valfidated finstrument, 





IBS (Wfiklund et al. 2003) albefit they are not part of the Rome dfiagnostfic crfiterfia. Fatfigue 
and other non-gastrofintestfinal symptoms are common non-GI symptoms fin IBS (Han and 
Yang 2016). Some other rather common non-GI symptoms or comorbfidfitfies finclude 
sleepfing dfifficultfies, palpfitatfions, headaches, dfizzfiness, jofint and chest pafin, anxfiety, 
depressfion, shortness of breath and fintercourse related pafin (Polster et al. 2017). 
 
The severfity of IBS can be evaluated by completfing a questfionnafire caled the “symptom 
severfity score”, fi.e. IBS-SSS developed by Francfis et al. (1997). Thfis fis one of the few 
valfidated finstruments avafilable for measurfing IBS symptoms fin clfinfical studfies. IBS-SSS 
consfists of ffive dfiferent questfions; of these, the ffirst fis about the severfity and the second 
about duratfion of pafin, the thfird fin concerned wfith bloatfing, the fourth assesses the overal 
satfisfactfion wfith bowel functfion wfith the ffifth questfion finqufirfing about the overal 
dfisturbance of lfife (global wel-befing) due to bowel symptoms. Each questfion can recefive a 
value 0-100, and thus the range of the total IBS-SSS score fis 0-500. People whose score fis 
under 75 are classfiffied as healthy, 75-174 fis classfiffied as mfild IBS, 175-299 as moderate 
and 300-500 as severe IBS (Francfis et al. 1997). The functfional bowel dfisorder severfity 
findex (FBDSI) fis another tool used fin the evaluatfion of symptom severfity; thfis 
concentrates solely on abdomfinal pafin and on the annual number of vfisfit to doctors 
(Drossman et al. 1995). The FBDSI score can range from 0 to 360 but fit has been rarely 
used fin clfinfical studfies.  
 
The clfinfical severfity of IBS varfies remarkably; some patfients sufer severely whereas some 
consfider thefir symptoms as rather mfild and bearable even although they fulffil the 
dfiagnostfic crfiterfia of IBS. Furthermore, the chronfic symptoms of IBS folow a fluctuatfing 
course. As there was no consensus on what fis severe IBS and how fit should be deffined, the 
Rome Foundatfion Workfing Team Commfittee produced a consensus report on the 
classfifficatfion and deffinfitfion on the severfity of IBS (Drossman et al. 2011). They adopted 
the IBS-SSS score as a crude finstrument for assessfing severfity (see above) but underlfine fin 
the report that severfity of IBS should not be understood sfimply as the fintensfity of pafin or 
other symptoms. Rather, fit fis “a bfiopsychosocfial composfite of patfient reported 
gastrofintestfinal and extra-fintestfinal symptoms, degree of dfisabfilfity, and filness related 
perceptfions and behavfiors”. Accordfing to the report, severfity can be understood as a 
contfinuum and can also be subcategorfized finto clfinficaly meanfingful subgroups as mfild (~ 
40%), moderate (~ 35%), and severe (~ 25%); the prevalence of each category and thefir 
dfistfingufishfing features wfil requfire further study. Table 1 depficts the typfical features 
encountered fin the dfiferent subgroups. A study of 172 IBS patfients from Sweden 
suggested that 12% of IBS patfients fulffilfing Rome 3 crfiterfia had mfild IBS, 37% moderate 
and 52% severe; fit fis noteworthy that patfients were classfiffied by GSRS, not by IBS-SSS 
(Polster et al. 2017). A vfisual analog scale (VAS) 100 mm fin length fis often also used for 
symptom assessment but thfis has not been comprehensfively valfidated; a recent revfiew 
paper descrfibed both the weaknesses and strengths of these symptom assessments when 
conductfing IBS related dfietary studfies (Whelan et al. 2018).  
 
The prevalence of IBS varfies accordfing to dfiagnostfic crfiterfia fin use. Accordfing to a 
systematfic revfiew, on average the global prevalence of IBS fis 11% (Lovel and Ford 2012). 





It fis noteworthy that prevalence of IBS seems to decrease as a functfion of tfime because the 
dfiagnostfic crfiterfia have become more strfingent, fi.e. the Mannfing crfiterfia from the 1980s 
were rather lfiberal wfith the more recent Rome crfiterfia befing more restrfictfive (Hfilfilä and 
Färkkfilä 2004, Lovel and Ford 2012). Rome IV crfiterfia halved the prevalence of IBS fin a 
Chfinese populatfion when compared to the sfituatfion when Rome III was utfilfized (Bafi et al. 
2017).  
 
Table 1. Proposed clfinfical proffile for patfient-rated severfity of IBSa accordfing to Drossman 




Clfinfical feature Mfild Moderate Severe 
Estfimated prevalence 40% 35% 25% 
IBS-SSS, total score 75-175 175-300 300 
FBDSI <36 36-109 >110 
Physfiologfical factors Prfimarfily bowel 
functfion 
Bowel dysfunctfion 
and CNS pafin 
dysregulatfion 













Gender Men=Women Women>Men Women>>Men 
Age Older>younger Older=younger Younger>older 
Abdomfinal pafin Mfild/fintermfittent Moderate, frequent Severe/very frequent 
or constant 
Other symptoms Low (1-3) Medfium (4-6) Hfigh (≥7) 
Health-related qualfity 
of lfife 
Good Fafir Poor 
Health-care 
utfilfisatfion 
0-1/year 2-4/Year ≥5/Year 
Actfivfity restrfictfion Occasfional (0-15 
days/year) 




Work dfisabfilfity <5% 6-10% ≥11% 
CNS, central nervous system; FBDSI, Functfional Bowel Dfisorders Severfity Index; IBS, firrfitable bowel 
syndrome; IBS-SSS, IBS Severfity Scorfing System. a Thfis fis based on exfistfing data on the severfity fin IBS 
and needs to be further tested and valfidated (Drossman et al. 2011). 
 
 
Accordfing to a systematfic revfiew, IBS fis more common among females (RR 1.67) and less 
common fin people over 50 years (RR 0.75) (Lovel and Ford 2012). The prevalence seems 





North Amerfica but substantfialy hfigher fin Latfin Amerfica (17.5%). The authors of the 
systematfic revfiew speculated that finaccurate translatfion of the survey questfionnafire and 
cultural dfiferences fin reportfing and finterpretfing symptoms may explafin, at least partly, 
the hfigher prevalence of IBS fin Latfin Amerfica. 
 
Patfients wfith IBS report thefir symptoms as occurrfing fin exacerbatfion epfisodes (Wefinland 
et al. 2011). Because of thfis fluctuatfion fin the symptoms, or alternatfively because there 
may be true healfing of IBS, 52 % of Amerfican IBS patfients finfitfialy dfiagnosed wfith IBS do 
not meet IBS crfiterfia fin a repeated examfinatfion at the 2-year folow-up (Wfilfiams et al. 
2006). In a Danfish cohort, 8% of the populatfion had “fluctuatfing IBS” and 2% “persfistent 
IBS” (Hefinsvefig Poulsen et al. 2015). Persfistent IBS was deffined as meetfing Rome III 
crfiterfia both at the 0 and 5 years’ examfinatfion and fluctuatfing IBS as meetfing crfiterfia at 
efither tfime pofint only once. These data clearly underlfine the fluctuatfing nature of 
symptoms. Furthermore, fit fis unsure fif IBS fis “fincurable”. It fis not known fif some patfients 
stop experfiencfing symptoms after a certafin pofint of tfime, or fif the re-appearance of IBS 
symptoms fis sfimply a matter of havfing a long enough folow-up tfime. 
 
A possfible model for ffindfing an answer to thfis questfion fis post-finfectfious IBS (PI-IBS). 
After vfiral, protozoal or bacterfial gastroenterfitfis, a certafin degree of the populatfion, around 
10% accordfing to a recent systematfic revfiew, develop IBS that persfists for years; thfis fis 
caled post-finfectfious IBS, PI-IBS (Klem et al. 2017). Some data fincluded fin the prevfious 
systematfic revfiew seem to findficate that the symptoms of IBS may declfine durfing the 
course of tfime, albefit the data fis somewhat finconsfistent. A Korean cohort study folowfing 
Shfigela-finfected IBS patfients for ten years found that the odds ratfio for IBS at ten years 
after the parasfite-finduced gastroenterfitfis was sfimfilar wfith the general populatfion whereas 
at three and ffive years, the correspondfing odds ratfios were 3.91 and 1.88. These data 
together wfith the data of Hefinsvefig Poulsen et al. (2015) suggest that IBS may heal by 
fitself, at least fin a mfinorfity of patfients. 
2.2  Pathogenesfis of firrfitable bowel syndrome 
It fis vfital to understand the key players and thefir role fin pathogenesfis, otherwfise fit fis 
chalengfing to apprecfiate why certafin IBS treatments may or may not work. As stated fin 
chapter 2.1., firrfitable bowel syndrome should not be deffined any longer as a functfional 
gastrofintestfinal dfisorder but as a dfisorder of gut-brafin finteractfion (Schmulsson and 
Drossman 2017).  
 
IBS has been consfidered as a dfisorder wfithout any underlyfing pathologfical explanatfion for 
the symptoms that patfients experfience, but thfis concept fis probably outdated (Holtmann 
et al. 2016), as the folowfing text wfil demonstrate. IBS has been dfivfided finto subgroups 
accordfing to the predomfinant stool pattern because thfis categorfisatfion deffines treatment. 
Accordfing to the Rome IV crfiterfia, the subtypes of IBS are dfiarrhoea predomfinant IBS 
(IBS-D), constfipatfion predomfinant IBS (IBS-C), mfixed type of IBS where dfiarrhoea and 
constfipatfion alternate (IBS-M) and ffinaly unclassfiffied IBS (IBS-U) fin whfich the bowel 






Holtmann et al. (2016) propose that there are, fin fact, several dfiferent dfisease 
mechanfisms underlyfing these subtypes and they argue: 
 
“Tradfitfionaly, firrfitable bowel syndrome has been consfidered to be a dfisorder wfith 
no known underlyfing structural or bfiochemfical explanatfion, but thfis concept fis 
lfikely to be outdated. In thfis revfiew we chalenge the wfidely accepted vfiew that 
firrfitable bowel syndrome fis an unexplafined brafin–gut dfisorder. There fis 
epfidemfiologfical evfidence that, fin a major subset of patfients, gastrofintestfinal 
symptoms arfise ffirst and only later do fincfident mood dfisorders occur. 
Addfitfionaly, possfible mechanfisms for gut–brafin dysfunctfion have been fidentfiffied, 
suggestfing prfimary gut dfisturbances mfight be the underlyfing cause fin a 
subgroup.” 
 
The Rome Foundatfion, the dfiagnostfic group for bowel dfisorders of Rome IV consensus has 
arrfived at sfimfilar conclusfions based on the recent studfies fin IBS. 
 
“IBS fis a multfifactorfial dfisorder wfith a complex pathophysfiology. Factors that 
fincrease the rfisk of developfing IBS finclude genetfic, envfironmental, and 
psychosocfial factors. Factors that trfigger the onset or exacerbatfion of IBS 
symptoms finclude a prfior gastroenterfitfis, food fintolerances, chronfic stress, 
dfivertficulfitfis, and surgery. The resultfing pathophysfiologfic mechanfisms are 
varfiable and patfient findependent, and finclude altered GI motfilfity, vfisceral 
hyperalgesfia, fincreased fintestfinal permeabfilfity, fimmune actfivatfion, altered 
mficrobfiota, and dfisturbances fin brafin−gut functfion” (Lacy et al. 2016)  
2.2.1 Vfisceral sensfitfivfity 
 
The bfiologfical functfion of the pafin sensatfion fis to detect potentfialy harmful stfimulfi. 
However, tfissue finjury may not be necessary for the finductfion of abdomfinal/vfisceral pafin, 
as fit fis for pafin from skfin, muscles, connectfive tfissues or bones. Under normal condfitfions, 
the gastrofintestfinal tract fis not a source of conscfious sensory experfiences apart from 
regfistratfion of physfiologfical sensatfions such as fulness, satfiety, hunger and urgency; we 
do not feel food movfing fin our gut. The gut typficaly fafils to feel cuttfing, crushfing or 
burnfing, but fin humans, a dfistensfion of the stomach, smal fintestfine, large bowel and 
rectum typficaly evokes sensatfions fincludfing pafin. Unpleasant sensatfions are generaly felt 
acutely or percefived as pafinful when stfimulfi exceed the normal physfiologfical range or 
when submucosal nerve endfings are sensfitfized as a consequence of tfissue finjury, such as fin 
finflammatory bowel dfisease (IBD), gastroenterfitfis or bowel cancer. (Keszthelyfi et al. 2012)  
 
Vfisceral sensfitfivfity, also named as vfisceral hyperalgesfia or hypersensfitfivfity, has long been 
acknowledged as a halmark of IBS (Camfilfierfi et al. 2001). It fis a sfituatfion when a person 
senses gastrofintestfinal symptoms and especfialy pafin at lower fintralumfinal pressure than 
healthy controls. It stfil has a central role fin IBS, even fif only 30-40% of IBS cases 





sensfitfivfity fis understood as havfing two dfistfinctfive domafins: 1) sensfitfisatfion of aferent 
nerve endfings at level of gut, fi.e. fin efither submucosal or myesentrfic plexus of enterfic 
nervous system (ENS) and 2) sensfitfised/altered handlfing of pafin efither at the cortfical or 
spfinal levels of the central nervous system (CNS). Ffigure 1 filustrates two focal pofints of 
vfisceral sensfitfivfity (accordfing to Keszthelyfi et al. 2012). 
 
Recent prospectfive cohort studfies have suggested that the orfigfin of vfisceral sensfitfivfity 
seems to be at the level of the submucosal and myentrfic plexus fin every second case and at 
the level of the CNS fin the others (Koloskfi et al. 2012, Koloskfi et al. 2016). However, more 
studfies are needed to conffirm these ffindfings.  
 
To summarfize, many, but not al patfients, wfith IBS demonstrate dfisturbed handlfing of 
pafin sfignals efither at the perfipheral level (aferent sensfitfisatfion fin submucosal or 
myenterfic plexus) or at the level of CNS; fin the CNS, the dfisturbance can be detected at 
efither the cortfical or spfinal level, or both.  
 
 
Ffigure 1. Schematfic presentatfion of two focal pofints of dfisturbed pafin handlfing fin vfisceral 
sensfitfivfity/IBS. Image drawn by Mats Vuorenjuurfi for the purpose of thfis thesfis.  
2.2.2 Gut mficrobfiota 
 
Emergfing evfidence suggests that the composfitfion of the gut mficrobfiota fis assocfiated wfith 
many dfiseases such as type 2 dfiabetes, cardfiovascular dfisease, cancer, alergy and 
neuropsychfiatrfic dfiseases (Nagpal et al. 2014). It fis perhaps less surprfisfing that an altered 






The gut mficrobfiota comprfises more than 400 specfies (Bennett et al. 2015) and the cel 
count of mficrobfiota fis estfimated to be approxfimately the same as the total count of human 
cels (Sender et al. 2015). Baquero and Nombela 2012 have caled fit “the neglected organ”. 
Commensal, fi.e. naturaly occurrfing, bacterfia fin gut are vfiewed as necessary for healthy 
dfigestfion, because some gut bacterfia produce enzymes, such as lactase, vfitamfins such as 
vfitamfins K/B and metabolfites such as short-chafin fatty acfids or branched-chafin amfino 
acfids whfich exert efither local or systemfic efects on health.  
 
The gut mficrobfiota fis also crucfial for the normal development of the gut fimmune system 
(Öhman and Sfimren 2015). The fimmune system must tolerate the presence of these 
commensal bacterfia. Furthermore, the gut fimmune system must recognfise pathogenfic 
bacterfia from thefir commensal counterparts and be able to mount an attack agafinst these 
pathogens fin order to re-establfish balance and health. The gut mficrobfiota seems to also 
play a role fin food alergy development; an altered gut mficrobfiota composfitfion early fin lfife 
fis an emergfing factor afectfing the development of food alergy (Nowak-Wegrzyn et al. 
2016, Afitero et al. 2017). 
 
Generaly, the fintestfinal mficrobfiota composfitfion of healthy findfivfiduals fis relatfively stable 
after finfancy (after 2-3 years of lfife) whereas there fis extensfive varfiabfilfity between 
findfivfiduals (Rajfilfić-Stojanovfić et al. 2014). However, several factors, such as antfibfiotfic 
treatment, dfiet, stress, the host fimmune system and the pH of the gut mfilfieu can afect the 
gut mficrobfiota to a certafin degree (Bennett et al. 2015, Maloney et al. 2016). After 
antfibfiotfic treatment or a specfial dfietary perfiod, the mficrobfiota tend to become restored 
back to thefir orfigfinal status.  
 
Over the past decade, the dfisturbances fin gut mficrobfiota fin IBS have attracted fincreasfing 
attentfion. The gut mficrobfiota may contrfibute to IBS symptoms by alterfing gut 
neuromotorsensory functfion, barrfier functfion or the brafin-gut axfis (Sfimrén et al. 2013).  
Most, fif not al studfies, that compare mficrobfial proffiles fin IBS patfients and healthy 
controls have been assocfiatfive and cannot dfistfingufish cause from consequence. The most 
convfincfing evfidence for a causatfive role of mficrobfiota fin IBS fis the exfistence of PI-IBS 
(Sfimrén et al. 2013). As stated prevfiously, around 10% of afected people develop IBS after 
gastroenterfitfis (Klem et al. 2017). The benefficfial efects of probfiotfics and the antfibfiotfic, 
rfifaxfimfin, are other dfirect evfidence conffirmfing the role of mficrobfiota fin IBS; see a more 
detafiled dfiscussfion fin the folowfing chapters “Probfiotfics” and “Drugs”. 
 
Furthermore, there fis growfing evfidence suggestfing that at least subgroups of IBS patfients 
have an altered gut mficrobfiota composfitfion, an abnormal sfite of fits resfidence (smal 
fintestfinal bacterfial overgrowth, SIBO) or finstabfilfity fin thefir gut mficrobfiota. There are 
several revfiew papers and doctoral theses devoted to thfis theme (Kassfinen 2007, Salonen 
and Vos 2010, Sfimrén et al. 2013, Jalanka 2014, Colfins 2014, Rajfilfić-Stojanovfić et al. 
2014, Maloney et al. 2016, Staudacher and Whelan 2016). It fis unclear how alteratfions fin 
the mficrobfiota then cause symptoms or finfitfiate the processes that lead to IBS; toxfic 







The typfical bacterfial dfisturbances encountered fin IBS seem to finclude a reduced 
abundance of many bacterfia wfith potentfial antfi-finflammatory propertfies such as 
bfiffidobacterfia, lactobacfilfi and Faecalfibacterfium, as wel as some other bacterfial changes. A 
systematfic revfiew of 13 cohorts finvolvfing 360 IBS patfients and 268 controls suggested that 
the abundance of lactobacfilfi, bfiffidobacterfia and Faecalfibacterfium prausnfitzfifi would be 
reduced fin IBS (Lfiu et al. 2017). A sub-group analysfis demonstrated that IBS-C patfients 
had a sfimfilar abundance of lactobacfilfi and bfiffidobacterfia as controls whfile subjects wfith 
IBS-D had the most promfinent loss of these benefficfial bacterfia groups. On the other hand, 
dfiferences fin gut mficrobfiota can be detected between IBS-D and IBS-C subtypes; an 
abundance of Streptococcus and Rumfinococcus, and furthermore findfivfiduals wfith IBS-D 
had a more severe reductfion of lactobacfilfi and bfiffidobacterfia than thefir counterparts wfith 
IBS-M or IBS-C. Methanfinobrevfibacter smfithfifi fis a key bacterfium producfing methane fin 
gut and people wfith IBS-C seem to have a hfigher abundance of thfis specfies than healthy 
controls or patfients wfith IBS-D (Trfiantafylou et al. 2014, Goshal et al. 2016). 
Furthermore, the relatfive abundance of Streptococcus, Rumfinococcus Roseburfia, Blautfia, 
Dorfia, Enterobacter and Enterobacterfiacaea may be fincreased fin IBS. The bfiodfiversfity of 
mficrobfiota may also be reduced fin IBS (Rajfilfić-Stojanovfić et al. 2014) albefit some studfies 
have detected no dfiference fin mficrobfial dfiversfity (Dlugosz et al. 2015a). Despfite extensfive 
research eforts, fit remafins unclear and debatable exactly how and the extent to whfich 
these changes contrfibute to the symptoms or are finvolved fin the natural course of IBS.   
 
It fis not only the abundance of certafin bacterfial groups that can be dfistorted fin IBS. 
Ffinnfish researchers ffirst showed that the mficrobfiota of subjects wfith IBS seems to be 
unstable when compared to healthy subjects (Mättö et al. 2005). They measured the 
composfitfion of mficrobfiota three tfimes over sfix months (at 0, 3 and 6 months) and noted 
that there were more and larger changes fin the mficrobfiota of the patfients wfith IBS when 
compared to healthy controls. Durbán et al. (2013) also reported finstabfilfity of the 
mficrobfiota fin IBS-D. However, fit fis unclear fif the finstabfilfity fis drfiven by sporadfic or 
perfiodfic external stfimulfi, fi.e. dfietary changes, or fis fit a true characterfistfic feature of the 
mficrobfiota of IBS patfients even fin stable lfife condfitfions (Durbán et al. 2013). Some data 
fimply that stress epfisodes mfight explafin, at least partly, the fluctuatfing nature of 
mficrobfiota (Mayer et al. 2014). Other factors that mfight be behfind the finstabfilfity of 
mficrobfiota finclude perfiodfic elfimfinatfion dfiets fin an attempt alevfiate the worsenfing 
symptoms, the common use of proton pump finhfibfitors or antfibfiotfics as treatment trfials 
agafinst excessfive colonfic fermentatfion/bloatfing because each of these are thought to have 
repercussfions on the mficrobfiota (Sfimrén et al. 2013). 
 
The large bowel, the colon, harbors most of the gastrofintestfinal bacterfia. However, IBS can 
be sometfimes characterfised by SIBO (Sfimrén et al. 2013). SIBO fis a condfitfion where the 
smal fintestfine harbors more mficrobes than normaly. Because mficrobes are able to 
ferment any unabsorbed carbohydrates, SIBO can cause excessfive fermentatfion processes 
fin smal fintestfine, and thereby cause bloatfing, dfiarrhoea and flatulence, before the remafins 






However, the dfiagnosfis of SIBO fis a chalenge. The gold-standard method fis the takfing of 
an aspfiratfion sample from jejenum but there are no unfiversaly agreed dfiagnostfic values 
for aspfirates (Sfimrén et al. 2013). The procedure finvolved fin takfing an aspfirate sample 
from jejenum fis burdensome both to the patfient and physficfian because fit finvolves the 
gastroscopy procedure. The lactulose hydrogen breath test or glucose hydrogen breath test 
are more often used fin clfinfical studfies but these tests are confounded by several factors; 
and thefir clfinfical value remafins unclear (Sfimrén et al. 2013). Nonetheless, despfite the lack 
of unfiversaly agreed dfiagnostfic crfiterfia and standardfized methods, fit fis estfimated that 4%- 
78% of patfients wfith IBS and from 1% up to 40% of healthy controls have SIBO, and many 
experts belfieve that SIBO has some relevance to IBS (Ghoshal et al. 2017). 
 
In summary, fit can be stated that findfivfiduals wfith IBS dfisplay several dfisturbances fin gut 
mficrobfiota; the abundance of several bacterfial groups fis altered, mficrobfiota can be labfile 
and mficrobes can be harboured fin the smal fintestfine fin abnormal amounts (SIBO). The 
exact role of the gut mficrobfiota fis stfil befing elucfidated; however, the mficrobfiota appears 
to be one of several fimportant factors that contrfibutes to the etfiology and pathophysfiology 
of IBS. The most convfincfing pfiece of evfidence that tfies the gut mficrobfiota finto IBS fis the 
very exfistence of post-finfectfious IBS. 
2.2.3 Increased fintestfinal permeabfilfity 
 
The surface of both the smal and large bowels fis composed of sfimple columnar cels. 
These cels of the gut lfinfing are caled enterocytes. There are so-caled tfight junctfions 
between enterocytes that control the fintracelular space. Tfight junctfions alow absorptfion 
of nutrfients, but on the other hand, form an epfithelfial barrfier agafinst pathogens and 
harmful substances (Uluwfishewa et al. 2011). 
 
The regulatfion of tfight junctfions seems to be dfisturbed at least fin subsets of IBS-D patfients 
(Pfiche 2014). In subjects wfith IBS-D and PI-IBS, the tfight junctfions may become loosened 
leadfing to fincreased fintestfinal permeabfilfity, thfis fis coloqufialy termed as “leaky gut” 
(Camfilerfi et al. 2012, Qufigley 2016). Food and mficrobfial antfigens, such as toxfins, protefins 
and peptfides may thereby stfimulate the mucosal fimmune system and cross the fintestfinal 
border and  more easfily gafin access to the cfirculatfion. Furthermore, water can pass from 
the body finto the lumen of the gut thus promotfing the development of dfiarrhoea. Both 
fincreased penetratfion of harmful substances and the flux of water finto lumen can cause the 
GI and non-GI symptoms related to IBS (Matrficon et al. 2012). 
 
The translocatfion of a probe molecule across the fintestfinal epfithelfium fis the basfic concept 
used when assessfing fintestfinal permabfilfity. There are several commonly used probe 
molecules finpermeabfilfity tests fin IBS e.g. lactulose, mannfitol and polyethylene glycols; 
findfirect measures of permeabfilfity also finclude molecules such as zonulfin, occludfin or 
claudfin-1 (Bertfiaux-Vandaële N et al. 2011, Kerckhofs et al. 2010, Rao et al. 2010). None 






Zhou et al. (2018) fed rats a dfiet hfigh fin FODMAPs and observed an fincrease fin faecal 
Gram-negatfive bacterfia and serum lfipopolysaccharfide (LPS) levels, together wfith barrfier 
dysfunctfion, fincreased fintestfinal finflammatfion and vfisceral hypersensfitfivfity. In addfitfion, a 
low FODMAP dfiet was found to reduce LPS levels and fimprove symptoms fin human 
subjects wfith IBS, albefit the number of patfients fin the trfial was low. These data suggest 
that a so-caled hfigh FODMAP dfiet (normal dfiet) can fincrease the systemfic exposure to 
LPS fin IBS due to fincreased permeabfilfity of the gut lfinfing.  
 
One way fin whfich hyperpermeabfilfity may take place fin IBS-D fis vfia altered mficroRNA 
(mfiRNA) expressfion proffile (Wouters 2017). MfiRNAs are partficularly relevant for 
fintestfinal dfisorders as recent research has descrfibed thefir fimpact fin the regulatfion of 
fimmune and finflammatory responses. Alteratfions fin mfiRNAs lead to reduced glutamfine 
synthesfis sfince glutamfine plays a crucfial role fin mafintafinfing fintestfinal barrfier functfion and 
fits depletfion leads to vfilus atrophy, decreased expressfion of the protefins needed for tfight 
junctfions and fincreased fintestfinal permeabfilfity (Wouters 2017). In an finnovatfive confocal 
mficroscopy study, Turcotte et al. (2014) found that IBS patfients had sfignfifficantly more 
epfithelfial gaps fin thefir smal fintestfine as compared wfith healthy controls. The medfian gap 
densfity of IBS patfients was 32 (range 17-42) gaps/1000 cels versus 6 (range 0-13) 
gaps/1000 cels for healthy controls (P =0.001). Thus, the authors concluded “Increased 
epfithelfial cel extrusfion may be a cause of altered fintestfinal permeabfilfity observed fin IBS”. 
 
It fis chalengfing to determfine the actual role of fintestfinal hyperpermabfilfity because 
fintestfinal permeabfilfity fis finterrelated to gut mficrobfiota, stress, dfiet and many other factors 
also contrfibutfing to the etfiology of IBS (Sfimrén et al. 2013). However, experts agree that 
fintestfinal permeabfilfity fis probably one of the mechanfisms behfind the symptoms 
encountered fin IBS. 
2.2.4 Immune actfivatfion and fintestfinal finflammatfion 
 
IBS fis not an overt finflammatory dfisease fin contrast to Crohn’s dfisease or ulceratfive colfitfis, 
whfich are commonly caled finflammatory bowel dfiseases (IBD). There are no detectable 
finflammatory lesfions on the gut wal, nefither fis there any fincrease fin conventfional markers 
of finflammatfion such as serum CRP, erythrocyte sedfimentatfion rate or fecal calprotectfin fin 
IBS (Spfiler and Major 2016). However, more subtle finflammatory changes, fi.e. low-grade 
finflammatfion or fimmune actfivatfion at the level of the mucosa can be observed, at least fin 
the subset of people wfith IBS. One of the finfitfial ffindfings on low-grade finflammatfion and 
fincreased permeabfilfity was made by Ffinnfish researchers from the Unfiversfity of Helsfinkfi; 
fin thefir finnovatfive study, Kajander et al. (2009) demonstrated that the mucosa of IBS 
patfients could be characterfised by a dfistfinct pro-finflammatory and lfipotoxfic metabolfic 
proffile. In partficular, there was an fincrease fin the levels of several lfipfids such as 
lysophospholfipfids and ceramfides. 
 
Wfith regards to elevated fimmune actfivatfion fin IBS, the general consensus and the most 
convfincfing body of evfidence hfighlfight the role of mast cels (Ford and Taley 2011, Wouters 
et al. 2016). Elevated mast cel actfivatfion and/or an fincreased abundance of mast cels over 





2013). Mast cels are mafinly located fin the lamfina proprfia of mucous membrane of the gut 
lfinfing; these cels are best known as key producers of hfistamfine. Apart from hfistamfine, 
mast cels produce tryptase and other proteases, serotonfin, finterleukfins, leukotrfienes, 
prostaglandfins and TNF-α and some other pro-finflammatory substances (Zhang et al. 
2016). It fis rather wel establfished that mast cel actfivatfion can generate epfithelfial and 
neuromuscular dysfunctfion and promote vfisceral hypersensfitfivfity and altered motfilfity 
patterns fin IBS, postoperatfive fileus, food alergy and finflammatory bowel dfisease (Wouters 
et al. 2016). Ostertag et al. (2015) reported that mucosal bfiopsfies of IBS patfients seemed to 
mount a weakened actfivatfion to a mfixture of hfistamfine, serotonfin, tryptase, and TNF-α 
when compared to healthy controls; the researchers argued that thfis was due to a 
desensfitfizatfion towards the medfiators constantly released by mucosal cels of IBS patfients. 
 
One sophfistficated study fin humans showed that supernatants from colonfic mucosa of IBS 
patfients, but not from healthy controls, actfivated human enterfic neurons fin vfitro whereas 
supernatants (Buhner et al. 2009). In addfitfion, the IBS supernatant-evoked excfitatfion was 
medfiated by proteases such as tryptase, hfistamfine, and serotonfin, wfith the proteases 
appearfing to play the greatest role. These results of Buhner et al. (2009) further emphasfize 
that altered sfignalfing from the mucosa to the ENS may be a relevant factor fin the 
pathophysfiology of IBS. These researchers speculated that mast cels and enterochromaffin 
cels fin the supernatant samples were lfikely to be the sources responsfible for the 
supernatant-medfiated excfitatfion. Indeed, a systematfic revfiew concluded that there fis some 
evfidence that enterochromaffin cel densfity fis elevated fin IBS (Martfin-Vfiñas and Qufickley 
et al. 2016).  
 
Many drugs that afect the cascades occurrfing fin mast cels are also befing developed and 
tested (Zhang et al. 2016). In fact, ebastfine, an oral antfi-hfistamfine fi.e a hfistamfine receptor 
blocker, reduced vfisceral sensfitfivfity and consequently abdomfinal pafin fin IBS fin a 
randomfised 3-month trfial (Wouters et al. 2016) and a low-FODMAP dfiet has dramatficaly 
reduced the levels of hfistamfine-metabolfites fin urfine samples of IBS patfients (McIntosh et 
al. 2017).  
 
In addfitfion to fincreased actfivatfion and a greater abundance of mast cels and 
enterochromaffin cels, several other subtle finflammatory processes have been descrfibed 
fin IBS. The numbers of T lymphocytes, B lymphocytes, and mucosal cytokfine productfion 
appear to be altered among cases wfith IBS, especfialy among those wfith IBS-D (Ford and 
Taley 2011). Two case-control studfies have reported that patfients wfith IBS exhfibfit hfigher 
levels of hfigh-sensfitfive CRP when compared to healthy controls (Hod et al. 2011, 2016). 
Accordfing to a systematfic revfiew, TNF-α levels were hfigher fin female patfients wfith IBS 
than fin healthy controls although no dfiference could be found fin males (Bashashatfi et al. 
2014). The same revfiew also descrfibed a sfignfifficantly lower serum/plasma IL-10 levels fin 
male patfients wfith IBS vs male controls.  
 
Furthermore, one meta-analysfis has shown that there are assocfiatfions between cytokfine 
gene polymorphfisms and IBS (Bashashatfi et al. 2012). Carrfiers of the hfigh producer antfi-
finflammatory cytokfine IL-10 gene polymorphfism were less lfikely to have IBS. 





IBS fin Asfian but not fin Caucasfian populatfions (Bashashatfi et al. 2012). One study also 
proposed that chfildren wfith IBS tended to produce lower amounts of the antfi-
finflammatory cytokfine IL-10 at baselfine and after LPS stfimulatfion, fimplyfing that defects fin 
fimmune modulatfion may contrfibute to IBS fin chfildren (Hua et al. 2011). Another case-
control study found that the levels or lfipopolysaccharfide (LPS) and antfibodfies to flagelfin 
were hfigher fin IBS-D than fin healthy controls (Dlugosz et al. 2015b). Ffinaly, a recent study 
reported fincreased expressfion of Tol-lfike receptors 4, 5, and 9 fin smal bowel mucosa 
from subjects wfith IBS (Dlugosz et al. 2017). These studfies on systemfic markers of 
finflammatfion suggest that IBS patfients may have an actfivated fimmune system when 
compared to healthy controls.  
 
Mficroscopfic colfitfis fis an finflammatory dfisorder afectfing the colon characterfised by long-
lastfing unresolved dfiarrhoea. Inflammatfion cannot be verfiffied fin regular colonoscopy, 
finstead hfistologfical analysfis fis needed for a dfiagnosfis, thus a bfiopsy specfimen from colon fis 
requfired for dfiagnosfis. It fis not known how often mficroscopfic colfitfis fis the actual cause of a 
condfitfion finterpreted as IBS-D but recent studfies suggest that at least 4% of IBS-D cases 
mfight be explafined by mficroscopfic colfitfis (Ozdfil et al. 2011, Stoficescu et al. 2012, Hfilpüsch 
et al. 2017). It fis fimpossfible to dfiferentfiate IBS-D and mficroscopfic colfitfis purely on the 
basfis of the patfient’s clfinfical presentatfion, but from the clfinfical pofint of vfiew, the 
dfiferentfiatfion fis crucfial; mficroscopfic colfitfis usualy responds to antfi-finflammatory drugs 
or cortficosterofids (Gentfile and Yen 2017) whereas IBS-D does not. It fis not known fif IBS-D 
can convert finto mficroscopfic colfitfis, or the other way round. What does seem certafin fis 
that mficroscopfic colfitfis mfight be mfistaken as IBS-D.  
 
Taken together, an abnormaly actfivated mucosal fimmune system/low-grade 
finflammatfion together wfith the prevfiously mentfioned dfisturbances fin gut mficrobfiota and 
fintestfinal permeabfilfity are al factors that now chalenge the tradfitfional vfiew of IBS as a 
purely functfional dfisorder and suggest that IBS mfight have an organfic cause.  
2.2.5 Gastrofintestfinal cels and hormones 
 
The gastrofintestfinal tract contafins at least 15 dfiferent types of endocrfine cels that are 
spread among the epfithelfial cels of the mucosa. These cels, whfich constfitute about 1% of 
al epfithelfial cels fin the gastrofintestfinal tract, have specfialfized sensors fin the form of 
mficrovfilfi that sense lumfinal condfitfions and respond to lumfinal stfimulfi (dfiet) by releasfing 
hormones (El-Salhy 2015). Promfinent cels fin lower GI tract finclude enterochromaffin 
cels, Delta cels (D cels) and L cels (Gunawardene et al. 2011). Enterochromaffin cels 
secrete serotonfin and hfistamfine, D cel somatostatfin and L cels neurotensfin and glucagon-
lfike peptfide-1, pancreatfic peptfide YY, oxyntomodulfin and glucagon-lfike peptfide-2. 
Pfinealocytes and enterochromaffin cels fin GI tract produce also melatonfin (Chojnackfi et 
al. 2013).  
 
Gastrofintestfinal hormones may have a role fin the pathophysfiology of IBS. It has been 
argued that the densfity of fintestfinal endocrfine cels fis reduced fin “normal” IBS patfients but 
fincreased fin PI-IBS (El-Salhy et al. 2017). The reductfion fin the numbers of gastrofintestfinal 





the fintestfinal stem cels (El-Salhy et al. 2017); they proposed that the abnormalfitfies fin the 
gastrofintestfinal endocrfine cels explafin the vfisceral hypersensfitfivfity, dfisturbed 
gastrofintestfinal motfilfity, and the abnormal gut secretfion observed fin subjects wfith IBS. It 
fis of consfiderable finterest to nutrfitfionfists and dfietfitfians that a low-FODMAP dfiet seems to 
restore the densfity of endocrfine cels fin IBS (Mazzavfi et al. 2015). However, these results 
wfil requfire conffirmatfion from other research teams; the reduced densfity of endocrfine cels 
has not been conffirmed but nefither has fit been refuted.  
 
Serotonfin secreted from enterochrommaffin cels fis thought to play a role fin IBS accordfing 
to Martfin-Vfiñas and Qufickley et al. (2016). The GI tract contafins 90% of the body’s 
serotonfin stores. Conventfional functfions of serotonfin are percefived as fintrfinsfic reflexes 
(e.g. stfimulatfion of propulsfive and segmentatfion motfilfity, epfithelfial secretfion and 
vasodfilatfion), and the actfivatfion of extrfinsfic vagal and spfinal aferents that alter gastrfic 
emptyfing, pancreatfic secretfion, feelfings of satfiatfion, pafin and dfiscomfort and may medfiate 
nausea and vomfitfing and furthermore serotonfin may also promote finflammatfion 
(Camfilfierfi 2012, Holtmann et al. 2016). There fis evfidence that there are abnormalfitfies fin 
serotonfin metabolfism fin IBS. Serotonfin levels seem to be hfigher fin IBS-C and lower fin 
IBS-D when analysed from platelet-depleted plasma (Camfilfierfi 2012, Holtmann et al. 
2016). It has also been suggested that IBS patfients wfith dfiarrhoea mfight have reduced 
serotonfin re-uptake, and those wfith IBS wfith constfipatfion mfight have fimpafired release of 
serotonfin (Camfilfierfi 2012, Holtmann et al. 2016). Both the serotonfin receptor 4 agonfist 
(tegaserod) and the receptor-type 3 antagonfist (alosetron) have been used to treat IBS-C 
and IBS-D (Camfilfierfi 2012, Holtmann et al. 2016). 
 
The levels of melatonfin fin the gastrofintestfinal tract exceed by 10-100 tfimes the blood 
concentratfions. On average, there fis 400 tfimes more melatonfin fin the gut than fin the 
pfineal gland. Melatonfin fis produced from fits precursor serotonfin (Esteban-Zubero et al 
2017). Melatonfin possesses antfi-finflammatory, analgesfic, sleep promotfing and GI motfilfity 
regulatfing propertfies. Treatment wfith melatonfin 3 mg/day at bedtfime has reduced 
abdomfinal pafin and vfisceral sensfitfivfity fin IBS (Song et al. 2005). Melatonfin 
supplementatfion has been proposed to fimprove abdomfinal pafin, but more studfies wfil be 
needed to conffirm these ffindfings and to understand the exact mechanfisms of actfion (Sfiah 
et al. 2014).  
 
Goblet cels are also located on the mucosa of gut lfinfing and thefir functfion fis to produce a 
gel-formfing mucus whfich protects the enterocytes from pathogens as wel as the 
physfiologfical firrfitatfion caused by dfietary components. Research eforts fin IBS have been 
lfimfited but dysregulatfion of mucus metabolfism has been postulated as one key feature fin 
IBS (Qfin 2011). IL-10 fis an antfi-finflammatory cytokfine that stfimulates the formatfion of 
mucus vfia Goblet cels (Bfirchenough et al. 2015). IL-10 seems to be downregulated fin IBS, 
as prevfiously dfiscussed fin thfis text related to finflammatfion and fimmune actfivatfion. IBS-D 
patfients commonly descrfibe thefir stools as mucus-lfike (Mannfing et al. 1978) whfich may 
further pofint to a dysregulatfion of Goblet cels and dfisturbed mucfin metabolfism fin IBS. 
Indeed, fincreased mucus productfion and thfinnfing of the mucus layer seemed to 
predomfinate fin subjects wfith IBS fin a clfinfical study (Dorofeyey et al. 2011).  
 
It seems reasonable to propose that IBS patfients have dfisturbances fin the endocrfine 
system of GI when compared to healthy subjects. Determfinfing the relatfive fimportance of 
these dfisturbances and finter-connectfions to mficrobfiota, low-grade finflammatfion, ENS and 





2.2.6 Intestfinal gas 
 
Intestfinal gas fis mafinly a product of bacterfial fermentatfion fin colon and to a lesser extent 
fin the smal bowel. As vfisceral sensfitfivfity fis one halmark of IBS, one can understand that 
efither hfigher productfion of gas or fits slower dfisappearance may cause abdomfinal pafin and 
feelfings of dfistensfion.  
 
Several gases are produced fin the gut e.g. hydrogen, methane and carbon dfioxfide and 
hydrogen sulphfide. There fis convfincfing evfidence that the handlfing of finfused fintestfinal gas 
fis fimpafired fin IBS; a key feature befing slow gas transfit and retentfion of gas (Serra et al. 
2001, Hernando-Harder et al. 2006, Salvfiolfi et al 2008, Hernando-Harder et al. 2010,). In 
contrast, feedfing wfith fermentable carbohydrates such as finulfin or fructose dfid not result 
fin dfiferences fin fintrafintestfinal gas volumes whfich were assessed wfith magnetfic resonance 
fimagfing wfith 5 hours’ folow up (Major et al. 2017). It remafins unclear why gas caused by 
finulfin/fructose feedfing does not seem to behave fin the same way as jejunal finfusfion of gas. 
One speculatfive explanatfion can be that the finfusfions sfimply contafin more gas than 40 
grams of finulfin or fructose are able to produce; an alternatfive explanatfion fis that the 
finfusfion sfite (jejenum) fis not so wel equfipped to handle gas as colon/rectum (Harder et al. 
2003). Furthermore, fin the normal postprandfial state, the colon fis the major source of 
fintestfinal gas rather than the smal bowel (jejunum). 
 
IBS patfients may produce more fintestfinal gas than healthy controls at least fin the fasted 
state (Kumar et al. 2010). Some studfies have detected fincreased productfion of gas fin IBS fin 
the post-prandfial state (Ong et al. 2011), as measured by hydrogen excretfion, but not 
conffirmed by others (Yao et al. 2014, Major et al. 2017). 
 
Indfivfiduals wfith IBS-C seem to produce more methane than healthy controls or people 
wfith IBS-D (Chatterjee et al. 2007, Kunkel et al. 2011, Goshal et al. 2016). Although 
thought of as an finert gas, there fis evfidence that methane can act lfike a neuromuscular 
transmfitter, resultfing fin reduced propagatfion of the perfistaltfic movement fin the fintestfine 
(Trfiantafylou et al. 2014). Methanfinobrevfibacter smfithfifi fis a key bacterfium producfing 
methane fin the gut and people wfith IBS-C seem have a hfigher abundance of thfis bacterfium 
fin thefir gut (Goshal et al. 2016, Trfiantafylou et al. 2014). The roles of nfitrfic oxfide and 
carbon dfioxfide fin IBS are far from clear, no studfies exfist on thefir specfiffic role fin IBS. 
 
It seems that persons wfith IBS experfience a slower dfisappearance of fintestfinal gas but the 
locatfion of the defect fis unclear; fin the evacuatfion process (flatus), fin fits excretfion finto 
breath or fin the consumptfion of gases by gut mficrobes. Accordfing to a meta-analysfis, 
breath testfing was four tfimes more often abnormal among IBS subjects than among 
healthy controls; thfis fimplfies that there fis altered handlfing or productfion of gas fin IBS 







2.2.7 Impafired fintestfinal motfilfity 
 
IBS fis conventfionaly classfiffied accordfing to GI motfilfity finto constfipatfion or dfiarrhoea 
predomfinant or mfixed IBS. Durfing the last decade, unclassfiffied IBS (IBS-U) has also been 
added because not al patfients have clear motfilfity dfisturbances. Nevertheless, fit fis 
estfimated that more than 75% of IBS patfients experfience motfilfity problems, fi.e. they have 
efither IBS-C, IBS-D, or IBS-M (Ersryd et al. 2007, Yao et al. 2012). As descrfibed earlfier, 
colonfic methanogenesfis seems to be assocfiated wfith constfipatfion whereas more severe 
finflammatfion appears to be assocfiated wfith IBS-D. In patfients wfith co-exfistfing functfional 
dyspepsfia, gastrfic emptyfing can be slowed and gastrfic accommodatfion to a food bolus can 
be fimpafired. Sfince these mechanfisms cause the stomach to be more ful, thfis can provoke 
symptoms fin the upper GI tract fin the presence of vfisceral sensfitfivfity (Haag et al, 2004, 
Farré et al. 2013, Stefinsvfik et al. 2016).  
 
One fintrfigufing observatfion fis that IBS patfients seem to have fintra-abdomfinal volume 
dfisplacement. Patfients wfith IBS-related bloatfing show an fimpafired abdomfino-phrenfic 
coordfinatfion wfith a paradoxfical contractfion of the dfiaphragm coupled wfith a relaxatfion of 
the abdomfinal wal, leadfing to an fincrease fin abdomfinal cfircumference (Iovfino et al. 2014).  
A functfional MRI study revealed that IBS-C patfients had a dfilated transversal colon and 
IBS-D and IBS-M patfients had a constrficted smal bowel whfich was speculated to be due to 
a decreased level of water fin the smal bowel fin IBS-C (Lam et al. 2017).  
 
Taken together, these data conffirm that the majorfity of IBS patfients sufer from altered 
motfilfity of the GI tract but there are also IBS patfients that do not have motfilfity 
dfisturbances, fi.e. they have IBS-U.  
2.2.8 Short-chafin faty acfids 
 
Commensal bacterfia harboured fin the dfistal fintestfine consume the carbohydrates that 
have not been absorbed fin smal fintestfine. Dfietary ffibre fis the most fimportant 
carbohydrate wfith respect to thfis bacterfial fermentatfive process. As a result of the 
fermentatfion, fintestfinal gas and short-chafin fatty acfids (SCFAs) are formed wfith butyrate, 
propfionate and acetate befing the most abundant SCFAs. Short-chafin fatty acfids have many 
regulatory functfions, such as enhancement of electrolyte and water absorptfion fin colon 
(Camfilfierfi et al. 2015). The antfi-finflammatory role of butyrate fis of major finterest sfince 
butyrate fis extensfively formed from dfietary ffibre and fis the key fuel for enterocytes. A 
depletfion of dfietary ffibre, fi.e. a low ffibre dfiet, results fin the reduced productfion of butyrate 
and thfis may cause a thfinnfing of the mucus layer fin the gut and cause fincreased 
permeabfilfity (Scott et al. 2013, Stfilfing et al. 2016). 
 
Lfittle fis known about the relevance of short-chafin fatty acfids fin IBS. A Norwegfian 
lactulose-feedfing study suggested that IBS patfients, possfibly due thefir altered mficrobfiota, 
mfight have reduced capacfity to produce short-chafin fatty acfids from unabsorbed 
carbohydrate lactulose (Undseth et al. 2015). In that study, the amount of short-chafin 





from IBS patfients produced less SCFAs fin an fin vfitro fermentatfion system fin response to 
varfious carbohydrates and ffibers (Treem et al. 1996). An finterventfion study showed that 
encapsuled butyrate reduced defecatfion assocfiated pafin among IBS patfients when 
compared to healthy controls but no dfiference was observed fin overal abdomfinal pafin or 
fin other symptoms (Banasfiewficz et al. 2013). In contrast to these ffindfings, the study of 
Tana et al. (2015) demonstrated that fecal samples of IBS patfients contafined more acetate 
and propfionate than those taken from healthy controls. In a more recent study (Rfingel-
Kulka et al. 2016), the total SCFA level fin IBS subjects was sfimfilar wfith that of healthy 
controls but fit was reduced fin IBS-C.  
 
It fis premature to draw any deffinfitfive conclusfions on the role of SCFAs fin IBS gfiven the 
somewhat contradfictory results fin the lfiterature. 
2.2.9 Heredfity 
 
Relatfives of a person wfith IBS are 2 to 3 tfimes more lfikely to have IBS, and studfies 
comparfing homozygotfic and dfizygotfic twfins have demonstrated that IBS fis two tfimes more 
lfikely among homozygotfic than among dfizygotfic twfins fif one of the sfiblfings has IBS (Levy 
et al. 2001, Safito 2011). The genetfic susceptfibfilfity fin twfin studfies has varfied from 1% up to  
20% and herfitabfilfity estfimates have ranged between 0–57% fin four studfies (Safito 2011). As 
both dfizygotfic and homozygotfic twfins share the same envfironment but only homozygotfic 
twfins share al the genes, thfis fimplfies that genes do play some role fin the development of 
IBS. Genetfic studfies have thus far focused on detectfing gene polymorphfisms and findeed 
several possfible gene polymorphfisms have been found to assocfiate wfith IBS; however, 
genome wfide assocfiatfions studfies (GWAS) are generaly lackfing (Makker et al. 2015). Thus 
far, the only publfished GWAS study fidentfiffied one locus on chromosome 7p22.1 whfich 
fincluded the genes KDELR2 (KDEL endoplasmfic retficulum protefin retentfion receptor 2) 
and GRID2IP (glutamate receptor, fionotropfic, delta 2 finteractfing protefin) and showed a 
consfistent fincreasfing rfisk fin the findex GWAS when al cohorts were fincluded (Ek et al. 
2015). 
 
One rather large and recent promfisfing example fis the assocfiatfion between polymorphfism 
of the gene codfing for sucrose-fisomaltase enzyme and IBS. The presence of sucrose-
fisomaltase gene varfiants codfing for dfisaccharfidases wfith defectfive or reduced enzymatfic 
actfivfity fincreased the rfisk of IBS by twofold and seemed to predfispose to IBS fin a cohort of 
1887 findfivfiduals wfith IBS (Henström et al. 2018). Polymorphfism fin the sucrose-fisomaltase 
gene reduced the enzymatfic actfivfity by 35%. Naturaly, such a reductfion may cause a 
reduced absorptfion of carbohydrates and consequently elevated fintestfinal fermentatfion of 
carbohydrate and retentfion of water fin the smal fintestfine, and ultfimately thfis could 
provoke the symptoms encountered fin IBS. 
 
It can be concluded that genes seem to play a role fin the development of IBS but more and 
larger studfies wfil be needed to understand the underpfinnfing physfiologfical mechanfisms 





assocfiate wfith IBS but so far, genes are not consfidered as the drfiver of the fincfidence of IBS 
(Makker et al. 2015). 
2.2.10 Dfivertficulosfis 
 
Recent data suggests that over half of populatfions over 60 years have dfivertficulosfis. The 
prevalence of dfivertficular dfisease fis as hfigh as 65% by 85 years of age as compared to an 
fincfidence as low as 5% fin those 40 years of age or younger. (Wefizman and Nguyen 2011) 
 
A Japanese case-control study suggested that left-sfided or bfilateral dfivertficulosfis was 
assocfiated wfith IBS whereas rfight-sfided dfivertficulosfis was not, the odds ratfios befing 3.1 for 
left-sfided and 2.6 for bfilateral dfivertficulosfis (Yamada et al. 2014). A study explofitfing the 
Veterans Admfinfistratfion Medfical Centre database showed that after admfissfion to hospfital 
for dfivertficulfitfis, fi.e. symptomatfic dfivertficulosfis, there was a 4.7-fold fincreased rfisk for 
developfing IBS over the next 6 years (Humes et al. 2012). Furthermore, fin another 
Amerfican prospectfive case-control study, patfients wfith dfivertficulfitfis were 4.7-fold more 
lfikely to be dfiagnosed wfith IBS after a 6.3 years’ folow-up (Cohen et al. 2014). The authors 
proposed that thfis dfisorder should be caled postdfivertficulfitfis IBS. The underlyfing 
mechanfisms fin dfivertficular dfiseases finclude vfisceral hypersensfitfivfity whfich may be 
postfinflammatory but altered central pafin processfing also seems to be present (Spfiler 
2016). These represent the same mechanfism that fis commonly present IBS.  
 
More data fis needed but recent prospectfive studfies have suggested that symptomatfic 
dfivertficulosfis fis a predfisposfing factor for IBS.  
2.2.11 Bfile acfids 
 
A recent meta-analysfis demonstrated that 28% of patfients wfith IBS-D dfisplayed a reduced 
absorptfion of bfile acfids (Slattery et al. 2015) and malabsorptfion of bfile acfids can lead to 
bfile acfid dfiarrhoea. The presence of prfimary bfile acfids fin feces and blood has been 
correlated wfith pafin fin IBS (Dfior et al. 2016). Mficrobes fin the begfinnfing of the colon 
deconjugate prfimary bfile acfids to secondary bfile acfids whfich are more hydrophobfic, and 
thus more lfikely to cause dfiarrhoea, and more toxfic than the prfimary bfile acfids. An 
fincreased level of bfile acfids fin the proxfimal colon can cause mficrobfial and pro-
finflammatory changes fin colon that perpetuate IBS (Pavlfidfis et al. 2015).  
2.2.12 Psychosocfial factors 
 
Stressful lfife events, poor copfing abfilfity and abuse may predfispose to IBS (Chfitkara et al. 
2009). Furthermore, findfivfiduals wfith IBS sufer more often than the general populatfion 
from anxfiety and depressfion. Acute experfimental stress causes fintestfinal 





water fimmersfion or a publfic speakfing test (Alonso et al. 2011, Vanuytsel et la. 2014). 
Furthermore, experfimental studfies have shown that acute stressful events, such as the 
Trfier Socfial Stress Test, can trfigger the symptoms of IBS (Murray et al. 2004, Kennedy et 
al. 2014). Thus, fit seems clear that brafin and gut finteract fin generatfing the symptoms of 
IBS. It has been suggested that IBS patfients wfith severe symptoms have more promfinent 
psychosocfial dfisruptfions whfich act as both an etfiologfical factor leadfing to IBS and as a co-
morbfidfity when already suferfing from IBS (Drossman et al. 2011). Maternal separatfion 
fincreases vfisceral sensfitfivfity and therefore fit has been occasfionaly adopted as an anfimal 
model of IBS (Moloney et al. 2012).  
 
Stress trfiggers the hypothalamus-pfitufitary axfis and the actfivatfion of the autonomfic 
nervous system, an fincrease fin the levels of cortfisol and profinflammatory cytokfines. 
Stress enhances the fintestfinal permeabfilfity by weakenfing the tfight junctfions and thus 
leadfing to fincreased bacterfial translocatfion finto the fintestfinal wal.  An fincreased mficrobfial 
load fin the colonfic tfissue and excessfive cytokfine release or mast cel actfivatfion, fi.e. 
hfistamfine release, may then cause IBS-lfike symptoms. (Konteruk et al. 2011).  
2.2.13 Conclusfion 
The IBS dfisease process fis multfifactorfial and complficated, as descrfibed fin the text. In the 
future, IBS fis lfikely to be splfit finto more precfise and descrfiptfive clfinfical sub-entfitfies as our 
understandfing of the dfisease’s pathophysfiology fincreases. Ffigure 2 depficts the major 














































































2.3  Non-coelfiac gluten/wheat sensfitfivfity –a hypothetfical 
clfinfical entfity related to gluten contafinfing grafins 
Non-coelfiac gluten sensfitfivfity (NCGS), also known as non-coelfiac wheat sensfitfivfity 
(NCWS), has attracted attentfion both fin the scfientfiffic and popular lfiterature 
(Hadjfivassfilfiou et al. 2010, Azfiz et al. 2012, Fasono et al. 2015, Tfime magazfine Aprfil 29, 
2015). The self-dfiagnosed prevalence of NCGS varfies hugely between the studfies; a 
systematfic revfiew of sfix cohorts revealed a prevalence range of 0.5%-13% (Molfina-Infante 
et al 2015). Despfite finterest and publficfity around gluten free dfiets, the bfiology underlyfing 
NCGS fis unclear. 
 
In 2012, an finternatfional consensus group proposed that NCGS would be a new clfinfical 
entfity characterfised by GI symptoms trfiggered by gluten-contafinfing grafins fin the absence 
of coelfiac dfisease, wheat alergy or gluten ataxfia. (Sapone et al. 2012). At the tfime of the 
publficatfion of thfis report, there was only one randomfised study suggestfing that NCGS 
realy exfists (Bfiesfiekfierskfi et al. 2011,a). Sfince the publficatfion of the consensus report, 
several randomfised studfies have been publfished. A revfiew of these studfies was publfished 
2016 (Volta et al. 2016).  
 
There fis no sfingle bfiochemfical marker of NCGS/NCWS avafilable, the only relfiable way to 
determfine the true exfistence of NCGS/NCWS fis to conduct hfigh-qualfity blfinded tests fin 
clfinfical settfings (DeGfiorgfio et al. 2016). The outcomes and features of these randomfised 
studfies fin NCGS/NCWS were compfiled fin a systematfic revfiew and meta-analysfis (Lfionettfi 
et al. 2017). Two randomfised gluten sensfitfivfity studfies have been publfished sfince Lfionettfi’s 
meta-analysfis (Skodje et al. 2017, Dale et al. 2018), and thefir results are fin lfine wfith the 
prevfious studfies. It seems to be seldom the case that gluten per se causes an aggravatfion of 
symptoms.  
 
In thefir meta-analysfis of randomfized studfies, Lfionettfi et al. (2017) concluded: “the meta-
analysfis of the exfistfing lfiterature on re-chalenge studfies fin patfients dfiagnosed wfith NCGS 
shows that the prevalence of conffirmed NCGS after re-chalenge test fis low”. Data of these 
trfials wfil be scrutfinfized fin detafil.  
 
There has been obvfious heterogenefity fin the desfigns of NCGS/NCWS studfies. The 
duratfion, method of comparfison, vehficle product of gluten, nature of placebo and 
background dfiets have dfifered substantfialy from study to study. In some trfials, IBS was 
screened at partficfipant recrufitment whfile fin the others fit was not, and consequently there 
was extensfive heterogenefity fin the partficfipants. These methodologfical dfiferences between 
the studfies make the comparfison of studfies very chalengfing. Nonetheless, fit seems that, at 
maxfimum, 14-30% of people wfith self-dfiagnosed NCGS/NCWS truly react specfifficaly to 
gluten fin blfinded protocols (Volta et al. 2016).  
 
One clear weakness fin these studfies has been the short duratfion of the randomfised perfiod; 





weakness has been the selectfion of placebo. No one knows fif whey protefin, rfice starch, 
xylose, gluten free flour or somethfing else constfitutes a gold standard placebo for studfies 
on NCGS/NCWS. It can be argued that rfice starch should be good because rfice does not 
contafin a sfignfifficant amount of gluten, ATI or FODMAPs (Bfiesfiekfierskfi et al. 2011,b, 
Zevalos et al. 2017). Whey protefin mfight also be a good placebo because fit fis also 
FODMAP, gluten and ATI free. Furthermore, accordfing to prelfimfinary human and 
experfimental evfidence, whey protefin may fimprove the epfithelfial barrfier and exert a mfild 
antfi-finflammatory efect (Benjamfin et al. 2012 and Kotler et al. 2013), and whey protefin 
alone was not able to trfigger symptoms fin people wfith non-alergfic mfilk sensfitfivfity 
(Bengtson et al. 1997).  
 
There are also several observatfional finterventfions fin NCGS/NCWS. They have finherent 
weaknesses but often these trfials have a much longer duratfion than randomfized studfies fin 
thfis partficular ffield, thus tacklfing the weakness of very short finterventfion perfiod typfical to 
randomfised NCGS/NCWS trfials. In a 6-month non-controled finterventfion, GFD 
decreased severfity of GI symptoms; partficfipants were not screened for IBS status at 
enrolment (Uhde et al. 2016). It was finterestfing that many markers of low-grade 
finflammatfion and fintestfinal permeabfilfity fimproved, e.g. cfirculatfing concentratfions of IL-8, 
IL-6, FABP2 and LBP were reduced. The authors finterpreted the results as folows: “These 
ffindfings reveal a state of systemfic fimmune actfivatfion fin conjunctfion wfith a compromfised 
fintestfinal epfithelfium afectfing a subset of findfivfiduals who experfience sensfitfivfity to wheat 
fin the absence of coelfiac dfisease”. 
 
Furthermore, Sapone et al. (2011) showed after a 4-month gluten-contafinfing dfiet that 
finnate fimmune actfivatfion at the level of duodenal epfithelfium was fincreased among 
subjects wfith NCGS when compared to controls (patfients wfith dyspepsfia about to undergo 
gastroscopy). Specfifficaly, the expressfion of Tol-lfike receptor (TLR) 2 was fincreased fin 
NCGS but not fin patfients wfith coelfiac dfisease and the expressfion of the T-regulatory cel 
marker FOXP3 was sfignfifficantly reduced fin gluten sensfitfive persons fin comparfison to 
controls and coelfiac patfients. 
 
Other non-controled studfies prfincfipaly support the concept of NCGS/NCWS both from 
the symptomatfic and low-grade finflammatfion pofints of vfiew (Volta et al. 2016). However, 
the finherent weakness of non-controled trfials must be taken finto account; the placebo 
efect fis always a chalenge fin open non-controled studfies and can have a substantfial 
fimpact fin dfisorders fin whfich responses are befing analysed on the basfis of subjectfive 
ratfings (Staudacher et al. 2017a). The placebo efect, the antficfipated alevfiatfion of 
symptoms, can skew the results towards false posfitfive ffindfings.  
 
A Dutch cohort study ofers an finterestfing perspectfive on NCGS (van Gfils et al. 2016). In 
thfis study, findfivfiduals wfith self-dfiagnosed NCGS were asked about thefir sensfitfivfity to 
other food fitems typficaly hfigh fin FODMAPs. It was clafimed that people wfith NCGS are 
more lfikely to have several other food fintolerances; the odds ratfios for experfiencfing 
symptoms from hfigh-FODMAP foods was found to be 3-16 hfigher among the findfivfiduals 
wfith NCGS when compared to controls. Abdomfinal dfiscomfort related to FODMAP 





populatfion (73.5% vs. 21.7%). Thfis populatfion study suggests that findfivfiduals wfith self-
dfiagnosed NCGS are very lfikely to be sensfitfive to FODMAP and may actualy represent a 
subset of IBS. 
 
Ultfimately, a recent wel-controled 1-week randomfised trfial demonstrated that people 
wfith self-dfiagnosed NCGS do no react to gluten more often than to placebo but do react to 
a FODMAP, to fructan fin thfis case (Skodje et al. 2017). In other words, unlfike fructan, 
gluten was not able to finduce symptoms more often than placebo. Thfis study fis the most 
convfincfing pfiece of evfidence questfionfing the exfistence of pure NCGS. In lfine wfith the 
study of Skodje et al. (2017), an Italfian randomfised study, whfich has been publfished only 
as a congress abstract, demonstrated that findfivfiduals wfith NCGS react more often to 
FODMAPs than to gluten (Zanfinfi et al. 2014).  
 
Role of amylase trypsfin finhfibfitors (ATIs) fin NCGS/NCWS 
 
Wheat, barley and rye contafin FODMAPs, gluten and ATIs whfich al mfight play a role fin 
trfiggerfing the symptoms of NCGS/NCWS. The role of gluten has been dfiscussed 
prevfiously, and a more detafiled descrfiptfion of the role of FODMAPs wfil folow fin chapter 
2.4.1. However, there fis also a need to understand role of ATIs.  
 
Gluten fis the domfinatfing protefin fin wheat, rye and barley but wheat also contafins other 
protefins such as ATIs (Zevalos et al. 2017). ATIs are defensfive protefins produced by plants 
to combat pests. ATIs may trfigger the finnate fimmune response and finduce fintestfinal 
finflammatfion fin the host. Currently, no randomfised studfies have been performed wfith 
ATIs fin IBS or NCGS/NCWS. However, the pre-clfinfical data fis rather convfincfing; ATIs are 
pro-finflammatory fin vfivo fin anfimals and fin vfitro explofitfing dfiferent kfind of human cel 
lfines (Junker et al. 2012, Zevalos et al. 2017). 
The report from Junker et al. (2012) demonstrated that the ATIs commonly found fin 
wheat, barley and rye are actfivators of Tol-Lfike Receptors 4 (TLR4) and therefore they can 
finduce an finnate fimmune response. ATIs elficfit release of profinflammatory cytokfines fin 
cels from coelfiac and noncoelfiac patfients and fin bfiopsfies taken from coelfiac patfients. Mfice 
defficfient fin TLR4 or TLR4 sfignalfing were found to be protected from fintestfinal and 
systemfic fimmune responses after an oral chalenge wfith ATIs. Zevalos et al. (2017) found 
that ATIs were hfighly resfistant to heat and dfigestfive enzymes (fintestfinal proteolysfis). They 
also concluded that gluten-contafinfing foods contafined 100-fold hfigher amounts of ATIs 
than fin most gluten-free foods. Processed or baked foods retafined thefir ATI bfioactfivfity. 
The authors stated: “Most older wheat varfiants (such as Emmer or Efinkorn) had lower 
bfioactfivfity than modern wheat. ATI specfies CM3 and 0.19 were the most prevalent 
actfivators of TLR4 fin wheat. Ingestfion of ATIs finduced modest fintestfinal myelofid cel 
finffiltratfion and actfivatfion, and release of finflammatory medfiators—mostly fin the colon, 
folowed by the fileum, and then fin the duodenum. Dendrfitfic cels became promfinently 
actfivated fin mesenterfic lymph nodes. Concentratfions of ATIs found fin a normal dafily 
gluten-contafinfing dfiet fincreased low-level fintestfinal finflammatfion [fin mfice wfith 
experfimental colfitfis.]”. These authors clafimed that modern wheat has become enrfiched 






These are finterestfing ffindfings but cautfion fis warranted fin finterpretfing the studfies. In fact, 
ATIs can be found fin gluten preparatfions (Junker et al. 2012, Zevallos et al. 2016); 
consequently, when gluten preparatfions or gluten grafins are used fin any randomfised 
study; these trfials test the ATI hypothesfis, at least findfirectly. Interestfingly, the authors dfid 
not address thfis fissue when revfiewfing the lfiterature fin thefir paper (Zevalos et al. 2017). 
 
Furthermore, the efect of ATIs may be a matter of dose; “fit fis the dose that makes the 
pofison” fis the basfic prfincfiple underlyfing toxficology. On the basfis of fin vfivo and 
experfimental studfies, fit has not been possfible to determfine a safe or hazardous dose for 
susceptfible findfivfiduals. Furthermore, people have been consumfing wheat, barley and rye 
for thousands of years, and therefore as a specfies, humans have been chalenged by ATIs 
for mfilennfia fi.e. for as long as we have been consumfing wheat, barley and rye. It fis also 
crucfial that these results should be conffirmed by the broader research communfity; fin 
scfientfiffic research, the replficatfion of a phenomenon can verfify the very exfistence of that 
phenomenon. Ffinaly, there are no dfirect randomfised clfinfical studfies that have specfifficaly 
addressed the role of ATIs; dfirect comparfisons are lackfing between ATI-free dfiet and ATI 
contafinfing dfiet, whfile controlfing gluten and FODMAP content of dfiets. Comparfing a 
gluten free dfiet to the habfitual dfiet does not dfirectly address the ATI-questfion because fit 
has become evfident that a gluten free dfiet fis not only lower fin fits gluten content but also fin 
the levels of FODMAPs 
 
It fis of finterest that when wheat fis fermented for a long tfime, such as fin the tradfitfional 
sourdough method, mficrobfial proteases cleave gluten and other protefin molecules finto 
smaler unfits. Several studfies have conffirmed the hydrolysfis of protefins durfing the 
fermentatfion process (Loponen et al. 2007, Rfizelo et al. 2007, De Angelfis et al. 2009, Dfi 
Cagno et al. 2010). If hydrolysfis fis extensfive enough, fit fis possfible that fit mfight finactfivate 
the ATIs. However, ATIs are very resfistant to heat and human dfigestfive enzymes (Junker 
et al. 2012, Zevalos et al. 2017), and therefore fit remafins to be seen fif ATIs truly could be 
hydrolysed finto finactfive peptfides and amfino acfids durfing bakfing methods that explofit long 
fermentatfion tfimes. Furthermore, there fis evfidence that fructans (FODMAPs) fin bread 
dough are also hydrolysed durfing the long fermentatfion process efither by usfing sourdough 
or a long 4-hour yeast bakfing method (Chavan and Chavan 2011, Zfigler et al. 2016). 
Consequently, the fructan content of sourdough breads mfight be lower than that of yeast 
breads (Monash Unfiversfity low FODMAP applficatfion).  
 
In summary, the avafilable studfies suggest that NCGS/NCWS can be verfiffied by blfinded 
tests only fin a mfinorfity of people wfith self-dfiagnosed NCGS/NCWS. It fis lfikely that a large 
part of NCGS/NWGS fis explafined by FODMAPs, whfich per se, suggests that patfients wfith 
NCGS/NCWS mfight be on the contfinuum of IBS and not represent a separate clfinfical 
entfity. The role of ATIs can only be ascertafined fin randomfised clfinfical trfials comparfing an 





2.4  Dfietary treatment of IBS 
People wfith IBS commonly assocfiate thefir symptoms wfith food; the percefived problematfic 
foods finclude mfilk and other dafiry products, legumes and pulses, crucfiferous vegetables, 
some frufits, and grafins, especfialy wheat and rye (Sfimrén et al. 2001, Gfibson 2017). The 
scfientfiffic lfiterature has expanded substantfialy durfing the past two decades wfith regards to 
dfiet and IBS; consequently, dfiet has now a central role fin the treatment of IBS fin many 
parts of the world.  
 
No robust evfidence exfists that the amount or proportfion of macronutrfients (protefin, 
carbohydrates and fat) would have a major efect fin IBS although on the basfis of 
mechanfistfic studfies, fat mfight be an exceptfion. There are laboratory studfies findficatfing that 
the duodenal finfusfion of lfipfids can finhfibfit smal bowel motfilfity and fimpafir fintestfinal gas 
clearance, finducfing gas retentfion and bloatfing (Passos et al. 2005, Salvfiolfi et al. 2006). 
Duodenal lfipfids also enhance colorectal hypersensfitfivfity (Caldarela et al. 2005, Sfimrén et 
al. 2007). These types of studfies should be always finterpreted wfith care especfialy sfince the 
evfidence assocfiatfing dfietary fat fintake to IBS fis very lfimfited; results derfived from 
experfiments conducted under artfifficfial condfitfions and extreme feedfing practfices are 
seldom transferable to the clfinfical settfing as such. One acute study showed that a meal 
hfigh fin dafiry fat (cream) and calorfies (800 kcal) fincreased acutely vfisceral sensfitfivfity fin 
patfients wfith IBS and these mfight provoke feelfings of abdomfinal pafin and dfistensfion after 
the consumptfion of fat (Törnblom et al. 2014). The partfial exclusfion of poorly absorbable 
carbohydrates has long been part of dfietary strategy fin IBS, even although there were no 
randomfised studfies before the era of low-FODMAP dfiets (Dapofigny et al. 2003). 
2.4.1  Fermentable carbohydrates  
 
Australfian researchers from Monash Unfiversfity fintroduced the concept of Fermentable 
Olfigo-, Dfi-, Monosaccharfides and Polyols (FODMAPs) (Gfibson 2017). FODMAPs are 
sfimple carbohydrates whfich are not absorbed fin the smal fintestfine but rapfidly and 
extensfively fermented fin the upper part of the colon. In the presence of fimpafired handlfing 
of fintestfinal gas, abnormalfitfies fin bowel motfilfity and vfisceral sensfitfivfity, fit fis the rapfid 
fermentatfion of these FODMAPs that fis postulated to trfigger the symptoms of IBS (Gfibson 
2017). It fis now wfidely accepted, based on randomfised and mechanfistfic studfies whfich wfil 
be detafiled fin the folowfing chapters, that FODMAPs can be vfiewed as one group of 
culprfits behfind the aggravatfion of symptoms fin IBS (Staudacher and Whelan 2017). 
 
Background and theory 
 
There are several revfiew artficles avafilable that explafin the theory and ratfionale of a low 
FODMAP dfiet fin great detafil (Gfibson and Shepherd 2010, Gfibson et al. 2015, Staudacher 
et al. 2015, Varney et al. 2017, Staudacher and Whelan 2017,). In brfief, a low-FODMAP 
dfiet fis a holfistfic dfietary pattern where the amount of poorly absorbable carbohydrates 
(FODMAPs) that are also prone to bacterfial fermentatfion fin colon fis substantfialy reduced. 





findfivfiduals finvolve osmosfis and fermentatfion (Staudacher and Whelan 2017). The afim of a 
low FODMAP dfiet fis not to reduce the quantfity of dfietary FODMAPs to zero, fin contrast to 
a gluten free dfiet where total restrfictfion of gluten fis requfired. Typficaly, after adoptfion of a 
low FODMAP dfiet, findfivfiduals stfil have a FODMAP fintake of approxfimately 15-60% of 
thefir habfitual dfiet (Ong et al. 2010, Staudacher et al. 2012, Halmos et al. 2014). FODMAPs 
are naturaly occurrfing fin many grafins, legumes, frufits,vegetables and fin some dafiry and 
findustrfialy processed foods such as prebfiotfic contafinfing yogurts, fructose-sweetened 
carbonated drfinks, protefin bars and chewfing gums. Edfible fats and anfimal-protefin rfich 
foods are usualy low or free from FODMAPs (Gfibson and Shepherd 2010). Lactose 
contafinfing dafiry products are an exceptfion; they are hfigh fin FODMAPs but fit fis noteworthy 
that lactose needs to be avofided only fin the co-presence of lactose fintolerance (Gfibson and 
Shepherd 2010). Lactose fis wel absorbed as long as there fis the presence of normal lactase 
enzyme actfivfity; relevant quantfitfies of lactose are thought to reach colon only fif the actfivfity 
of lactase fis low or absent. 
 
Table 2 detafils the FODMAPs groups and thefir dfietary sources. The basfis of a low-
FODMAP dfiet fis to swfitch from a hfigh FODMAP food to a low FODMAP alternatfive from 
the same category; for example rye bread can be replaced by oat bread. Hfigh FODMAP 
foods can aggravate the symptoms fin at least two ways: a) they cause fincreased retentfion of 
water fin the dfistal smal fintestfine and b) fincrease gas productfion fin the colon due to the 






























Table 2. Categorfisfing of FODMAPs, thefir typfical dfietary sources and optfions for 
substfitutfion. Note! The lfist of dfietary sources fis not exhaustfive*.  
 




It fis noteworthy that the lfist of FODMAPs does not contafin al of the rapfidly and 
extensfively fermentable carbohydrates that are found fin food fitems, for example, 
researchers have fidentfiffied arabfinoxyloolfigosaccharfide (AXOS) (Cloetens et al. 2008, 
Scarpelfinfi et al. 2018) whfich fis derfived vfia the fermentatfion of arabfinoxylan. Arabfinoxylan 
fin turn fis a promfinent ffibre fin rye, wheat and fin barley (Frølfich et al. 2013).  
 
AXOS fis produced finto rye or wheat products vfia the use of findustrfial enzymes or vfia 
yeast/sourdough fermentatfion. Choetens et al. (2010) have estfimated that reffined wheat 















Wheat, rye, barley, 
beans, onfion, garlfic, soy, 
some artfifficfial 
sweetener powders 
Oats, qufinoa, rfice, 
tef, amaranth, tofu, 
potate, low-FODMAP 
gluten free pasta 
 
Dfisaccharfides Lactose (only when 
lactose fintolerance fis 
present) 
Lactose contafinfing mfilk, 
unrfipened cheese and 
yogurt  
Orange, clementfine, 
kfiwfi, honey dough 
melon, oat mfilk, some 
soy mfilk products, 
low-lactose/lactose 
free mfilk dafiry 
products 
 
Monosaccharfides Fructose (only when 
fin excess of glucose) 
Apple, pear, 
watermelon, orange 
jufice, apple jufice, 
mango, honey, hfigh-
fructose corn syrup 
 
Orange, clementfine, 




Polyols Isomalt, lactfitol, 
mannfitol, maltfitol, 
sorbfitol and xylfitol 
(excludfing 
erythrfitol)  











pecan nuts, pumpkfin 






contafins 1·32 g AXOS per 100 g dry matter whfile rye bread contafins 2·64 g AXOS per 100 g 
dry matter. Beer fis a product whfich has a partficularly hfigh AXOS content (Broekaert et al. 
2011). However, there fis vfirtualy nothfing fin the lfiterature about the presence of AXOS fin 
grafin products. There are no clfinfical studfies on AXOS fin IBS, but gfiven the abundance of 
AXOS fin bread products, and fits extensfive fermentatfion fin colon, the role of AXOS fin IBS 
should be addressed fin the future studfies. 
 
Randomfised studfies on the efficacy of low FODMAP dfiet for IBS symptoms 
 
There are at least two publfished meta-analyses of randomfised controled trfials fin IBS wfith 
the ffirst befing publfished by Khan et al. (2015) and the second by Marsh et al. (2016). 
Khan’s meta-analysfis fincluded four randomfised studfies and fit concluded that a low 
FODMAP dfiet fis a relatfively sfimple and safe treatment to reduce the symptoms of IBS. On 
the basfis of thefir meta-analysfis, the authors added that the number needed to treat (NNT) 
was 2.2 wfith respect to the overal fimprovement of symptoms (95 % conffidence finterval: 
1.89–2.51). An NNT value of 2.2 can be consfidered as hfighly efectfive when compared to 
other chronfic pafin condfitfions such as neuropathfic pafin fin adults; typfical NNTs for the 
drugs of chofice fin neuropathfic pafin vary fin a range 3.6-7.7 (Ffinnerup et al. 2015).  
 
Marsh et al. (2016) analysed sfix randomfised studfies and sfixteen observatfional 
finterventfions. In the meta-analysfis that concccentrated on the randomfised trfials, IBS-SSS 
was reduced (OR 0.44, 95 % CI 0.25-0.76) and the qualfity of lfife was fimproved (OR 1.84, 
95 % CI 1.12-3.03). Furthermore, adherence to a low FODMAP dfiet was found to 
sfignfifficantly reduce symptom severfity for abdomfinal pafin (OR 1.81, 95 % CI 1.13-2.88;), 
bloatfing (OR 1.75, 95 % CI 1.07-2.87) and overal symptoms (OR 1.81, 95 % CI 1.11-2.95). 
In addfitfion, the sfixteen non-randomfised studfies lastfing 1-35 months found very sfimfilar 
perhaps even more, benefficfial efects. Sfince the appearance of the meta-analysfis of Marsh 
et al. (2016), at least ffive randomfised studfies have been publfished on a holfistfic low 
FODMAP dfiet (Harvfie et al. 2017, Vfincenzfi et al. 2017, Esweran et al. 2017, Staudacher et 
al. 2017b, Pedersen et al. 2017). In al of these new studfies, a low FODMAP dfiet reduced 
overal symptoms vs. control treatment. It fis finterestfing that a low FODMAP dfiet has been 
also applfied fin IBD, and a recent systematfic revfiew showed that a low FODMAP dfiet could 
reduce IBS lfike symptoms (abdomfinal pafin, bloatfing, fatfigue and dfiarrhoea) also fin IBD 
whfich fis an overt finflammatory condfitfion (Zhan et al. 2018). The currently publfished 















Table 3. Features of the publfished randomfised controled studfies on holfistfic low FODMAP 
dfiet among adults wfith IBS. 
 
Study (Year), Country Duratfion  Randomfised (n) Mafin efect on symptom control 
Low FODMAP vs. Other kfind of IBS Dfiet* 
 
Eswaran et al. (2016), USA  4 weeks 92 Low FODMAP dfiet resulted fin a hfigher 
proportfion of abdomfinal pafin responders 
(51% vs. 23%, P=0.008); no dfiference fin 
adequate relfief 
Böhn et al. (2015), Sweden 4 weeks 75 No dfiference fin IBS-SSS 
Staudacher et al. (2012), 
Unfited Kfingdom 
4 weeks 41 More patfients fin the low FODMAP group 
reported adequate control of symptoms 
compared wfith controls (68% vs. 23%; P 
= 0.005). 
    
Low FODMAP vs. Medfium/Hfigh FODMAP Dfiets 
 
Staudacher et al. (2017), 
Unfited Kfingdom 
4 weeks 102 IBS-SSS was lower for patfients on the 
low FODMAP dfiet than on the sham** 
dfiet (173 vs. 224; P = .001) 
Harvfie et al. (2017), New 
Zealand 
3 months 50 IBS-SSS was reduced more fin the low 
FODMAP group compared wfith the hfigh 
FODMAP group (-146.8 pofints vs. -43.2 
pofints from baselfine; P<0.0002) 
McIntosh et al. (2016), 
Canada 
3 weeks 40 IBS-SSS was reduced more fin the low 
FODMAP group compared wfith the hfigh 
FODMAP group (72% vs. 21%; P<0.009) 
Halmos et al. (2014), 
Australfia 
3 weeks 30 Sum of IBS symptoms on VAS was 
reduced more fin the low FODMAP group 
compared wfith the hfigh FODMAP group 
(44.9 mm vs. 22.8 mm; p<0.001) 
Pedersen et al. (2014), 
Denmark 
6 weeks 82 IBS-SSS was reduced more fin the low 
FODMAP group compared wfith the hfigh 
FODMAP group (-133 pofints vs. -34 
pofints from baselfine; P<0.01) 
Ong et al. (2010), Australfia 11 days 15 Sum of sfix IBS symptoms on scale 0-
4/each was hfigher on the hfigh FODMAP 
dfiet than when consumfing the low 
FODMAP dfiet (medfian 6 vs. 2; P = 
0.002) 
*) IBS dfiet of Natfional Instfitute of Clfinfical Excelence or Swedfish tradfitfional IBS dfiet; **) In the sham 
dfiet group, partficfipants were gfiven false finformatfion on the content of FODMAPs fin food fitems; thfis can be 
consfidered as a placebo group 
 
 
Despfite the fact that many randomfised studfies have shown efficacy fin IBS, some 
methodologfical chalenges are finevfitable fin dfietary finterventfions and these have led some 
researchers to crfitficfise the current evfidence base for the beneffits of a low FODMAP dfiet fin 
IBS (Kroogsgaard et al. 2017). In thefir systematfic revfiew of nfine randomfised studfies, these 
authors pofinted out that low FODMAP studfies tended to have a short duratfion, fi.e. usualy 





control dfiets were often habfitual dfiets or commonly consumed natfional average dfiets. 
When the control group fis not adequately actfive, fi.e. there fis no change towards a 
theoretficaly healthfier dfiet, the placebo efect wfil favor the low FODMAP group rather 
than usual or natfional average dfiet. Italfian researchers publfished another crfitfical paper 
(Catassfi et al. 2017). They argued that the crfiterfia for finclusfion of foods fin the FODMAP 
lfist are not wel deffined. They also added that the drastfic reductfion of FODMAP fintake 
could possfibly also exert negatfive physfiologfical consequences on the fintestfinal mficrobfiota 
and colonocyte metabolfism and even on the nutrfitfional status of subjects wfith IBS.  
 
Kroogsgaard et al. (2017) dfid not finclude fin thefir systematfic revfiew the tfightly double-
blfinded controled studfies on findfivfidual FODMAPs; fin other words, Kroogsgaar’s revfiew 
pafints only a partfial pficture of the evfidence base. The folowfing wel-controled studfies 
were excluded from Kroogsgaard’s revfiew and therefore deserve attentfion. Shepherd et al. 
(2006) conducted a double-blfind cross-over study on 25 IBS patfients. When comparfing a 
fructose drfink, a fructan drfink or thefir combfinatfion fin a drfink to placebo (glucose) drfink, 
70% of patfients recefivfing fructose, 77% recefivfing fructans, and 79% recefivfing the 
combfinatfion drfink reported that thefir symptoms were not adequately controled, 
compared wfith 14% recefivfing glucose. Thfis endpofint “not adequately controled” was thefir 
answer to the questfion, “Were your symptoms adequately controled fin thfis phase?”. In a 
Norwegfian study, IBS patfients reported clear worsenfing of symptoms when consumfing a 
FOS drfink for ten days whfile placebo drfink (maltodextrfin) dfid not cause any worsenfing of 
symptoms (Hustoft et al. 2016). In both the Hustoft and Shepherd finvestfigatfions, the 
background dfiet was a low-FODMAP dfiet. In addfitfion, fin a thfird placebo-controled study, 
FOS caused a worsenfing of functfional GI symptoms whfile nefither gluten nor placebo 
evoked any deterfioratfion fin people wfith a subjectfive gluten sensfitfivfity (Skodje et al. 2018). 
 
Staudacher et al. (2017 b) attempted to tackle the fissue of a placebo efect. They were the 
ffirst to report the results of a sham dfiet fincludfing 104 partficfipants wfith IBS. Thfis fis the 
only study that sought to blfind the low FODMAP dfiet advfice gfiven to the patfients. Half of 
the partficfipants were randomfised to a low FODMAP dfiet and the other half to a sham dfiet. 
The partficfipants who were randomfised to the sham dfiet recefived an fidentfical amount of 
attentfion as those on low FODMAP dfiet, but also recefived wrong advfice on the low 
FODMAP dfiet. For example, the food lfist of the sham dfiet stated that rfice and oats would 
not be sufitable chofices (even although they actualy are low fin FODMAPs) whereas wheat 
and barley would be sufitable (even although they are hfigh fin FODMAPs). The partficfipants 
were aware of the desfign of the study before enterfing the study; thfis fis fimportant fin studfies 
wfith a sham desfign fin order to comply wfith the ethfical norms of research. The results of 
thfis study showed that a low FODMAP dfiet was more efectfive fin reducfing GI symptoms 
than a sham dfiet. The total mean IBS-SSS was sfignfifficantly lower for patfients on a low 
FODMAP dfiet. One potentfial weakness of thfis partficular desfign fis that the blfindfing may 
have been lost durfing the treatment because fin the era of an open finternet, partficfipants on 
the sham dfiets may have sought out finformatfion on an authentfic low FODMAP dfiet, and 
thereby become aware of the true nature of thefir dfiet. Thfis hfighlfights the real-world 






Ffinaly, a recent fintragastrfic FODMAP finfusfion test demonstrated that a fructan finfusfion 
provoked the prompt generatfion of GI symptoms fin IBS and elevated the fintragastrfic 
pressure when compared to  healthy subjects (Masey et al. 2017). Thfis fis an fintrfigufing 
ffindfing as the symptoms could not be related to colonfic fermentatfion because the 
symptoms appeared already wfithfin 30-60 mfinutes after finfusfion.  
 
To summarfise, fit seems that FODMAPs, or at least fructans such as FOS, cause symptom 
aggravatfion fin IBS patfients even fin double-blfind condfitfions.   
 
Efects on mficrobfiota 
 
It has become fincreasfingly evfident that there needs to be a holfistfic understandfing of the 
role of FODMAP on an findfivfidual’s health. FODMAP researchers fin Kfing’s Colege, 
London and Monash Unfiversfity, who are pfioneers of the FODMAP concept, recommend 
that more research should be conducted fin thfis area (Staudacher and Whelan 2017, Hfil et 
al. 2017). The mafin reason for the fincreased cautfion fis the potentfial negatfive efect of a low 
FODMAP dfiet on fintestfinal mficrobfiota. Several clfinfical studfies have shown that a low 
FODMAP dfiet tends to lead to a reductfion fin the amount of benefficfial fintestfinal bacterfia, 
fi.e. the relatfive of absolute abundance of bfiffidobacterfia, lactobacfilfi, Faecalfibacterfium 
prausnfitzfifi and Akkermansfia mucfinfiphfila fis clafimed to be lower durfing the low FODMAP 
dfiet (Staudacher et al. 2012, Chumpfitazfi et al. 2014, Halmos et al. 2015, Hustoft et al. 
2016, McIntosh et al. 2016, Staudacher et al. 2017b, Bennett et al. 2018) Furthermore, the 
dfiversfity of the mficrobfiota mfight also be reduced (Bennett et al. 2018). The most 
consfistent ffindfing fin these studfies has been the decreased abundance of fintestfinal 
bfiffidobacterfia. These dysbfiotfic changes mfight exert an overal negatfive efect on health, 
especfialy because people wfith IBS tend to have a decreased level of these bacterfia even 
before startfing the FODMAP dfiet (Lfiu et al. 2017). Due to the above mentfioned reasons, a 
low FODMAP dfiet fis not fintended for lfife but for a short duratfion of 1-3 months after 
whfich a slow re-fintroductfion of FODMAPs should be pursued wfithfin the boundarfies of 
findfivfidual tolerance (Tuck and Barrett 2017, Harvfie et al. 2017). One ffinal note, the role of 
the observed changes fin mficrobfiota for overal health fis stfil speculatfive because there are 
no long-term prospectfive studfies finvestfigatfing a low FODMAP dfiet. The efect of low 
FODMAP dfiet on long-term health can be only tested fin long-term clfinfical trfials; fit fis too 
early to draw any deffinfitfive conclusfions on the role of mficrobfial changes. 
 
Efects fin fimmune system and permeabfilfity 
 
In thfis context, fit fis finterestfing that exclusfive enteral nutrfitfion, whfich fis often low fin 
FODMAPs, causes dramatfic negatfive changes fin the fintestfinal mficrobfiota but also finduces 
remfissfion fin patfients suferfing from dfifficult-to-treat Crohn’s dfisease (MacLelan et al. 
2017). Conventfionaly, dfietary studfies fin IBS have measured mafinly symptoms and 
occasfionaly hydrogen/methane excretfion and/or mficrobfial changes. Recently, studfies 
have started to emerge suggestfing that a low FODMAP dfiet could reduce low grade 
finflammatfion or fimmune actfivatfion fin people wfith IBS (McIntosh et al. 2016, Hustoft et al. 
2017). McIntosh et al. found that the fintroductfion of a low FODMAP dfiet reduced the 





that a low FODMAP dfiet reduced levels of two pro-finflammatory markers, IL-6 and IL-8, 
fin blood. The former ffindfing suggested that mast cel finduced actfivatfion of the fimmune 
system was reduced durfing the low FODMAP dfiet, and the latter study suggested that a 
low FODMAP dfiet may have systemfic antfi-finflammatory propertfies fin people wfith IBS. 
These are potentfialy fimportant ffindfings because pro-finflammatory markers such as IL-6 
are assocfiated wfith an fincreased rfisk of coronary heart dfisease (IL6R Genetfics Consortfium 
Emergfing Rfisk Factors Colaboratfion 2016).  
 
A Danfish randomfised study was performed among IBD patfients fin remfissfion or wfith mfild 
symptoms (Pedersen et al. 2017). A statfistficaly sfignfifficant reductfion fin the Sfimple Clfinfical 
Colfitfis Index was observed for the low FODMAP dfiet fin patfients wfith ulceratfive colfitfis 
(UC) but not fin Crohn’s dfisease, IBS lfike symptoms were also reduced by low FODMAP 
dfiet fin both UC and Crohn’s dfisease patfients. However, despfite these encouragfing ffindfings 
on the beneffits of a low FODMAP dfiet, many more studfies wfil be needed to clarfify the 
antfi-finflammatory potentfial of a low FODMAP dfiet fin IBS. Whatever fis the case, one can 
argue that a low FODMAP dfiet has potentfialy benefficfial antfi-finflammatory efects fin IBS 
but the downsfide fis the possfibfilfity of dysbfiotfic changes fin gut mficrobfiota. It needs to be 
clarfiffied whfich of these phenomena fis more fimportant for overal health. 
 
To summarfise, a low FODMAP dfiet fis efectfive fin reducfing the symptoms of IBS fin most 
patfients. Its long-term efects are stfil unknown and therefore long-term randomfised 
studfies are needed; currently strfict adherence to a low FODMAP dfiet fis recommended for 
some months only. A low FODMAP dfiet reduces the abundance of benefficfial bacterfia fin 
gut but fin contrast, fit may also reduce elevated fimmune actfivatfion fin IBS. The FODMAP 
concept does not cover al rapfidly fermentable carbohydrates such as AXOS whfich also 
mfight cause symptoms fin IBS patfients.  
2.4.2  Grafins contafinfing gluten and amylase trypsfin finhfibfitors  
 
Gluten-contafinfing grafins are often suspected to be behfind IBS lfike GI symptoms. In short, 
the lfiterature strongly suggests that fin the most of the cases of subjectfive NCGS or NCWS, 
gluten or ATIs per se are not the “culprfit” behfind the symptom aggravatfion experfienced 
when consumfing gluten-contafinfing grafins such as wheat, rye or barley. It fis clafimed that 
some other compound, not the gluten fin grafins, must be behfind the symptoms. 
 
In an finterestfing study, Uhde et al. (2016) showed that a sfix-month gluten free dfiet 
fimproved symptom control and reduced several finflammatory/permeabfilfity markers fi.e. 
IL-8, LBP, flagelfin and FABP2. However, because there was no proper control group, fit fis 
not known fif the observed efect was due to gluten wfithdrawal, to a reduced fintake of 
FODMAPs, or ATIs, or to some unknown factor. One randomfised study showed that 
fintestfinal permeabfilfity fin the smal fintestfine but not fin the large bowel was decreased fin 
IBS-D patfients consumfing a gluten free dfiet and fin paralel, stool consfistency was 
fimproved (Vazquez-Roque et al. 2013). Thfis fis the only exfistfing randomfised study that has 





controled study had shown that people wfith IBS-D gafined beneffits from a gluten free dfiet 
(Wanschafe et al. 2007).  
 
Avofidance of wheat, rye and barley leads to a decreased fintake not only of gluten but also 
FODMAPs and ATIs. Table 4 filustrates the amount of gluten, FODMAPs and ATIs fin 
dfiferent grafin products. As the table demonstrates, when people are placed on a gluten 
free dfiet, fit fis lfikely that thefir fintake of FODMAPs and ATIs wfil be reduced fin addfitfion to 
the decrease fin thefir gluten fintake. Currently, there are no dfirect comparfison studfies 
between FODMAPs and gluten/ATIs, that would reveal whether fit fis FODMAPs or gluten 
or ATIs that are responsfible for the fincrease of GI symptoms fin NCWS and/or fin IBS. 
 
Table 4. Comparfison of the gluten, fructans and ATI contents of some grafin products. Data 
fis compfiled from the folowfing sources: Bfiesfiekfierskfi et al. 2011 a, Frølfich et al. 2013 and 
Zevalos et al. 2016.   
  
 Gluten FODMAPs  
(Fructans mafinly) 
ATIs 
Wheat Hfigh Hfigh Hfigh 
Rye  Hfigh Hfigh Hfigh 
Barley Hfigh Hfigh Hfigh 
Oats Non-exfistent Low Low 
Rfice Non-exfistent Low Low 
 
An finnovatfive confocal endomficroscopy study showed that fin 13 out of a total of 36 IBS 
patfients wfith a suspected unspecfiffied food fintolerance, exposure to wheat antfigen mfixture 
caused fimmedfiate breaks, fincreased fintervfilous spaces, and fincreases fin the numbers of 
fintraepfithelfial lymphocytes fin the fintestfinal mucosa but none of the subjects reacted to 
wheat fin the control group (Frfitscher-Ravens et al. 2014). Patfients wfith coelfiac dfisease and 
food alergfies were excluded. These changes were assocfiated wfith patfient responses to 
exclusfion dfiets fin the open folow-up study. These data suggest that not al symptoms are 
related to colonfic fermentatfion but finstead the food fitself can exert fimmedfiate local efects 
fin gut. 
 
Robert Spfiler and co-workers have conducted a serfies of finterestfing functfional MRI 
studfies fin humans. One of these studfies compared the efect of wheat and rfice on GI 
motfilfity fin healthy subjects (Marcfianfi et al. 2013). They found out that whole wheat bread 
forms a homogeneous bolus fin the stomach, whfich finhfibfits gastrfic sfievfing and hence 
emptfies slower than the equficalorfic rfice meal. In addfitfion, the wheat meal remafined fin fits 
postprandfial form fin the smal fintestfine and decreased the smal fintestfine water content. 
In another MRI study, the same research group has shown that people wfith IBS-D or IBS-
M seem to have a constrficted smal bowel when compared to healthy subjects (Lam et al. 
2017). These data can be finterpreted that wheat has negatfive dfigestfive efects unrelated to 
colonfic fermentatfion, fin especfialy fin the upper GI tract. However, the bfiochemfical 







Many grafins contafin relatfively hfigh amounts of phytfic acfid (Gupta et al. 2015) but no 
studfies exfist on the role of phytfic acfid fin functfional gastrofintestfinal dfisorders such as 
NCGS/NCWS or IBS. In theory, phytfic acfid mfight evoke symptoms by bfindfing mfinerals 
and thus exposfing the colon to an fincreased level of unabsorbed mfinerals such calcfium and 
magnesfium, whfich fin turn mfight cause firrfitatfion of epfithelfium. There fis evfidence from 
anfimal experfiments that fincreasfing amounts of phytfic acfids fin the dfiet may finduce 
benefficfial efects on long-term gut health; the productfion of short-chafin fatty acfids was 
fincreased and a reductfion fin systemfic finflammatfion was observed when mfice were fed 
wfith a dfiet hfigh fin phytfic acfid (Okazakfi and Katayama 2014).  
 
Grafins also contafin lectfins whfich serve as defense mechanfisms agafinst other plants and 
fungfi (De Punder and Prufimboom 2014). No clfinfical studfies exfist on the role of lectfins fin 
NCGS/NCWS or IBS but prelfimfinary anfimal and fin vfitro studfies suggest that wheat 
agglutfinfin, lectfin fin wheat, may cause finflammatfion or provoke hfistamfine release (De 
Punder and Prufimboom 2014). 
 
To conclude, gluten free grafins also have lower FODMAP and ATI concentratfions. It fis not 
clear fif fit fis the combfinatfion of both FODMAPs and gluten/ATI that fis requfired to trfigger 
symptoms fin IBS or fif one component fis more domfinant fin symptom generatfion. 
Furthermore, the role of AXOS fin grafins fis not wel understood and has been poorly 
studfied. MRI and confocal endomficroscopy studfies suggest that some of the symptoms can 
appear qufickly, wfithfin mfinutes or a couple of hours, from consumptfion of the culprfit food, 
and therefore cannot be dfirectly related to colonfic processes such as fermentatfion.  
2.4.3 Dafiry  
 
Lactose fis a dfisaccharfide present fin mfilk consfistfing of glucose and galactose. Lactose 
fintolerance fis a very common condfitfion caused by lactase defficfiency. The global prevalence 
estfimate of lactose fintolerance fis 68%, rangfing from 28% fin Europe to 70% fin the Mfiddle 
East; the Ffinnfish prevalence fis 19% (Storhaug et al. 2017). Lactase defficfiency results fin 
fincreased lactose levels enterfing the colon where bacterfia ferment thfis sugar. Increased 
fermentatfive processes may cause gas problems and symptom aggravatfion especfialy fin the 
presence of functfional gastrofintestfinal dfisorders (Gfibson and Shepherd 2010). Avofidance 
of lactose fis not necessary durfing a low FODMAP dfiet fif the patfient does not have lactase 
defficfiency.  
 
In addfitfion to lactose, other components, such as protefins or fat globules, present fin dafiry 
products, or fintroduced durfing thefir processfing could cause symptoms fin IBS, at least fin 
theory. Paajanen et al. (2003) and Korpela et al. (2005) performed a serfies of smal scale 
studfies fin patfients wfith apparent mfilk fintolerance. Patfients were not pre-screened for IBS 
before enterfing the studfies and thus fit fis not known fif patfients had IBS or not. Paajanen et 
al. (2003) undertook ffive-day chalenge tests and clafimed that patfients tolerated 
homogenfised and unhomogenfised mfilk sfimfilarly; no dfiference fin tolerance could be 
observed fin any of three tests performed fin two separate studfies. In a 4-day randomfised 





efects on symptoms fin people wfith lactose fintolerance when homogenfised and non-
homogenfised mfilk were compared. 
 
There are some smal experfiments that suggest that mfilk protefins together wfith lactose or 
other mfilk components can trfigger symptoms. However, the lfimfitatfions of these studfies 
must be acknowledged; they are smal, typficaly have a very short duratfion (acute 
experfimental studfies) and have been performed fin subsets of functfional gastrofintestfinal 
dfisorders. A dafiry free dfiet has never been adequately tested fin IBS fin a randomfised 
controled study. A large Italfian study reported that 22.4% of IBS patfients who were 
subjectfively fintolerant to wheat also reacted negatfively (experfienced GI symptoms) to mfilk 
protefin (casefin and whey) pfils fin a blfinded two-week test (Caroccfio et al. 2012). Very 
much agafinst expectatfions, the authors reported that none of the 904 patfients reacted to 
placebo (xylose). It must be noted that thfis study was not desfigned to test mfilk protefin 
fintolerance but finstead concentrated on wheat fintolerance.  
 
In smal acute studfies conducted fin patfients wfith subjectfive-based fintolerance to cows’ 
mfilk, the consumptfion of mfilk has produced fincreased fimmune actfivatfion fin the fintestfinal 
epfithelfium and/or symptom aggravatfion wfith no such efect befing detected fin healthy 
controls (Bengtsson et al. 1997, Pelto et al. 1998, Krfistjánsson et al. 2007). Some authors 
have also speculated that the currently common varfiant of mfilk casefin, so caled A1-casefin, 
would be more pro-finflammatory than the more ancfient A2-casefin predomfinant mfilk. 
There are two randomfised studfies that have examfined thfis topfic; nefither of them found 
dfiferences fin tolerance of the two mfilk products fin subjects wfith subjectfive cow mfilk 
fintolerance (Ho et al. 2014, Jfianqfin et al. 2015). 
 
In a Ffinnfish study, patfients wfith subjectfive feelfings of fimproved tolerance of mfilk when 
abroad were studfied (Paajanen et al. 2004). As there was no ratfional explanatfion for the 
reports of fimproved mfilk tolerance when abroad, the authors speculated that people wfith 
thfis kfind of experfience mfight be especfialy sensfitfive to findfigestfible carbohydrates such as 
polyols or fructans. By performfing an acute meal test, the authors concluded that xylfitol 
and rye bread, whfich are hfigh fin fructans, cause more GI symptoms fin people wfith 
experfiences of fimproved tolerance of mfilk when abroad fin comparfison to those who 
experfience no dfiferences firrespectfive of where the mfilk fis consumed. As such, thfis study 
can be vfiewed as one of the ffirst studfies pavfing the way to the FODMAP concept. Another 
Ffinnfish randomfised acute meal study reported aggravatfion of GI symptoms fin people wfith 
subjectfive cow mfilk fintolerance vs. healthy controls when consumfing fructo-
olfigosaccharfides or lactulose (not lactose) (Teurfi et al. 1999).  
 
In the prevfiously mentfioned confocal endomficroscopy study (Frfitscher-Ravens et al. 2014) 
fin 9 out of 26 IBS patfients wfith suspected food fintolerance, exposure to a mfilk antfigen 
mfixture caused fimmedfiate breaks, fincreased fintervfilous spaces, and fincreased 
fintraepfithelfial lymphocytes fin the fintestfinal mucosa whfile fit caused no such efects fin any 
of the controls (Frfitscher-Ravens et al. 2014). When foods that had caused the epfithelfial 
breaks were excluded from the dfiet, the gastrofintestfinal symptoms were reduced fin the 






In summary, these data suggest that mfilk or dafiry per se could cause a worsenfing of GI 
symptoms and/or actfivatfion of fimmune system at the level of gut epfithelfium fin a smal 
subset of people wfith functfional gastrofintestfinal dfisorders. The studfies have 
methodologfical weaknesses and robust studfies are lackfing. Furthermore, although some 
people may consfider that dafiry products are the sole trfiggers of thefir symptoms, fin realfity, 
fit fis the total amount of FODMAPs fin the dfiet that fis truly responsfible for thefir symptoms.  
 
2.4.4 Other dfietary approaches 
 
In a Swedfish randomfised study, Böhn et al. (2015) compared a conventfional IBS dfiet to a 
low FODMAP dfiet but detected no dfiferences fin symptoms. It must be noted that the 
tradfitfional IBS dfiet fincorporated a partfial FODMAP restrfictfion because certafin foods such 
as onfions, legumes and chewfing gum were to be avofided. In addfitfion, soda, cofee, fatty 
foods and spficy foods were restrficted and consumptfion of ffibre was encouraged fin the 
tradfitfional dfiet. It fis noteworthy that thfis was the ffirst study (Böhn et al. 2015) to dfirectly 
compare a tradfitfional IBS dfiet to any other dfiet (control) fin a randomfised settfing. The fact 
that a tradfitfional IBS dfiet had never before been tested fin a randomfised trfial underlfines 
that fact that progress fin dfietary management has truly taken of only durfing the past 
decade or so.  
 
A low carbohydrate dfiet reduced also GI symptoms fin a non-controled finterventfion; al 
patfients had IBS-D (Austfin et al. 2009) but no randomfized studfies exfist finvestfigatfing a low 
carbohydrate dfiet. A recent study compared a specfiffic carbohydrate dfiet, commonly known 
as the SCD dfiet for IBD, to a low FODMAP dfiet fin subjects wfith IBS; the low FODMAP dfiet 
resulted fin less bloatfing than the SCD.  
 
Ffinaly, a wel-controled study was performed fin patfients wfith IgG antfibodfies agafinst 
several food fitems (Atkfinson et al. 2004). An findfivfidualy tafilored exclusfion dfiet resulted 
fin a 10% greater reductfion fin the symptom score than the sham dfiet. The global ratfing also 
sfignfifficantly fimproved fin the exclusfion dfiet group as a whole (p=0.048, NNT=9) but not fin 
the sham dfiet group. Unfortunately, detafils and formulatfion of the sham dfiet were not 
provfided. The authors concluded “Food elfimfinatfion based on IgG antfibodfies may be 
efectfive fin reducfing IBS symptoms and fis worthy of further bfiomedfical research”. 
Sfimfilarly, a recent study also found out that an findfivfidualfised dfiet gufided by leucocyte 
actfivatfion tests reduced symptoms compared to a sham-gufided dfiet (Alfi et al. 2017). 
Overal, there fis a paucfity of randomfised studfies regardfing dfietary patterns other than a 
low FODMAP dfiet.  
2.4.5 Ffibre 
 
People wfith IBS have commonly gastrofintestfinal dysmotfilfity, and more than half of the IBS 





has been a long tradfitfion to recommend an fincreased amount of dfietary ffibre fin IBS 
(Mannfing et al. 1979). However, recent systematfic revfiews and crfitfical revfiews of 
randomfised studfies have hfighlfighted the fimportance of choosfing the rfight type of ffibre 
both fin people wfith IBS and fin healthy controls; fi.e. fit fis not only the total ffibre fintake that 
fis fimportant but also about the qualfity of ffibre (Nagarajan et al. 2015, Chrfistodoulfides et al. 
2016, McRorfie et al.2016).  
 
One common recommendatfion across the medfical lfiterature fis to recommend soluble ffibre 
fin IBS (Moayyedfi et al. 2014, Nagarajan et al. 2015). However, these data are 
overwhelmfingly based on studfies on psylfium (fisphagula husk, plantago ovata) (Moayyedfi 
et al. 2014, Nagarajan et al. 2015). FOS, finulfin and GOS are also soluble ffibres but fin 
addfitfion, they are hfigh fin FODMAPs and prone to cause worsenfing of IBS symptoms as 
shown by Hustoft et al. (2016), Shepherd et al. (2008) and Major et al. (2017). 
Furthermore, these soluble ffibre preparatfions do not even relfieve constfipatfion, at least 
accordfing to recent systematfic revfiews of randomfised studfies (Chrfistodoulfides et al. 2016, 
McRorfie et al.2016). 
 
The advantage of fructans and GOS fis that they are prebfiotfic (Macfarlane et al. 2008); 
therefore they have some potentfial to correct the dysbfiotfic changes found fin the mficrobfiota 
of IBS patfients. However, fit fis unclear how thfis would be possfible wfithout trfiggerfing of IBS 
symptoms. In one randomfised study, a smal dose of GOS actualy fimproved most of the 
IBS symptoms; GOS also stfimulated the amount of bfiffidobacterfia (Sfilk et al. 2009). It 
remafins to be seen fif a cautfious, fincremental, fincrease fin the consumptfion of fructans/GOS 
lastfing many weeks could possfibly alow consumptfion of these prebfiotfic substances 
wfithout causfing an aggravatfion of IBS symptoms. Currently there fis a dfiscrepancy between 
the study ffindfings of Sfilk et al. (2009) vs. Hustoft et al. (2016), Shepherd et al. (2008) and 
Major et al. (2017) as mentfioned above. Indeed, Hertzler and Savafiano (1997) have shown 
that the mficrobfiota seems to adapt to an fincreased lactose fintake by reducfing the 
fermentatfion rate. At the same tfime, lactose tolerance was sfignfifficantly fincreased fin people 
wfith lactose fintolerance. In healthy subjects, GOS caused mficrobfial adaptatfion and 
reduced flatulence after weeks of admfinfistratfion when compared to the ffirst day of 
admfinfistratfion (Mego et al. 2017). 
 
More than a decade ago, fit was a common practfise to recommend wheat bran fin IBS. 
Unfortunately, wheat bran fis hfigh fin FODMAPs, fi.e. fructans, and therefore fits efects on 
IBS are unfimpressfive (Nagarajan et al. 2015); fin many trfials, wheat bran caused efither 
worsenfing of bloatfing and/or abdomfinal pafin and/or flatulence (Hotz et al. 1994, Snook 
and Shepherd 1994, Hebden et al. 2002). Rye bran has not been studfied fin IBS, but fit must 
be acknowledged that sfimfilar to wheat bran, rye bran fis also hfigh fin FODMAPs. 
 
Psyllfium fis a poorly-fermentable, soluble ffibre that fis benefficfial fin relfievfing constfipatfion 
both fin healthy subjects and fin people wfith IBS (Nagarajan et al. 2015, Chrfistodoulfides et 
al. 2016, McRorfie et al.2016). It also seems to fimprove overal symptom control fin IBS 
(Ford et al. 2014, Nagarajan et al. 2015) but fit fis unknown fif other mechanfisms apart from 
fimproved bowel habfits play any role fin overal symptom reductfion. Psylfium  fis 






There fis some evfidence that lfinseeds mfight be helpful; but overal, the evfidence fis stfil 
unconvfincfing (Nagarajan et al. 2015). Only two studfies have shown that ground lfinseed 
mfight fimprove some of the symptoms of IBS (Cockerel et al. 2012, Tarpfila et al. 2003). 
Partfialy hydrolysed guar gum fis another type of soluble ffibre, whfich may help fin IBS; 
prelfimfinary studfies revealed that fit could alevfiate symptoms of IBS albefit methodologfical 
weaknesses of the studfies complficate the finterpretatfion of the data (Parfisfi et al. 2002, Nfiv 
et al. 2016). Oat bran, whfich contafins soluble ffibre, so far has not been studfied fin IBS. 
 
In conclusfion, psylfium, partfialy hydrolysed guar gum and lfinseeds have been shown to 
reduce the symptoms assocfiated wfith IBS. These ffibres should be used as ffirst-lfine 
treatments fin IBS. Data on other soluble ffibre supplements FOS, GOS, finulfin and wheat 
bran have been mostly dfiscouragfing. Therefore, health care professfionals should stop 
promotfing the consumptfion of soluble ffibre wfithout precfisely namfing the actual ffibre 
supplement. There fis a need for more robust and finnovatfive ffibre studfies fin IBS, especfialy 
as add-on treatments to supplement a low FODMAP dfiet. 
2.4.6  Drfinks 
 
Bfinge drfinkfing fis an firrfitant of the gut mucosa; fit leads to a pro-finflammatory status 
characterfised by fincreased levels of endotoxfin fin blood (Bala et al. 2014), and cautfion fin 
the consumptfion of alcoholfic beverages fis recommended fin IBS (McKenzfie et al. 2012). 
Alcohol consumptfion has been assocfiated wfith a worsenfing of GI symptoms among IBS 
and dyspepsfia patfients (Hadler et al. 2006, Redfing et al. 2016). However, no clfinfical 
studfies have been performed fin IBS. 
 
Carbonated drfinks are often percefived as trfiggers of IBS symptoms (Lfigaarden et al. 2012), 
but no clfinfical research has been performed fin IBS. Cofee fis low fin FODMAPs but fin some 
people, fit can fincrease rectosfigmofid motor actfivfity wfithfin 4 mfin after fingestfion. Its efects 
on the colon are found to be comparable to those of a 1000 kcal meal (Boekema et al. 1999) 
and therefore mfight not be sufitable fin IBS-D. No randomfised controled studfies have been 
performed wfith tea or cofee fin IBS. However, very large doses (2 L/day) of tea mfight cause 
constfipatfion fin healthy subjects (Højgaard 1981) and cofee can worsen upper GI 
symptoms (Brazer et al. 1995).  
2.4.7 Spfices and herbal products 
 
Chfilfi spfice fis low fin FODMAPs but many patfients assocfiate thefir symptoms wfith chfilfi or 
other hot spfices (Sfimren et al. 2001, Esmafilzadeh et al. 2013). In an acute meal study, chfilfi 
fincreased abdomfinal pafin and burnfing sensatfions fin patfients wfith IBS-D (Gonlachanvfit et 
al. 2009). However, a clfinfical sfix-week study suggested that fif consumed for long enough, 
then chfilfi could actualy decrease the symptoms of IBS (Bortolottfi and Porta 2001). 





prematurely fin the group recefivfing chfilfi pfils due to abdomfinal pafin. Interestfingly, IBS 
patfients seem to undergo an upregulatfion of the so-caled capsaficfin receptor fi.e. TRPV1, fin 
thefir colonfic mucosa (Akbar et al. 2008); thfis suggests that IBS patfients mfight be more 
sensfitfive than healthy controls to the capsaficfin present fin chfil. Turmerfic, or fits actfive 
fingredfient curcumfin, has only been studfied fin IBS fin mfixtures efither wfith fennel ofil or 
wfith curry and pomegranate (Lauche et al. 2016). In the former study but not fin the latter, 
turmerfic showed some efficacy over placebo. Aloe vera has been tested fin three IBS studfies 
but only fin one dfid fit demonstrate better efficacy vs. placebo (Davfis et al. 2006, Hutchfings 
et al. 2011, Størsrudet al. 2015).  
 
The efficacy of enterfic-coated peppermfint ofil capsules has been demonstrated fin multfiple 
randomfised studfies (Khanna et al. 2014). Its use fis recommended fin IBS by the Amerfican 
Colege of Gastroenterology (Ford et al. 2014). Peppermfint ofil possesses antfi-finflammatory 
and spasmolytfic efects (Harrfis 2016) and fit seems to alevfiate abdomfinal pafin and cramps. 
However, fit also seems to fincrease the occurrence of heartburn. A herbal preparatfion, STW 
5 (contafinfing fiberfis, peppermfint, chamomfile) was able to reduce IBS symptoms fin one 
randomfised study (Madfisch et al. 2004); fits efficacy has been wel documented fin upper GI 
symptoms (Melzer et al. 2004).  
2.5 Enzymes 
 
Many commonly avafilable dfigestfive enzymes are classfiffied as nutrfitfional supplements fin 
Ffinland, even fif some exceptfions exfist such as a preparatfion contafinfing pancreatfic 
enzymes (Creon®, Abbott Laboratorfies GmbH, Neustadt, German) whfich fis avafilable only 
on prescrfiptfion. Some enzyme supplements may theoretficaly reduce efither the pro-
finflammatory potentfial of wheat protefins or the fructan/GOS content by actfing as 
proteases fi.e. they break down protefins finto peptfides and amfino acfids. Invertase and α-
galactosfidase hydrolyse fructans/GOS finto monosaccharfides. A recent randomfised study 
showed that the α-galactosfidase enzyme could reduce some IBS symptoms related to olfigo-
galactosaccharfides (GOS) (Tuck et al. 2017) but an earlfier study findficated that α-
galactosfidase dfid not confer any true beneffit as a sole treatment optfion when background 
dfiet was not controled (Hfilfilä et al. 2016). The data from these trfials suggest that α-
galactosfidase may reduce symptoms caused by foods hfigh fin GOS such as beans, almonds 
or lentfils but fit fis not able to hydrolyse thefir FODMAPs such as fructans, lactose or polyols. 
Grafins are partficularly hfigh fin fructans, not fin GOS. As far as I known, finvertase, whfich 
hydrolyses fructans, has not been tested fin IBS.  
2.6 Probfiotfics 
 
It fis noteworthy that many randomfised studfies have been performed wfith probfiotfics fin 
IBS. Several meta-analyses of these studfies have been publfished fi.e. 35 randomfised studfies 





et al. concluded that probfiotfics seemed to alevfiate overal symptoms modestly vs. placebo; 
however, the efects have been finconsfistent across the studfies. A further chalenge fis that 
there are no studfies comparfing the efficacfies of dfiferent probfiotfics. No recommendatfion 
can be drawn from the lfiterature whfich specfiffic strafins of probfiotfics to use fin IBS. In thefir 
dfietary gufidelfines of IBS, Brfitfish Dfietetfic Assocfiatfion recommends (McKenzfie et al. 2016): 
 
“Advfise that probfiotfics are unlfikely to provfide substantfial beneffit to IBS symptoms. 
However, findfivfiduals choosfing to try probfiotfics are advfised to select one product at a 
tfime and monfitor the efects. They should try fit for a mfinfimum of 4 weeks at the dose 
recommended by the manufacturer. For findfivfiduals wfith IBS, takfing a probfiotfic product fis 
consfidered safe fin IBS.” 
 
The World Gastroenterology Organfisatfion publfished thefir gufidelfine on probfiotfics and 
prebfiotfics fin March 2017. Thfis report names the bacterfial strafins that have shown some 
efectfiveness at least fin one of the IBS-related parameters, and suggests that certafin 
probfiotfics mfight reduce efither findfivfidual symptoms or overal symptom control but the 
strength of the evfidence was not consfidered as partficularly strong.  
 
Very recently, Staudacher et al. (2017) reported that a probfiotfic contafinfing 8 dfiferent 
strafins dfid not reduce symptoms fin IBS when co-admfinfistered wfith a low-FODMAP dfiet 
but fincreased the numbers of Bfiffidobacterfium specfies, as compared to placebo, when gfiven 
at the same tfime wfith a low FODMAP dfiet.  
2.7 Drugs 
 
Many other factors finfluence the course of IBS fin addfitfion to dfietary factors. Drug 
treatment fis common practfice especfialy fin more severe cases of IBS (Chey et al. 2015): 
antfidepressants and antfispasmodfics are used for abdomfinal pafin and overal relfief, 
prosecretory agents such lfinaclotfide and lubfiprostone for constfipatfion and overal relfief, 
the localy actfing antfibfiotfic, rfifaxfimfine, for bloatfing and overal relfief and 5-HT3 receptor-
antagonfists, alosetron or ramosetrfin, for dfiarrhoea and overal relfief. 
 
Camfilerfi and Boeckxstaens (2017) have recently revfiewed upcomfing and exfistfing drug 
treatments agafinst abdomfinal pafin fin IBS. These approaches finclude antfispasmodfics, 
antfidepressants (trficyclfic agents, selectfive serotonfin reuptake finhfibfitors), 5-HT3 receptor 
antagonfists (alosetron, ondansetron, ramosetron), a non-absorbed antfibfiotfic (rfifaxfimfin), 
secretagogues (lubfiprostone, lfinaclotfide), µ-opfiofid receptor (OR) and κ-OR agonfist, δ-OR 
antagonfist (eluxadolfine), a hfistamfine H1 receptor antagonfist (ebastfine), a neurokfinfin-2 
receptor antagonfist (fibodutant) and GABAergfic agents (gabapentfin and pregabalfin). Only 
three drugs (eluxadolfine, lfinaklotfide and rfifaxfimfin) are findficated for the treatment of IBS 
and avafilable for clfinfical use fin EU. 
 
Drug therapy of IBS-D has recently been revfiewed (Dothel et al. 2018). Admfinfistratfion of 





studfies but fis currently unavafilable fin the EU or USA. Eluxadolfine, a µ- and κ-opfiofid 
receptor agonfist and δ-opfiofid receptor antagonfist that acts localy fin the enterfic nervous 
system and mfight also decrease the adverse efects on the central nervous system; fit fis 
marketed for IBS-D both fin the EU and USA (Dothel et al. 2018). The officfial product 
finformatfion text of eluxadolfine fin EU warns about serfious sfide efects; pancreatfitfis and 
spasm fin the sphfincter of Oddfi can occur. 
 
Lfinaklotfide, a prokfinetfic drug, fis currently avafilable for pharmcologfical treatment of IBS-
C fin the EU and USA (Shah et al. 2018). Lfinaclotfide belongs to the class of guanylate 
cyclase-C agonfists; fit seems to reduce constfipatfion but also fincreases the fincfidence of 
dfiarrhea (Shah et al. 2018).  It fis also findficated fin the treatment of fidfiopathfic constfipatfion.  
 
Rfifaxfimfin, a localy actfing antfibfiotfic, has demonstrated efficacy agafinst feelfings of 
dfistensfion and overal wel-befing fin gut but has not reduced the prevalence of other 
findfivfidual symptoms accordfing to a meta-analysfis of randomfized studfies (Lfi et al. 2016). 
The efects of thfis kfind of antfibfiotfic treatment on the gut health over the long term are far 
from clear; clfinfical studfies have ben shorter than 6 months (Lfi et al. 2016). 
 
It fis fimportant to acknowledge that some medficatfions used for condfitfions other than IBS 
may worsen the symptoms experfienced by IBS patfients. Chey et al. (2015) warned that 
antfibfiotfics, antfidepressants, antfiparkfinsonfian drugs, antfipsychotfics, calcfium-channel 
blockers, dfiuretfics, metformfin, opfiofids such as codefine and sympathomfimetfics would al 
be prone to cause symptom aggravatfion fin IBS. In addfitfion, some over-the-counter drugs 
(non-sterofidal antfi-finflammatory drugs) and supplements (firon, calcfium, magnesfium) are 
also potentfial trfiggers of the symptoms of IBS (Chey et al. 2015).  
2.8  Exercfise, sleep and psychologfical factors  
Exercfise and sleep patterns afect the symptoms of IBS. Physfical exercfise finterventfions 
have achfieved a clear fimprovement fin IBS symptoms when dafily physfical actfivfity was 
fincreased (Vfilorfia et al. 2006, Johanssen et al. 2011). It seems that already dafily walkfing 
of 30 mfinutes has the potentfial to reduce the symptoms of IBS (Johannessen et al. 2015). 
On the day after a poor nfight’s sleep, IBS patfients seem to sufer from more severe 
symptoms (Buchanan et al. 2015) and a systematfic revfiew suggested that sleep 
dfisturbances were related to a hfigher rfisk of havfing IBS (Tu et al. 2017). However, more 
studfies wfil be needed to clarfify the role of sleep fin IBS. 
 
Ffinaly, dfiferent kfinds of psychosocfial finterventfions have the potentfial to reduce 
symptoms fin IBS. Gut-dfirected hypnotherapy, mfindfulness and cognfitfive behavfioural 
therapy are al clafimed to be efectfive fin reducfing symptoms of IBS accordfing to systematfic 






2.9 Placebo and nocebo efect 
As fin any dfisorder where severfity or the dfisorder state fis measured by subjectfive 
evaluatfion, measurement of IBS status fis also prone to a placebo efect. A recent systematfic 
revfiew demonstrated that the pooled mean placebo response rate fin IBS was 41.4% and fit 
does not seem to dfifer substantfialy between treatment modalfitfies such as dfiet, drug 
treatment of psychosocfial finterventfions (Flfik et al. 2017). Sfimfilar placebo rates have been 
reported fin systematfic revfiews examfinfing mfigrafine (Fernandes et al. 2008) and major 
depressfion (Walsh et al. 2002). Due to the very exfistence of placebo and nocebo efects, 
dfietary studfies should be wel controled and blfinded whenever possfible, and there fis an 
fincreasfing need to measure objectfive parameters fin paralel to symptoms, fi.e. hydrogen 
excretfion, markers of fimmune actfivatfion and mficrobfiota (Rao et al. 2015, Gfibson et al. 
2017, Molfina-Infante and Carroccfio 2017). As detafiled fin the text, thfis has been 
fincreasfingly the case fin many IBS studfies publfished durfing the past 5 years. On the basfis of 
randomfised studfies, fit has been estfimated that the nocebo efect fis 3 tfimes larger than 
gluten specfiffic negatfive reactfions fin people wfith NCGS/NCWS.  
2.10  Summary and hypotheses 
The symptoms of IBS are often assocfiated wfith the consumptfion of specfiffic food fitems. 
Several finterventfion studfies have shown that a low FODMAP dfiet, peppermfint ofil, 
psylfium ffibre and possfibly certafin probfiotfics may reduce the symptoms fin patfients 
afected by IBS. In fact, fit seems that fin IBS no other dfietary pattern has ever been studfied 
as much as a low FODMAP dfiet. Nevertheless, there fis stfil a paucfity of placebo controled 
FODMAP studfies on food fitems naturaly rfich fin FODMAPs. Furthermore, gluten 
sensfitfivfity overlaps strongly wfith IBS and accordfing to randomfised controled trfials fit fis 
only seldom a truly gluten specfiffic condfitfion. It fis more lfikely that the typfical FODMAPs of 
grafins, fi.e. fructans as wel as a nocebo efect and hypothetficaly ATIs are the actual causes 
of symptom aggrevatfion fin findfivfiduals wfith gluten sensfitfivfity. Randomfised studfies are 
needed especfialy to clarfify the detafiled role of ATIs fin gluten sensfitfivfity as no clfinfical 
studfies have been performed on ATIs fin gluten sensfitfivfity. 
 
The ffirst hypothesfis of thfis thesfis was that the consumptfion of a rye bread lower fin 
FODMAPs would cause less IBS symptoms, evoke favourable changes fin fintestfinal 
functfion (colonfic fermentatfion, pH, transfit tfime or fintestfinal pressure) and not cause any 
negatfive efects on fintestfinal mficrobfiota sfince the FODMAP content was lower than 
regular rye bread, whfich has a hfigh fructan content. The second hypothesfis was that the 
consumptfion of sourdough wheat bread wfith fits lower levels of ATIs and fructans would 
reduce gastrofintestfinal symptoms and low grade finflammatfion fin people wfith gluten 
sensfitfivfity when compared to regular yeast leavened wheat bread whfich has a hfigher 








3  AIMS 
The afims of thfis thesfis work were as folows: 
 
1. To determfine whether low FODMAP rye bread reduces gastrofintestfinal 
symptoms and colonfic fermentatfion among findfivfiduals wfith IBS when compared 
to regular rye bread fin a four-week randomfised trfial (Study I) 
 
 
2. To assess whether wheat bread baked fin long fermentatfion process wfithout yeast 
and addfitfives, fi.e. wheat bread lower fin ATIs and FODMAPs, reduces symptoms 
when compared to regular wheat bread among findfivfiduals wfith non-coelfiac 
wheat sensfitfivfity and IBS. (Study II) 
 
3. To study fif low-FODMAP rye bread changes gastrofintestfinal pressure, transfit 
tfime and pH dfiferently from regular rye bread fin an acute meal study fin 
findfivfiduals wfith IBS (Study III) 
 
 
4. To deffine the efects of low-FODMAP rye and regular rye bread on fintestfinal 










4 MATERIALS AND METHODS 
As the methodologfies applfied fin studfies I-IV varfied, the brackets after the subheadfings 
descrfibe fin whfich studfies a partficular method was used.  
4.1 Subjects and study desfigns (I-IV) 
The study settfings, subjects and finterventfions fin each study are shown fin Table 5 and the 
findfivfidual study desfigns fin Ffigure 3. 
 
Table 5. Characterfisatfion of the study settfings, finterventfions and subjects. 
 
Study Subjects Number of 
subjects 





I Free-lfivfing IBS 
subjects 
87 Double blfind, 
cross-over, 
randomfised 
Low FODMAP rye 
bread vs. regular 
rye bread 








Yeast wheat bread 
vs. sourdough 
wheat bread 
26 (100%) 7 days 
III IBS subjects fin 
a laboratory 
9 Double blfind, 
cross-over, 
randomfised 
Low FODMAP rye 
bread vs. regular 
rye bread 
7 (78%) 12 hours 
IV Free-lfivfing IBS 
subjects 




Low FODMAP rye 
bread vs. regular 
rye bread  
50 (100%)  4 weeks 
 
Al the studfies were performed as double blfind randomfised clfinfical studfies. Papers I and 
IV are derfived from the same study. Computer assfisted randomfisatfion was used.  
 
Study candfidates were pre-screened by nutrfitfionfists and those findfivfiduals meetfing the 
finclusfion crfiterfia were subsequently referred to a screenfing consultatfion wfith a 
gastroenterologfist to ensure thefir elfigfibfilfity for partficfipatfion. Blood count, sedfimentatfion 
rate, transglutamfinase antfibodfies for coelfiac dfisease and thyrofid functfion tests (P-
tyreotropfine and thyroxfine) were done before the physficfian’s screenfing vfisfit fif these tests 
had not already been performed wfithfin the past 12 months. Partficfipants were recrufited 
from the Helsfinkfi Metropolfitan area vfia the finternet (pronutrfionfist.net) and through 





by gastroenterologfists before enterfing the studfies fin order to ensure that they met the 
finclusfion crfiterfia. Al partficfipants fulffiled Rome III crfiterfia for IBS. In studfies I and IV, 
only subjects wfith IBS-D, IBS-M and IBS-U were recrufited. In studfies II and III, al IBS 
subtypes were fincluded. In addfitfion, the partficfipants fin study II needed to have 
subjectfively based poor tolerance of wheat. A further finclusfion crfiterfion for al studfies was 












In studfies I and IV, the exclusfion crfiterfia fincluded the presence of an organfic GI dfisease, 
such as finflammatory bowel dfisease, coelfiac dfisease, major abdomfinal surgery, any 
malfignancy, pregnancy or breastfeedfing, finabfilfity to tolerate rye, a strfict low-FODMAP 
dfiet or other elfimfinatfion dfiet, or takfing some medficatfion potentfialy finfluencfing 
gastrofintestfinal functfion. Study II had otherwfise sfimfilar exclusfion crfiterfia but tolerance to 
rye was not requfired. The exclusfion crfiterfia were coelfiac dfisease, Crohn’s dfisease, 
dfivertficulfitfis, dfifficult dyspepsfia, stomach bezoar, bowel obstructfion, dfifficult constfipatfion, 
medficatfion used fin the management of fintestfinal motfilfity, major abdomfinal surgery, 
dysphagfia, pregnancy or breastfeedfing, regular smokfing, fimplanted medfical devfice and 
hormonal, renal, hepatfic or hematologfic dfisease or partficfipatfion fin some other clfinfical trfial 
durfing the past two months. The exclusfion crfiterfia fin study III were otherwfise sfimfilar as fin 
studfies I and IV, except that mfild/moderate constfipatfion was alowed; nefither attendance 
fin clfinfical studfies durfing the past two months nor havfing any medfical finstrument wfithfin 
the body was alowed. No partficfipants were fincluded fin study IV that had not partficfipated 
fin study I, fin other words, study IV was a sub-study of study I. 
4.2 Dfietary fintake (I-IV) 
Food dfiarfies for 4 days were ffiled fin by the partficfipants fin studfies I and IV. In study III, 3 
day food dfiarfies were used to calculate dfietary fintake. In study IV, al the food was 
provfided for the partficfipants on the evenfing before the test and durfing the test day. Dfietary 
fintake was calculated by usfing a nutrfitfion programme (Afivodfiet Ltd, Turku, Ffinland) fin al 
other studfies, except fin study II fin whfich the Ffinelfi finternet finterface (www.ffinelfi.ffi) was 
used to calculate the nutrfitfional composfitfion of the test meals. In studfies I and IV, the 
partficfipants were asked to adhere to thefir normal background dfiet whereas fin study III, al 
partficfipants were finstructed to folow a strfict gluten free dfiet for the whole study perfiod of 
14 days (and breads were provfided as the sole source of gluten/wheat). 
4.3 Bakfing of study breads (I-IV) 
The breads were developed and supplfied by Fazer Bakerfies (Vantaa, Ffinland). Both rye 
bread recfipes (studfies I, III and IV) contafined the same amount of wholegrafin rye flour, 
wheat flour and other fingredfients. The breads had a sfimfilar appearance, 
taste and were packaged fin transparent plastfic pouches fin studfies I and IV. The control 
bread (regular rye bread) was prepared usfing tradfitfional rye sourdough whereas the low 
FODMAP rye bread was prepared usfing a specfiffic sourdough system whfich resulted fin a 
rye bread wfith a clearly lower FODMAP content; the fructan content of the low FODMAP 
rye bread was 0.3 g/100 g whereas that of the regular rye bread was 1.1 g/100 g wfith the 
correspondfing mannfitol contents befing 0.1 g/100 g and 0.3 g/100 g, respectfively.  
 
The wheat breads (study II) were also developed by Fazer Bakerfies. Both test breads were 
made usfing the same baker's wheat flour. The findustrfial yeast wheat bread was prepared 
usfing a strafight-dough bread makfing process that lasts for approxfimately 2 hours 





yeast wheat bread contafined added wheat gluten 2% (of flour wefight), bread fimprovers 
(such as an emulsfiffier) and sorbfic acfid (E200) as a preservatfive. The sourdough wheat 
bread was baked usfing a dough mfixer and moulded by hand. The sourdough bread utfilfised 
wheat sourdough fin the recfipe wfith a long bulk fermentatfion stage. Overal, the sourdough 
stage lasted more than 12 hours. No fimprovers or any added gluten or preservatfives were 
used fin the sourdough bread. Both breads were packaged fin whfite plastfic pouches fin order 
to prevent the partficfipants from comparfing the appearance of the breads. 
4.4 FODMAP, ATI and nutrfitfional composfitfion of breads (I-IV) 
The nutrfitfional composfitfion of the breads fin al studfies was analysed by Euroffins scfientfiffic 
Ffinland, Rafisfio (Food & Agro), Ffinland. The dfietary ffiber content of the breads was 
determfined wfith the AOAC method 2011.25, dfiscrfimfinatfing between soluble vs. finsoluble, 
low vs. hfigh molecular wefight dfietary ffibres. The mannfitol content was analysed by the 
HPLC method used by Euroffins Food &Agro, Lfidköpfing, Sweden. The fructan content was 
analysed by the AOAC 999.03 method (Megazyme assay kfit K-FRUC, Megazyme 
Internatfional Ireland Ltd, Bray, Ireland). The nutrfitfional composfitfion along wfith the 
FODMAP and ATI contents of the study breads fis filustrated fin tables 6 and 7. 
 
Table 6. Nutrfitfional composfitfion of the breads examfined fin studfies I, III and IV 
 
 Study I and IV Study III 
 Low FODMAP 
rye bread /100 g 
Regular  
rye bread /100 g 
 Low FODMAP  
rye bread /100 g 
Regular  
rye bread /100 g 
Energy, kJ (kcal) 1024 (245) 1033 (247) 1031 (245) 1037 (246) 
Protefin, g 9.2 9.3 7.5 7.5 
Fat, g 1.3 1.2 2.6 1.1 
Carbohydrates, g 43.6 44.0 42.4 45.1 
Dfietary ffibre, g 10.2 10.5 10.8 12.8 
Fructans, g 0.3 1.1 0.4 1.2. 
Mannfitol, g 0.1 0.3 0.1 0.4 






















Bread /100 g 
Energy, kJ (kcal) 972 (229) 1116 (264) 
Protefin, g 9.3 9.9 
Fat, g 1.2 2.4 
Carbohydrates, g 43.4 48.4 
Dfietary ffibre, g 3.9 4.5 
Fructans, g 0.06 0.23 
Resfistant starch 0.7 0.8 
ATIs* Monomerfic Dfimerfic 
*) Could not be quantfiffied precfisely as methods for 
quantfifficatfion of ATIs were not avafilable to the researchers at 
the tfime of the study executfion. 
 
The analysfis of monomerfic, dfimerfic and tetramerfic ATIs was performed by Dr. Xfin Huang 
and Dr. Tuula Sontag-Strohm fin the Unfiversfity of Helsfinkfi, Department of Food Scfience. 
Sourdough bread and yeast-fermented bread were cut finto smal pfieces, excludfing the 
crusts. Albumfin was extracted from 1 g of bread and flour samples finto 20 ml bufer 
contafinfing 10 mM Trfis-HCl, 0.1 M EDTA, pH 7.5 at 4 °C for 1 hour wfith gentle shakfing. 
Folowfing centrfifugatfion at 10000 × g at 4 °C, the supernatant was colected and 
precfipfitated wfith 50% ammonfium sulfate at room temperature. The precfipfitates were 
dfissolved fin the same bufer and fits protefin concentratfion was determfined wfith a DC 
protefin assay Kfit (5000111, Bfio-Rad Laboratorfies Inc, CA, USA) wfith a bovfine serum 
albumfin standard. The protefin concentratfions of albumfin fin sourdough bread, yeast-
fermented bread and flour were adjusted to the same level. The albumfin composfitfion was 
analysed by SDS-PAGE wfith 12% Bfis-Trfis protefin gel (NP0341BOX, ThermoFfisher 
Scfientfiffic, MA, USA). The albumfin solutfions were mfixed wfith LDS sample bufer 
(NP0008, ThermoFfisher Scfientfiffic), wfith or wfithout sample reducfing agent (NP0009, 
ThermoFfisher Scfientfiffic), and then bofiled for 3 mfin. The runnfing bufer used was MOPS 
(NP0001), and protefin standard respectfively SeeBlue Plus2 (LC5925, ThermoFfisher 
Scfientfiffic). The applfied voltage was 200 V, and the run tfime was 50 mfin. The gel was 
stafined wfith Coomassfie R-250 brfilfiant blue. 
 
 
The bakfing methods used fin the studfies resulted fin a lower FODMAP content fin the low 
FODMAP rye breads and sourdough wheat bread. The ATI content was measured only 
fin study III, fi.e. fin the case of wheat breads and wheat flour, and fit was found to be 
reduced fin the folowfing order: wheat flour>yeast bread>sourdough bread. Wfith the 
avafilable methods, we could not accurately quantfify the amount of ATIs but finstead 
could demonstrate a reductfion/hydrolysfis of ATIs fin the Western blot analysfis (Ffigure 
4). 
 





fin rye  breads fermented wfith a sourdough system. The mannfitol content of regular rye 
breads was 0.30 h/100 g fin studfies I/IV; fin study III, fit was 0.26 g/100 g. The 
correspondfing values for low FODMAP rye breads were 0.10 and 0.09 g/100 g. The 
fructan content of regular rye breads was 1.10 g/100 g fin studfies I/IV; fin study III fit 
was 1.2 g/100 g. The correspondfing ffigures for low FODMAP rye breads were 0.30 and 
0.4 g/100 g. 
 
The analysfis of ATI content was based on the Western blot method. The Western blot 
fimage (Ffigure 4) demonstrates the reductfion of tetramerfic ATIs of wheat flour; 
tetramerfic ATIs have a molecular wefight of approxfimately 49 000- 62 000 Daltons. In 
the yeast wheat bread, the tetramerfic ATIs are reduced to dfimerfic ATIs, wfith 
molecular wefights of approxfimately 17 000-24 000 Daltons; fin the sourdough wheat 
bread, ATIs are further reduced to monomerfic ATIs whfich have molecular wefights fin a 





Ffigure 4. SDS-PAGE of albumfins from bread and flour. Lanes 1 and 8, protefin molecular 
wefight standard; lanes 2 and 3, albumfin extract from sourdough bread; lanes 4 and 5, 
albumfin extract from yeast-fermented bread; lanes 6 and 7, albumfin extract from wheat 
flour. Lanes 2, 4 and 6, marked ‘+’, samples were reduced wfith dfithfiothrefitol, and those 
marked ‘-’ were wfithout reductfion. Arrows findficate ATIs fin dfiferent forms, monomer fin 
lane 2, dfimer fin lane 4 and tetramer fin lane 6. Prfinted wfith Creatfive Commons wfith 





4.5  Adherence to treatments (I-IV) 
Adherence to the treatments was monfitored fin studfies I, III and IV by food dfiarfies and 
specfial questfionnafires desfigned to evaluate the number of bread slfices consumed by each 
partficfipant. Wfithdrawal reasons were asked efither fin person or vfia emafil when a 
partficfipant dropped out from the study. Al food was prepared and provfided by study 
assfistants fin study II and the study nutrfitfionfist monfitored the consumptfion of the food.  
4.6 Symptoms (IBS-SSS and VAS) and qualfity of lfife 
Two methods were used for measurfing symptoms. In study I, the prfimary outcome 
measure was IBS-SSS whfich fis a total score of ffive dfiferent symptoms (Francfis et al. 1997). 
IBS-SSS consfists of two questfions on abdomfinal pafin, one questfion on bloatfing, one on 
overal satfisfactfion of bowel habfit and one on how much IBS afects/finterferes wfith one’s 
lfife fin general. IBS-SSS was measured twfice durfing each treatment perfiod: after 10 days 
and at the end of the 4th week.  
 
Ffirst, vfisual analog scale (VAS) whfich fis a subjectfive measure severfity of dfiferent 
symptoms wfith a scale of 0-100 mm, was used fin al studfies. the value of 0 mm represents 
the absence of symptom and 100 mm desfignates the utmost severfity of symptoms. VAS 
measurements were of prfimary finterest fin studfies II and III even fif they were not used as a 
basfis for the power calculatfion, fi.e. they were not deffined as officfial prfimary outcomes fin 
any of the studfies.  VAS fis a commonly used method fin IBS studfies (Shepherd et al. 2008, 
Bfiesfiekfierskfi et al. 2013, Halmos et al. 2014, Elfi et al. 2016) even although fit has not been 
formaly valfidated for overal symptoms control fin IBS. The VAS assessmens were done 
once a week fin each treatment week fin study I and IV, once a day fin study II and hourly fin 
study III.  
 
The qualfity of lfife was measured fin study I wfith a specfial questfionnafire developed 
specfifficaly for the purpose of studyfing IBS (Drossmann et al. 2000). The qualfity of lfife 
measurements were done once at the end of each perfiod.  
 
The partficfipants were finstructed on how to use the dfiferent questfionafires before startfing 
the treatments.  
4.7 Hydrogen excretfion –a marker of fermentatfion (I, II, IV) 
Studfies I and IV 
Hydrogen excretfion, a marker of colonfic fermentatfion and fintestfinal gas productfion 
(Rumessen 1992) was measured wfith a breath hydrogen monfitorfing devfice (Gastrolyzer, 
Bedfont Scfientfiffic Ltd, Kent, UK) at the baselfine and 12 tfimes at 30 mfin fintervals durfing 
the 6 h after eatfing the study breads. To mfinfimfise varfiables that mfight afect breath 
hydrogen productfion, partficfipants were asked to restrafin from vfigorous physfical actfivfity 





spread, cheese or ham, tomato and/or cucumber and water. Cofee and tea were alowed. 
Subjects were asked to refrafin from eatfing anythfing more for the next 6 h after the 
begfinnfing of the test, fi.e. at lunch-tfime, and to eat a sfimfilar lunch, fif any, durfing the two 
study perfiods. These tests were performed fin the homes of the partficfipants after they had 
been trafined to use the devfice by the study dfietficfian. 
 
Study III 
Breath hydrogen was analysed wfith the Gastrolyzer® before the test breakfast (0 mfin) and 
every 30 mfinutes for 11 hours (660 mfin) on the test day and every 3 hours on the folowfing 
days. 
4.8 Gastrofintestfinal transfit tfime, pH and pressure (II) 
An findfigestfible wfireless motfilfity devfice (SmartPfil®, Gfiven Imagfing ltd, Yoqneam, Israel) 
was used fin study III. Thfis devfice contafins sensors for temperature, pH and pressure; fit fis 
a capsule wfith the folowfing dfimensfions; 26.8 mm length and 11.7 mm dfiameter. It sends 
data to a recefiver devfice worn by the subject. After the measurement, the data fis uploaded 
to a computer from the recefiver and analysed by the MotfilfiGI® program. The program 
calculates mean pressure, medfian pH, contractfions/mfin and transfit tfimes based on the 
changes fin pH and temperature, fin the dfiferent parts of the GI tract. In study III, the 
capsules were swalowed wfith the test breakfast and the subjects were requested not to eat 
for sfix hours after the meal so that the capsule would proceed to the smal fintestfine. The 
study perfiod for each subject ended when the capsule was defecated. 
4.9  Low grade finflammatfion (I) 
Inflammatory bfiomarkers finterleukfin 8 (IL-8), finterleukfin 6 (IL-6) and lfipopolysaccharfide 
bfindfing protefin (LBP) were measured at the baselfine and after the treatment perfiod wfith 
the study breads. Serum samples were taken at Aava Medfical Centre laboratorfium 
(Helsfinkfi, Ffinland) by laboratory technficfians and frozen at -22°C untfil analysed by a 
bfiochemfist (Hanne Salmenkarfi) at Unfiversfity of Helsfinkfi, Faculty of Medficfine, 
Department of Pharmacology. Serum IL-6 (BMS213HS, ThermoFfisher Scfientfiffic, 
Waltham, MA USA), IL-8 (HS800, R&D Systems, Abfingdon, UK) and LBP (HK315-01, 
LBP; Hycult Bfiotech, Uden, The Netherlands) were quantfiffied usfing sensfitfive enzyme-
lfinked fimmunosorbent assays (ELISA). 
4.10 Measurement of fintestfinal mficrobfiota (IV) 
Fecal samples were colected finto tubes by the partficfipants at home at the folowfing tfime 
pofints: baselfine and on the 2nd last day of each finterventfion arm. The partficfipants put the 
fecal samples fimmedfiately finto a refrfigerator (−20°C) and transported them later to the 
study centre for DNA extractfion whfich was done wfithfin 6 months. Bacterfial DNA was 





method wfith modfifficatfions for automated DNA purfifficatfion as descrfibed fin detafil fin study 
IV. 
 
Sample preparatfion for Ilumfina MfiSeq pafired-end sequencfing of the hypervarfiable V3-V4 
regfions of the 16S rRNA gene was done. Samples wfith less than reads 3000 were excluded. 
4.11 Statfistfical methods (I-IV) 
Study I 
The overal IBS-SSS score was the prfimary outcome varfiable fin the ffirst study. The weekly 
IBS symptoms, the weekly symptom scores and the IBS-QOL score were chosen as the 
secondary outcomes fin the ffirst study. The sample sfize calculatfion for the study was based 
on the prfimary varfiable IBS-SSS. Sufitable prevfiously publfished studfies were not avafilable 
to be utfilfised fin the calculatfions. Thus, we assumed that the dfiference between study 
breads would be at least 50 pofints on the 500-pofint IBS-SSS score and that the standard 
devfiatfion of that dfiference would be 150 pofints. In that case, a sample sfize of 73 would 
have 80% power to detect a 50 pofints’ dfiference when usfing a pafired t-test wfith a 0.05 
two-sfided sfignfifficance level. We antficfipated that the drop-out rate would be 15–20% and 
therefore 84–88 patfients were targeted for thfis cross-over study. The patfient 
characterfistfics were expressed as mean (range) for contfinuous varfiables and as number of 
patfients (%) for categorfical varfiables. The prfimary and the secondary outcome varfiables 
were analysed usfing the repeated measures ANOVA for a cross-over desfign. The efects of 
treatment (low-FODMAP rye bread vs. regular rye bread), the tfime efect and the carry-
over efect were also calculated by usfing repeated measures ANOVA for cross-over desfign. 
Thfis fis a multfivarfiable parametrfic method analysfing al those efects sfimultaneously. 
Dfiferences between study breads were expressed as mean (95% CI). 
 
Area under curve estfimates of breath hydrogen test were determfined usfing the absolute 
breath hydrogen values (AUC 0–360 mfin). The trapezfium rule was used fin AUC 
calculatfions. The number of slfices of study breads was assessed at week 1 and durfing weeks 
2–4. The Wfilcoxon sfigned-rank test was used wfith respect to the breath hydrogen level and 
the number of consumed slfices of study breads and pafired samples t-test was used to 
compare wefight between the low-FODMAP rye bread vs. regular rye bread. 
 
Study II 
We performed no sample sfize calculatfions because of the pfilot-nature of the study and 
because no clfinfical benchmark studfies exfisted on ATIs at the tfime of the finfitfiatfion of the 
study. However, the total score for the 12 gastrofintestfinal symptoms was the prfimary 
outcome varfiable. The patfient characterfistfics are expressed as medfian (range) for 
contfinuous varfiables and as number of patfients (%) for categorfical varfiables. 
 
Dfietary fintake was measured durfing the run-fin perfiod and durfing the tfime when the 
partficfipants consumed the study breads. Mann-Whfitney U test was used to compare the 
study breads wfith respect to dfietary fintake. The quantfity of consumed slfices of study 





was used to compare the average number of consumed slfices of study breads. Dfietary 
fintake was expressed as medfian (finter-quartfile range) because of the skewed dfistrfibutfions. 
A p-value ≤ 0.05 was consfidered statfistficaly sfignfifficant. The statfistfical analysfis was 
performed usfing IBM SPSS Statfistfics for Wfindows (versfions 22.0 and 23.0, Armonk, NY, 
USA, IBM Corp). 
 
Wfith regards to the finflammatory markers, the study groups were compared usfing the 
analysfis of covarfiance (ANCOVA), where the baselfine was fincluded as a covarfiate. The 
dfistrfibutfions of IL-8 and IL-6 were skewed to the rfight and were thus logarfithmficaly 
transformed before analysfis. Due to logarfithmfic transformatfion, the comparfisons  for IL-8 
and IL-6 are gfiven as ratfios such as yeast wheat bread/sourdough wheat bread, fi.e. as 
proportfional dfiferences of logarfithmficaly transformed means. Dfiference fin logarfithmfic 
means as such would not be finterpretable and therefore a ratfio fis preferable fin comparfing 
logarfithmficaly changed means (Bland and Altman 1996). 
 
Gastrofintestfinal symptoms and the other symptoms were measured dafily usfing VAS (0-
100 mm) durfing the 7-day run-fin perfiod and durfing the 7-day treatment perfiod wfith study 
breads. The run-fin perfiod was consfidered as the baselfine. The symptom scores for al 
symptoms were calculated for baselfine and for the treatment perfiod. In addfitfion, the total 
symptom scores were calculated for gastrofintestfinal symptoms (mean of 12 symptoms) 
and for other symptoms (mean of 5 symptoms). Analysfis of covarfiance (ANCOVA) was 
performed when the symptom scores were compared between the study breads and the 
symptom score durfing the baselfine was fincluded as a contfinuous covarfiate. The dfiferences 
between study breads (yeast wheat bread vs. sourdough wheat bread) are gfiven as 
baselfine-adjusted means wfith 95% conffidence fintervals.  
 
Study III 
The breath hydrogen was the prfimary outcome varfiable used fin the study power 
calculatfions. Sufitable prevfiously publfished data was not avafilable, and thus the study 
power was calculated based on a prelfimfinary test made fin Fazer Bakerfies fin whfich healthy 
partficfipants ate regular rye bread or low-FODMAP rye bread and the breath hydrogen 
content was analysed durfing a 6 hour postprandfial perfiod. The dfiference fin breath 
hydrogen content (ppm) between fastfing and 6 hours after the meal was used to evaluate 
the number of subjects fin the current study. Based on the power calculatfion, the sample 
sfize of 8 would have 80 % power to detect a 25 ppm dfiference fin breath hydrogen when 
usfing a pafired t-test wfith a two-sfided sfignfifficance level of 0.05. 
 
The subject characterfistfics and outcome varfiables are expressed as a medfian (range) and 
as the number of cases for categorfical varfiables. The dfiference fin outcome varfiables 
between study perfiods was calculated usfing the Wfilcoxon sfigned rank test for related 
samples. Correlatfions between mean symptom severfity and mean breath hydrogen, and 
between mean symptoms and SmartPfil® findfices durfing the colonfic phase, were analysed 
usfing the Spearman’s rho. Statfistfical analysfis was performed wfith IBM SPSS Statfistfics 
(Versfion 23, IBM Co., New York, USA) and Mficrosoft Office Excel 2013 (Mficrosoft Co., 







As thfis was a sub-study of study I, no officfial prfimary endpofint was deffined but dfiferences 
between the treatments fin mficrobfiota were of prfimary finterest. Two models were ffitted for 
each taxon: one wfith al data pofints and one wfith only the data pofints wfith non-zero 
values. The efect of varfiable read count was controled by usfing the read count as an ofset 
fin al statfistfical models. Age, BMI and treatment order were used as confounders fin al 
models and subject as a random factor. Al p-values obtafined from these models were 
adjusted for multfiple testfing usfing Benjamfinfi-Hochberg method, reported as P.adjust and 
values <0.05 consfidered as statfistficaly sfignfifficant. In addfitfion, the spread of the data was 
checked manualy for al sfignfifficant taxa obtafined from the models to avofid reportfing false 
posfitfives. The b-dfiversfity was estfimated usfing Bray-Curtfis dfissfimfilarfity as the dfistance 
measure. The functfion “CorrelatfionMap” of the mare package was used to study the 
assocfiatfions between bacterfia and IBS symptoms. In the unfivarfiate data, statfistfical 
dfiferences were evaluated usfing t-test for two groups, and wfith ANOVA fin combfinatfion 
wfith Tukey’s post-hoc test. The mficrobfiota dfiferences between the study groups were 
analysed usfing generalfised lfinear models wfith negatfive bfinomfial dfistrfibutfion for bacterfial 
genera detected fin >10% of the samples.  
 
 The patfients were also grouped based on the change fin thefir IBS-SSS and abdomfinal pafin 
scores durfing the rye bread finterventfions. The classfifficatfion of responders was as folows: 
Efither a reductfion of IBS-SSS score of at least 50 pofints, as prevfiously determfined by 
Francfis et al. (1997), and/or symptoms of pafin more than 10 mm fin the VAS (mean of 
weekly measures) compared to baselfine durfing the low-FODMAP bread, or an fincrease of 
IBS-SSS score of at least 50 pofints and/or symptoms of pafin more than 10 mm fin the VAS 
(mean of weekly measures) compared to baselfine durfing the regular rye bread. The 
symptom data were mfissfing from one patfient for each bread perfiod. Therefore, 49 subjects 
were left for the responder analysfis.  
 
The fintestfinal mficrobfiota analysfis of 50 subjects who provfided fecal samples and whose 
samples were analysed fincluded 10 554 - 66 363 (mean 35 757) hfigh-qualfity MfiSeq 
sequences per sample, representfing 357 operatfional taxonomfic unfits (OTUs) and 84 
bacterfial genera. 
4.12 Ethfics (I-IV) 
Al partficfipants fin each study sfigned the finformed consent form prfior to the start of the 
studfies and they were free to wfithdraw at any stage. Partficfipants had an opportunfity to 
contact the study physficfian or dfietficfians at any stage fin any need. The study protocols were 
approved by the Ethfics Commfittee of the Hospfital dfistrfict of Helsfinkfi and Uusfimaa, 
Ffinland. Studfies I, II and IV were regfistered at clfinficaltrfials.gov and study III was 









The baselfine characterfistfics of the partficfipants are presented fin Table 8. 
 












Use of rye/ 
wheat bread at 
baselfine (%) 









23.4 (17.3–36.6) 87.5% 43 (21–64) 62.5% (rye) 2.9 (0.0-8.0) 
II 
(N=26) 
Al sub-types of 
IBS 
24.8 (18.0-36.6) 96.2% 42 (21-64) 15.5% (wheat) 3.1 (1.0-7.5) 
III 
(N=7) 
Al sub-types of 
IBS 






24.8 (18.0-36.6) 92.7% 44 (21-64) 54.5% (rye) 2.8 (0.0-8.0) 
N/I: No finformatfion, was not asked 
 
At baselfine fin study I, the mean of IBS-SSS score was 228 (range 80-430), fi.e. these 
partficfipants sufered on average from moderate IBS accordfing to the classfifficatfion of 
Drossman et al. (2011).  
 
The presence of lactose fintolerance was reported by 28.7% of the partficfipants enterfing 
study I, and by 19.2% of those enterfing study II. The majorfity, 69.2%, of the 
partficfipants fin study I had been gfiven a dfiagnosfis of IBS prfior to the commencement of 
the study. The correspondfing ffigure fin study II was 77%. Altogether, 78 % reported 
regular use of some dfietary supplement fin study I and 92% fin study II. Furthermore, 
30% of partficfipants took ffibre supplements regularly at the baselfine of study I and 39% 
fin study II/IV. In study III, these data were not colected as fit was a tfightly controled 
24-hour acute meal study (no ffibre supplements were alowed). 
5.2 Dfietary fintake (I, I and IV) 
In study I, ffibre fintake fincreased from 21 g/d durfing the baselfine to 27 g/d durfing the 
perfiod wfith low FODMAP rye bread (P<0.001) and to 29 g/d durfing the perfiod wfith 





study I. No statfistficaly sfignfifficant changes fin the fintakes of macronutrfients or ffibre were 
observed fin study II, nefither between the bread perfiods nor when compared wfith baselfine. 
Ffibre fintake fincreased by 7 grams/day durfing the low-FODMAP rye bread perfiod and by 8 
grams/day durfing the regular rye bread perfiod as compared to the baselfine perfiod 
(P<0.001 for both vs. baselfine); no other statfistficaly sfignfifficant changes were observed 
between the bread perfiods fin study IV. Dfietary fintakes were not calculated fin study III 
because fit was a tfightly controled feedfing study where al food was provfided and the only 
dfiference between the groups was fin the qualfity of rye bread. 
5.3 Symptoms (I-IV) 
Study I 
We found no sfignfifficant dfiference fin our prfimary outcome IBS-SSS between the study 
bread perfiods. To refresh, IBS-SSS fis a composfite outcome (scale 0-500) of four dfiferent 
symptoms durfing the last 10 days and fit was measured twfice durfing the treatment perfiods 
of 28 days. The estfimated mean was 199 (95% CI 179–220) durfing the low-FODMAP rye 
bread vs. 207 (187–227) durfing the regular rye bread. There was no statfistfical dfiference 
between the bread perfiods as can be seen fin Ffigure 5. 
 
However, our secondary outcome, VAS measurements of findfivfidual symptoms showed 
statfistficaly sfignfifficant dfiferences between the bread perfiods based on the mean values of 
weekly measurements of symptoms (Table 9). Flatulence, abdomfinal pafin, cramps and 
stomach rumblfing were mfilder when the subjects were eatfing the low-FODMAP rye bread 
(P-values: 0.04; 0.049; 0.01 and 0.001 respectfively). There was also a sfignfifficant 
dfiference between the bread perfiods fin the total symptom score, fi.e. fin the mean of al 10 
VAS-based symptoms, 30 (95% CI 27–30) durfing the low-FODMAP rye bread vs. 33 (95% 
CI 30–37) when consumfing the regular rye bread. The mean dfiference was –3 (–6 to –1), 
P = 0.02) favorfing the low FODMAP rye bread perfiod. 
 
A carryover efect was observed wfith respect to cramps but not fin any of the other 
symptoms.  A tfime efect was observed fin dyspepsfia. Therefore, the results for cramps and 
dyspepsfia were reanalysed usfing the ffirst treatment perfiod only (ANCOVA). The results 








Ffigure 5. Box-plot on IBS-SSS scores durfing the treatments perfiod fin study I. Whfiskers 





Gastrofintestfinal symptoms were not statfistficaly sfignfifficantly dfiferent between the breads 
when the weekly means were analysed (Table 10). Unexpectedly, tfiredness, jofint symptoms 
and decreased alertness were more fintense when the subjects were consumfing the 
sourdough bread compared to wheat yeast bread (Table 11, p-values: 0.01; 0.03 and 0.003 
respectfively). There was no sfignfifficant dfiference between the bread treatments fin the total 
gastrofintestfinal symptom score, fi.e. the mean of 12 symptoms whfich was 27 (SD 12) mm 
for the sourdough bread vs. 23 (SD 11) mm for the yeast bread. The baselfine-adjusted 
dfiference between breads was not statfistficaly sfignfifficant. There was a sfignfifficant 
dfiference between the bread treatments fin the non-gastrofintestfinal symptoms, the mean 
of 5 symptoms was 26 (SD 18) mm for the sourdough bread vs. 11 (SD 10) mm for the yeast 
bread. The baselfine-adjusted dfiference fin non-gastrofintestfinal symptoms between bread 
treatments was 8 (95% CI 2 to 14) mm, p=0.02.  
 
Study III 
The mean of the findfivfidual gastrofintestfinal symptoms durfing the folow-up (30 to 630 
mfin) dfid not reveal any statfistficaly sfignfifficant dfiferences between the bread perfiods 
(Table 12). The occurrence of flatulence was nearly sfignfifficantly less after the fingestfion of 
the low-FODMAP rye bread (p=0.06). The dfiference fin AUCs of total symptom score (23 
520 (6 885–113 610) mm•mfin 41 130 (10 785–83 220) mm•mfin, for low-FODMAP and 





between the bread perfiods was found fin pH, fintralumfinal pressure or transfit tfimes fin 
relatfion to the symptoms fin any parts of gastrofintestfinal tract. 
 
The correlatfion between colonfic pressure and overal symptom severfity durfing the tfime 
when the devfice was fin the colon was sfignfifficant after the partficfipants had consumed 
regular rye bread (ρ=0.786, P=.036) and was nearly sfignfifficant after the low-FODMAP 
bread consumptfion (ρ=0.750, P=.052). The correlatfion coefficfients between symptom 




Correlatfion analysfis between the mficrobfiota and hydrogen productfion or symptoms durfing 
the finterventfion demonstrated two sfignfifficant assocfiatfions; hydrogen excretfion was 
posfitfively correlated wfith the abundance of Anaerostfipes (r=0.31, p= 0.003), and a weak 
posfitfive correlatfion was observed between constfipatfion and Clostrfidfia FamfilyXIII 
IncertaeSedfis (r=0.17, P= 0.035).  
 
A responders’ analysfis was conducted on the patfients who experfienced the strongest relfief 
fin symptoms durfing the finterventfions; thfis examfined fif patfients who gafined symptom 
relfief (responders) after consumptfion of the low-FODMAP bread had a dfiferent 
mficrobfiota composfitfion as compared to the others (non-responders).  
 
Based on the crfiterfia descrfibed fin the methods, we fidentfiffied 23 responders and 26 non-
responders. The findfivfidual GI symptoms that dfifered sfignfifficantly between the groups 
were flatulence (P=0.004), dyspepsfia (P=0.005) and heartburn (P=0.04). They were 
sfignfifficantly decreased fin the responders durfing the fintake of low-FODMAP bread. The 
excreted breath hydrogen was sfignfifficantly hfigher fin the non-responders (P=0.01).  
 
Consfiderfing the overal mficrobfiota, a hfigher fractfion of the varfiatfion was attrfibutable to 
the low-FODMAP bread-related responder status (2%, P=0.005) than the finterventfion 
fitself (1%, P=0.3). The abundance of Blautfia was hfigher fin the responders at baselfine 
(P.adjust=0.01, fc=1.6) and the abundance of Barnesfiela (Porphyromonadaceae, 
Bacterofidales) was lower fin the responders at baselfine (P.adjust =0.03, fc=0.22). In 
summary, composfitfional mficrobfiota dfiferences between the response groups were evfident 
at baselfine, but not at the end of the finterventfions. 
 
We also compared the mficrobfiota between the subjects whose symptoms were strongly 
trfiggered after the fintake of the regular rye bread to those wfithout a major symptom 
change. Here, we fidentfiffied 19 responders and 30 non-responders, wfith no mficrobfiota 



































































































































































































































































































































































































































































































































































































































   





































Table 10. Gastrofintestfinal symptoms (VAS 0-100mm) and gastrofintestfinal total score 
durfing the baselfine (mean of days 1-7) and durfing consumptfion of the study breads (mean 
of days 8-14), study III. Prfinted wfith Creatfive Commons permfissfion as provfided by the 






Yeast bread (n=13) 









 Baselfine-adjusted  
Dfiference  P value* 
Flatulence 25 (16) 37 (20)  22 (12) 32 (17)  3 (-11 to 17) 0.66 
Bloatfing 23 (17) 38 (16)  23 (15) 38 (20)  1 (-13 to 15) 0.93 
Dfiarrhea 10 (8) 13 (15)  12 (10) 13 (10)  1 (-9 to 10) 0.90 
Constfipatfion 16 (13) 22 (17)  14 (13) 24 (20)  -4 (-16 to 8) 0.54 
Abdomfinal pafin 16 (14) 32 (15)  20 (15) 29 (15)  4 (-7 to 15) 0.44 
Abdomfinal cramps 12 (17) 27 (19)  10 (10) 16 (13)  10 (-1 to 21) 0.06 
Borgorygmfia 20 (20) 34 (24)  19 (12) 23 (13)  10 (-1 to 21) 0.07 
Heartburn  13 (16) 18 (16)  9 (7) 12 (10)  3 (-5 to 12) 0.43 
Dyspepsfia 14 (14) 29 (17)  18 (17) 24 (23)  8 (-6 to 22) 0.25 
Incomplete defecatfion 30 (25) 37 (25)  24 (16) 32 (24)  -1 (-14 to 13) 0.93 
Urgent need for defecatfion 18 (14) 21 (19)  20 (15) 21 (16)  1 (-10 to 12) 0.90 
Nausea 12 (17) 21 (15) 
 
10 (16) 15 (16) 
 
5 (-4 to 13) 0.29 
Gastrofintestfinal total score  17 (12) 27 (12)  17 (9) 23 (11)  4 (-4 to 11) 0.33 
Results are gfiven as mean (SD) and mean (95% CI). 
*) The study breads were compared usfing the analysfis of covarfiance (ANCOVA), where the symptom score 
durfing the baselfine was fincluded as a covarfiate 
 
Table 11. Non-gastrofintestfinal symptoms (vas 0-100mm) and thefir total score durfing the 
baselfine (mean of days 1-7) and durfing consumptfion of the study breads (mean of days 8-
14), study II. Prfinted wfith Creatfive Commons permfissfion as provfided by the publfisher, 






 bread (n=13) 









 Baselfine-adjusted  
Dfiference p value* 
Tfiredness 30 (24) 40 (25)  17 (15) 14 (15)  16 (4 to 27) 0.01 
Jofint symptoms 17 (19) 23 (21)  9 (14) 7 (13)  7 (1 to 13) 0.03 
Skfin rash 11 (18) 14 (18)  3,5 (3) 5 (5)  3 (-5 to 11) 0.45 
Decreased alertness  22 (25) 35 (26)  12 (15) 13 (12)  14 (5 to 22) 0.003 
Loss of appetfite 12 (18) 19 (15)  9 (12) 15 (15)  2 (-6 to 9) 0.62 
Other symptoms total core  19 (17) 26 (18)  10 (11) 11 (10)  8 (2 to 14) 0.02 
Results are gfiven as mean (SD) and mean (95% CI). ) The study breads were compared usfing the analysfis of 






Table 12. Means (mm) of the gastrofintestfinal symptoms on VAS durfing 30-630 mfinutes 
after the test meals; medfian (range), study III. Prfinted wfith Creatfive Commons permfissfion 
as provfided by the publfisher, Bafishfideng Publfishfing Group (Pfirkola et al. 2018). (n=7) 
 
 Low-FODMAP rye bread Regular rye bread p-value* 
Abdomfinal pafin 2.4 (0.0–28.2) 4.8 (0.1–21.9) 0.74 
Cramps 1.2 (0.1–29.2) 3.0 (0.1–10.0) 0.92 
Bloatfing 12.3 (1.0–48.4) 23.1 (1.1–37.8) 0.87 
Flatulence 3.3 (0.5–7.6) 4.2 (0.5–28.2) 0.06 
Rumblfing 3.0 (0.1–6.6) 3.8 (1.4–11.4) 0.40 
Nausea 1.0 (0.0–22.4) 2.1 (0.0–15.5) 1.00 
Heartburn 1.4 (1.0–20.8) 1.8 (0.1–20.3) 1.00 
Dyspepsfia 7.4 (1.0–26.1) 11.8 (1.2–23.2) 0.31 
Urge of defecatfion 1.5 (0.0–29.5) 2.1 (0.3–22.4) 0.74 
*Wfilcoxon sfigned rank test 
5.4 Qualfity of lfife (I) 
No sfignfifficant dfiference was observed between the study breads fin the qualfity of lfife. The 
mean (95% CI) was 29.2 (25.0–33.5) durfing the low FODMAP rye bread vs. 30.0 (25.5–
34.5) durfing the regular rye bread. The dfiference was –0.8 (–2.9–1.3), P = 0.45. 
5.5 Hydrogen excretfion (I, II) 
Study I 
Breath hydrogen excretfion was sfignfifficantly lower durfing the low-FODMAP rye bread meal 
as compared to the regular rye bread meal (Ffigure 6). The medfian (finter-quartfile range) 
AUC was 52.9 (32.4–76.8) ppm durfing low-FODMAP rye bread vs. 72.6 (46.7–114.9) ppm 
durfing the regular rye bread (P = 0.01, Wfilcoxon sfigned-rank test). Only subjects for whom 
there were complete breath hydrogen measurements durfing both study breads were 







Ffigure 6. AUC0-360mfin of breath hydrogen excretfion durfing the test meals (p=0.01, 
Wfilcoxon sfigned ranks test). Whfiskers (error bars) above and below the columns findficate 
the finter-quartfile ranges. (n=60). 
 
Study III 
Postprandfial excretfion of hydrogen expressed as AUC (0-630 mfin) was [medfian (range)] 
6300 (1785-10800) ppm•mfin for low-FODMAP rye bread and 10 635 (4215-13080) 
ppm•mfin for regular bread. The two bread tests dfifered sfignfifficantly (p=0.028) findficatfing 
that there was more fintensfive colonfic fermentatfion when the partficfipants were consumfing 
the regular rye bread. Ffigure 7 filustrates the hourly development of hydrogen excretfion 







Ffigure 7. Medfians of expfired hydrogen concentratfion (ppm•mfin) after consumptfion of the 
study breads durfing the test days. Prfinted wfith Creatfive Commons permfissfion as provfided 
by the publfisher, Bafishfideng Publfishfing Group (Pfirkola et al. 2018). (n=7) 
5.6 Low grade finflammatfion (I) 
None of the serum finflammatfion markers dfifered statfistficaly sfignfifficantly between the 
treatments; the baselfine-adjusted dfiference ratfio for IL-6 was 0.91 (95% CI 0.73-1.14, 
P=0.94), for IL-8 fit was 1.01 (CI95% 0.74-1.39, P=0.38) and baselfine adjusted dfiference fin 











































Ffigure 8A,B,C A) S-IL-6 (pg/ml), B) S-IL-8 (pg/ml) and S-LBP (µg/ml) at the baselfine and 
after the treatment perfiods (Day 7) wfith sourdough (◆) and yeast (○) breads. 
Dashes/cfircles wfith error bars findficate geometrfic means wfith 95% conffidence fintervals for 
IL-8 and IL-6, and arfithmetfic mean wfith 95% conffidence fintervals for the LBP level. 
(n=24) 
5.7 Gastrofintestfinal transfit tfime, pH and pressure (II) 
Transfit tfimes, medfians of pH-values, mean pressures and contractfions can be found fin 
Table 13. These measures from any part of the gastrofintestfinal tract dfid not dfifer between 
the bread tests. An assocfiatfion was observed between the colonfic pressure and the overal 
symptom severfity. The correlatfion was statfistficaly sfignfifficant when the partficfipants had 
been consumfing regular rye bread (ρ=0.786, p=0.036) and was nearly sfignfifficant durfing 





between symptom severfity and colonfic contractfion frequency were 0.775 (p=0.041) and 
0.786 (p=0.036) after regular and low-FODMAP breads. Colonfic pH and hydrogen 
excretfion were assocfiated wfith symptom severfity after the regular bread (ρ=0.821, 
p=0.023 and ρ=0.857, p=0.014, respectfively) but not after low-FODMAP bread (ρ=0.342, 
p=0.452 and ρ=0.536, p=0.215, respectfively). 
 
Table 13. SmartPfil derfived transfit tfimes, pH-values, mean pressure and 
contractfions/mfin; medfian (range). Prfinted wfith Creatfive Commons permfissfion provfided 
by the publfisher. (n=7) 
 
 
Low-FODMAP rye bread Regular rye bread p-value* 
Transfit tfime (h)      
Stomach 18.1 (5.3–22.3) 5.6 (4.5–18.0) NS 
Smal fintestfine 4.0 (2.1–5.6) 4.6 (3.2–6.6) NS 
Colon 25.2 (12.2–50.0) 32.1 (14.7–47.6) NS 
Whole GI tract 46.5 (22.6–73.5) 45.8 (24.3–70.4) NS 
      
Medfian pH      
Stomach 1.5 (0.8–4.1) 1.5 (1.0–2.4) NS 
Smal fintestfine 7.5 (5.0–8.0) 7.6 (7.0–7.8) NS 
Colon 7.2 (5.8–7.5) 6.5 (5.9–8.5) NS 
      
Mean pressure (mmHg)      
Stomach 2.2 (1.9–2.7) 2.5 (2.0–3.0) NS 
Smal fintestfine 3.1 (1.6–8.6) 4.5 (2.4–7.0) NS 
Colon 4.8 (3.2–6.3) 4.0 (2.0–6.7) NS 
      
Contractfions /mfin      
Stomach 1.2 (0.6–1.7) 1.0 (0.8–1.8) NS 
Smal fintestfine 3.2 (0.5–6.1) 4.9 (1.9–6.5) NS 
Colon 1.7 (1.3–2.9) 1.7 (0.6–3.3) NS 
*Wfilcoxon sfigned rank test 
5.8  Mficrobfiota (IV) 
The mficrobfiota of the subjects at baselfine consfisted of Actfinobacterfia (mean 5.3 %), 
Bacterofidetes (7.8 %), Ffirmficutes (86.3 %), Proteobacterfia (0.3 %) and Verrucomficrobfia 
(0.3 %). The most abundant bacterfia at the genus level were Lachnospfiraceae 
IncertaeSedfis (mean relatfive abundance 20.1%), Bacterofides (12.6%), Faecalfibacterfium 






Prfincfipal coordfinates analysfis (PCoA) was performed fin order to estfimate β-dfiversfity 
(communfity dfissfimfilarfity), usfing Bray-Curtfis dfissfimfilarfity as the dfistance measure. There 
was no dfistfinct mficrobfiota clusterfing nor sfignfifficant separatfion based on the treatments or 
tfimepofints (P>0.05). Permutatfional multfivarfiate ANOVA, wfith Bray-Curtfis dfissfimfilarfitfies, 
was used to assess the proportfion of varfiatfion fin the mficrobfiota composfitfion attrfibutable 
to the tfime pofints (baselfine, 1st and 2nd bread) and the treatments (low FODMAP rye 
bread and regular rye bread). Only mfinor efects on the overal communfity structure were 
observed as the tfime pofints and treatment order both explafined only 1% of the mficrobfial 
varfiatfion fin these patfients (P>0.5).  In addfitfion, nefither α-dfiversfity nor rfichness was 
afected by the finterventfion (P>0.4 for al comparfisons). 
 
When comparfing the relatfive abundance of bacterfial genera between the two finterventfions 
(Ffigure 9), the abundance of Klebsfiela was lower when the subjects were consumfing the 
low FODMAP rye bread compared to the tfime when they ate the regular rye bread 
(P.adjust=0.048, fc= 14.8). Thfis was the only statfistfical dfiference fin bacterfial taxa when 
comparfing the breads. Both breads finduced modest, partly overlappfing efects on the 
mficrobfiota. Of al the analysed bacterfial taxa, ffive dfifered between the low FODMAP rye 
bread and baselfine (Ffigure 9). Durfing the low FODMAP rye bread perfiod, the abundance 
of Bacterofides (P.adjust=0.03, fold change fc= 1.59), two Ffirmficute genera fi.e. 
Flavonfifractor (Rumfinococcaceae, P.adjust =0.06, fc=1.55) and Holdemanfia 
(Erysfipelotrfichaceae, P.adjust=0.08, fc=1.84), and two Proteobacterfial genera fi.e. 
Klebsfiela (Gammaproteobacterfia, P.adjust=0.05, fc=136.14) and Parasutterela 
(Betaproteobacterfia, P.adjust=0.04, fc=1.97) were reduced fin comparfison to baselfine. 
 
The only dfiference between the regular rye bread versus baselfine samples was the 
reductfion fin Flavonfifractor (Rumfinococcaceae) (P.adjust=0.01, fc=14.83 ). There was a 
trend towards an fincrease fin the abundance of Bfiffidobacterfium durfing the low-FODMAP 
rye bread perfiod (P=0.03, P.adjust=0.22, fc=1.42), and a sfimfilar but weaker upward trend 
was observed durfing the regular rye bread perfiod (P=0.28, P.adjust=0.70, fc=1.20). The 
finterventfions had no efects on other bacterfia fincludfing Faecalfibacterfium prausnfitzfifi, 







Ffigure 9. Relatfive abundance (± standard error) of the bacterfial genera that were 
sfignfifficantly dfiferent between the bread treatments. Sfignfifficant dfiferences calculated 







6.1 General dfiscussfion 
Hydrogen excretfion and symptoms 
Studfies I and III demonstrated that the low FODMAP rye bread reduced gas formatfion 
measured by the hydrogen excretfion test when compared to regular rye bread as 
hypothesfized. No other studfies conducted fin acute meal tests among healthy subjects have 
assessed the efects of rye products on gas formatfion fin IBS. Prevfious studfies fin healthy 
subjects have shown that rye products produce more fintestfinal gas than whfite wheat bread 
(Nfilsson et al. 2008, Rosén et al. 2011). The formatfion of gas fin the colon seems to be 
partly dependent on the FODMAP content of the bread. 
 
There are no prevfious randomfised studfies on rye products among people wfith Rome 
crfiterfia deffined IBS. A reductfion was observed fin flatulence, abdomfinal rumblfing, cramps 
and pafin fin the 4-week study I but not fin the acute meal study II. The chofice of a low-
FODMAP bread as the only dfietary modfifficatfion dfid not seem have a large efect on IBS 
symptoms because there dfid not appear to be any dfiference fin IBS-SSS or qualfity of lfife 
whfich both assess symptom control more holfistficaly than VAS measurements on 
findfivfidual symptoms. Consequently, fit fis unlfikely that sfimply by consumfing a bread low fin 
FODMAPs would help an findfivfivfidual alevfiate all IBS symptoms, or achfieve adequate 
symptom control. 
 
The observatfion that rye products hfigh fin FODMAPs may provoke some IBS symptoms fis 
supported by a study conducted among healthy findfivfiduals (Vuholm et al. 2017); these 
finvestfigators examfined the efects of rye, whole wheat bread and whfite wheat bread on 
metabolfic health, mficrobfiota and GI symptoms. Thefir 6-week paralel study demonstrated 
that rye, whole wheat and whfite wheat al fincreased abdomfinal bloatfing and fatfigue when 
consumed ad lfibfitum. In addfitfion, the study of Lappfi et al. (2014) fincluded healthy 
patfients wfith mfild rye-related GI symptoms finto thefir study. The authors reported that rye 
bread had fincreased flatulence when compared to whfite wheat bread. 
 
Furthermore, Paajanen et al. (2004) have also shown, as conffirmed here, that fin people 
wfith functfional gastrofintestfinal symptoms, rye products wfith hfigh FODMAP contents 
cause more abdomfinal dfiscomfort than whfite wheat sfimfilarly low fin FODMAPs. They 
studfied findfivfiduals wfith subjectfive mfilk fintolerance and exposed them to rye and whfite 
wheat products. It was found that people wfith a subjectfive mfilk fintolerance wfithout lactose 
fintolerance experfienced more symptoms from rye than from wheat; bloatfing, flatulence 
and abdomfinal pafin and thefir total symptom score was hfigher durfing the rye bread perfiod 
vs. whfite wheat bread perfiod. The most lfikely explanatfion for the observed dfiference fis 
that rye generates more fintestfinal gas than wheat due to fits content of fermentable 






No dfiferences were found fin gastrofintestfinal symptoms between the breads fin our wheat 
bread study (II) despfite the lower ATI and FODMAP content fin the sourdough bread. One 
can speculate that the fafilure to alevfiate gastrofintestfinal symptoms mfight have been due 
to a nocebo efect, maskfing any true dfiferences, or perhaps there was too smal a 
dfiference fin the FODMAP fintake achfieved by the breads (0,3 g/d). Another explanatfion fis 
the fact that the study groups were slfightly dfissfimfilar at baselfine. Moreover, fit fis also 
theoretficaly possfible that the ATI reductfion achfieved fin sourdough bread was not 
sufficfiently extensfive. No prevfious clfinfical studfies have compared sourdough and regular 
wheat bread fin subjects wfith IBS but a 6-week randomfised study compared modern 
(common) wheat products and Kamut (ancfient) wheat products fin IBS (Soffi et al. 2014). 
Ancfient wheat varfietfies are known to be lower fin FODMAPs and ATIs (Zfiegler et al. 2016, 
Zevalos et al. 2017) but fin thefir study, the authors dfid not measure efither the ATI or the 
FODMAP contents of regular or Kamut wheat products (Soffi et al. 2014). Nonetheless, 
Kamut products resulted fin fimproved gastrofintestfinal tolerance whfich suggests that 
FODMAPs and ATIs mfight play a role fin non-coelfiac gluten sensfitfivfity. It fis noteworthy 
that fin thfis trfial the dfiferentfial efects of breads were only shown after 4-6 weeks. It fis thus 
possfible that seven days, the length of observatfion fin the present study, was too short to 
alow detectfion of dfiferences between the treatments.   
 
The sourdough wheat bread used fin the present study was lower also fin gluten than the 
yeast bread because gluten was added only finto the yeast wheat bread (a regular practfice fin 
commercfial productfion). A recent randomfised study demonstrated that enzymatfic 
processfing of dough fin order to reduce gluten content of bread does not help fin reducfing 
symptoms fin non-coelfiac gluten sensfitfivfity (Rees et al. 2018). These results are further 
evfidence that gluten mfight not be the key factor evokfing gastrofintestfinal symptoms related 
to grafins, albefit that study was also short, as was study II. 
 
Furthermore, the present study wfith wheat breads does not support the clafim that 
commonly used bakfing addfitfives such as yeast, added gluten, sorbfic acfid 0r emulsfiffiers 
would be major drfivers of IBS symptoms. 
 
Inflammatfion, pH, transfit tfime and fintralumfinal pressure  
Despfite a substantfial reductfion of putatfive pro-finflammatory substances such as ATIs 
(Junker et al. 2012, Zevalos et al. 2017) fin sourdough wheat bread, we could not 
demonstrate any changes fin the systemfic markers of finflammatfion examfined fin study II; 
IL-6, IL-8 and LBP remafined unchanged also durfing the yeast bread perfiod of seven days. 
Thfis ffindfing fis fin contrast to prevfious pre-clfinfical studfies (Junker et al. 2012, Zevalos et al. 
2017) that have suggested that the ATIs present fin wheat cause relatfively rapfid changes fin 
finflamatory markers. These present ffindfings may be attrfibuted to the desfign and 
methods used fin our study (see next chapter), or alternatfively, our ffindfings suggest that 
durfing an otherwfise gluten free dfiet, the ATIs fin yeast wheat bread are not capable of 
finducfing clfinficaly relevant finflammatfion when consumed fin moderatfion (5 slfices/day). 
 
It was determfined that the SmartPfil® stayed fin stomach much longer (4.5-22 hours; mean 
stomach emptyfing for regular bread perfiod was 5.6 hours and low FODMAP bread perfiod 





eatfing was adopted after breakfast to ensure emptyfing of the stomach. Only one trfial has 
prevfiously reported a slfightly lengthened stomach transfit tfime fin a subset of IBS-C subjects 
(Rfingel-Kulka et al. 2015), but others have consfistently reported substantfialy shorter 
transfit tfimes fin the stomach. Emptyfing of the SmartPfil® capsule occurred at about 4 h fin 
the finvestfigatfions conducted by Kuo et al. (2007) and Casfidfily et al. (2008). Thus, our 
study fimplfies that the SmartPfil mfight not be an optfimal devfice to evaluate the 
gastrofintestfinal functfion fin IBS durfing meal studfies lastfing less than 24 hours, due to the 
devfice’s finabfilfity to measure gastrfic propertfies fin a tfimely manner. Based on our ffindfings 
on hydrogen excretfion durfing the rye bread treatments, fit fis obvfious that the rye bolus 
moved from the stomach to the fintestfine many hours before the SmartPfil®. 
 
There was a correlatfion between fincreased fintracolonfic pressure and symptom severfity, 
and fit fis argued that thfis further emphasfizes the central role of vfisceral sensfitfivfity fin IBS. 
Thfis ffindfing hfints that IBS symptoms mfight be worsened by any property that fincreases 
the colonfic pressure. There do not appear to be any other SmartPfil derfived outcomes fin 
IBS suggestfing outcomes sfimfilar to ours or refutfing our ffindfings. 
 
No other comparatfive dfietary studfies usfing SmartPfil® exfist among subjects wfith IBS; thfis 
present study was ffirst of fits kfind. SmartPfil® has been used only fin one prevfious study 
among subjects wfith IBS (Rfingel-Kulka et al. 2015); the researchers demonstrated that IBS 
patfients have a lower fintracolonfic pH when compared to healthy subjects, whfich they 
finterpreted as hfigher colonfic fermentatfion fin these patfients but no dfietary finterventfion 
was performed fin that study.  
 
Mficrobfiota 
There were only modest changes fin mficrobfiota after consumptfion of the rye breads. There 
was only one statfistficaly sfignfifficant dfiference between the bread perfiods fi.e. fin the 
abundance of Klebsfiela, thefir amount was lower durfing the low FODMAP rye bread 
perfiod. Prevfiously, overgrowth of Klebfisela fin the smal fintestfine of IBS patfients has been 
documented; a mficrobfial specfimen was obtafined vfia endoscopy as aspfirates (Gfiamarelos-
Bourboulfis et al. 2015). It fis possfible that consumptfion of low FODMAP rye bread reduces 
the abundance of Klebsfiela fin the smal fintestfine but thfis fis speculatfive as fit was not 
possfible to determfine the orfigfin of Klebsfiela fin the gastrofintestfinal tract.  
 
However, some other changes were observed when compared to baselfine. Changes fin 
mficrobfiota were more promfinent durfing the low FODMAP rye perfiod than durfing the 
regular rye bread. The abundances of Bacterofides, Flavonfifractor, Holdemanfia, 
Parasutterela and Klebsfiela were reduced durfing the low FODMAP rye bread perfiod, 
whereas only the abundance of Flavonfifractor was reduced durfing the regular rye bread 
perfiod. Wfith regards to other mficrobfial factors, no statfistficaly sfignfifficant changes were 
observed although there was an fincreased abundance of bfiffidobacterfia when the 
partficufipants consumed a low FODMAP rye perfiod fin the uncorrected model of analysfis. 
Currently, as far as fis known, no other studfies reportfing efects of rye or wheat products on 






Some studfies comparfing efither regular rye or whole grafins vs. reffined grafins have reported 
outcomes on the mficrobfiota of healthy subjects (Lappfi et al. 2013, Vuholm et al. 2017, 
Roager et al. 2017, Vanegas et al. 2017). In these studfies, the observed efects on 
mficrobfiota have also been modest. Lappfi et al. (2013) found a 37% decrease of 
Bacterofidetes fin the reffined grafins group compared to baselfine. Furthermore, they also 
found that there was a decreased abundance of bacterfia related to Bacterofides vulgatus, B. 
plebefius, and Prevotela tannerae, whereas those of bacterfia related to Colfinsela and 
members of the Clostrfidfium clusters IV and XI were fincreased when reffined grafins were 
consumed. Vuholm et al. (2016) dfid not observe any dfiferences fin the abundances of any 
taxa between any of the dfiet groups (whole grafins, rye or reffined grafins) fin healthy but 
overwefight subjects. Roager et al. (2016) found out that the abundance of 
Faecalfibacterfium prausnfitzfifi and one Prevotela coprfi fincreased after the whole grafin 
perfiod but thefir abundance decreased after the reffined grafin consumptfion. In contrast, the 
abundance of Bacterofides thetafiotaomficron changed fin the opposfite dfirectfion but no 
sfignfifficant changes were found fin the abundance of findfivfidual bacterfial specfies. Venegas et 
al. (2017) detected a sfignfifficant relatfive change toward a decrease fin Enterobacterfiaceae 
abundance fin the whole grafins group as compared to the reffined grafins group. At the 
genera level, there was a sfignfifficant relatfive change toward an fincrease 
fin Lachnospfira abundance fin the whole grafins group compared to the reffined grafins group 
(Venegas et al. 2017). Taken together, these data show that no unfiform change fin 
mficrobfiota fis observed when whole wheat or rye fis consumed regularly. The clfinfical 
sfignfifficance of our observatfions on mficrobfiota regardfing low FODMAP rye bread remafins 
to be determfined. 
 
The only sfignfifficant ffindfing fin regards to macronutrfient fintake found here was the 
fincreased fintake of dfietary ffibre durfing the rye perfiods as compared to baselfine (study I 
and IV). The fintake of ffibre was fincreased by 6 grams fin the 4-week rye study durfing the 
low FODMAP rye bread perfiods and by 9 grams durfing the regular bread perfiod. Thfis 
fincrease fin the fintake of dfietary ffibre durfing the low FODMAP rye bread perfiods was 
almost as hfigh as that achfieved when usfing 10 grams of psylfium dafily or 20 grams of 
wheat bran/day whfich are the typfical doses whfich have been used fin randomfised IBS trfials 
(Bfijkerk et al. 2004). The consumptfion of a low FODMAP rye bread mfight be a feasfible 
means of achfievfing a hfigher fintake of dfietary ffibre among people wfith IBS, and potentfialy 
fin thfis way, reduce the rfisk of chronfic dfiseases such as colorectal cancer (Aune et al. 2011) 
or cardfiovascular dfiseases (Threapleton et al. 2013).  
 
Gfiven that there was a lower than recommended fintake of dfietary ffibre (approxfimately 21 
grams/day) fin our patfient populatfions and fin some other IBS populatfions folowfing low 
FODMAP dfiet (Böhn et al. 2015, Harvfie et al.2017), consumptfion of a low FODMAP rye 
bread may help a patfient wfith IBS to reach the recommended fintake of ffibre. The major 
ffibre component responsfible for the fincreased fintake of ffibre fin low FODMAP rye perfiods 
was arabfinoxylan whfich fis the domfinant component of ffibre fin rye and barley (Frølfich et 






6.2 Methodologfical consfideratfions  
 
The major strength of thfis serfies of studfies fis that they were double blfinded. It fis almost 
fimpossfible to mask a holfistfic low FODMAP dfiet from both finvestfigators and study subjects 
but the present study desfigns alowed maskfing of the true nature of treatment and control 
breads. Thus, the present rye studfies and the acute meal study, are an fimportant pfiece of 
evfidence further strengthenfing the relevance of the FODMAP concept fin IBS fi.e. the 
double blfind settfing and the cross-over desfign help to avofid the placebo efect often 
consfidered as a chalenge fin low FODMAP studfies (Kroogsgaard et al. 2017). 
 
The reductfion of FODMAPs fin the developed breads was successful and verfiffied fin the 
laboratory analyses. The FODMAP contents fin the low FODMAP rye bread and the 
sourdough wheat bread were approxfimately 70% lower than fin control breads (Tables 6 
and 7), fi.e. the regularly consumed counterparts. Our results are fin lfine wfith other studfies 
hfighlfightfing the potency of long prooffing of dough to reduce the FODMAP content of 
bread (Zfiegler et al. 2016, Zamaratskafia et al. 2018), and fin that way make sourdough 
breads more sufitable for IBS patfients. Interestfingly, Zfiegler et al. (2016) also showed that 
fit does not have to be a sourdough technfique but usfing common baker’s yeast also results 
fin a reduced FODMAP content of bread fif the prooffing tfime fis long enough. It was 
demonstrated that a prooffing of the dough for more than 4.5 hours wfith yeast reduced the 
amount of FODMAPs by up to 90%. Based on thefir results, a reductfion of FODMAPs may 
not be specfiffic to the sourdough method but related to the duratfion of the prooffing perfiod, 
fi.e. a long prooffing tfime fis needed to achfieve substantfial fermentatfion. Currently, most 
findustrfial wheat breads are baked usfing qufick prooffing tfimes, fi.e. the Chorleywood 
method, whfich typficaly employs less than 1.25 hours’ prooffing tfimes (Cauvafin and Young 
2005).  
 
There fis no other data avafilable on the efect of sourdough fermentatfion of wheat on the 
ATI-levels fin bread. In thfis respect, the present outcomes provfide finnovatfive finformatfion 
and questfion the potentfial central role of ATIs fin wheat sensfitfivfity. No other clfinfical study 
has compared a wheat product hfigh fin ATIs to a wheat product wfith reduced ATIs.  
 
The methods used here made fit possfible to scrutfinfize the efect of smaler dfiferences fin 
the fintake of FODMAPs better than fin most prevfious studfies. In addfitfion to the report of 
Skodje et al. (2017), the present rye studfies are some of the ffirst to demonstrate that a 
dfiference of 2 grams fin the fintake of FODMAPs per day fincreases gas formatfion and can 
consequently trfigger some gastrofintestfinal symptoms among patfients wfith IBS or non-
coelfiac wheat sensfitfivfity. On the other hand, the present wheat study suggested that a 
dfiference fin the fintake of fructans of 0.3 grams per day fis unlfikely to evoke any dfiscernfible 
efects on GI symptoms. In holfistfic low FODMAP dfiet studfies, the dfiference fin the fintake 
of FODMAPs has been typficaly more than 10 grams per day (Ong et al. 2010, Staudacher 
et al. 2011, Halmos et al. 2014) and fin these trfials, larger beneffits have been achfieved fin the 






 Our studfies alowed the partficfipants to consume thefir habfitual dfiet and dfid not swfitch 
patfients to a low FODMAP dfiet. It can be argued that thfis approach fis more valfid from the 
long-term perspectfive than havfing low FODMAP dfiet as a background dfiet. Adherence to 
a strfict low FODMAP dfiet fis only fintented for short perfiods of tfime (Whelan et al. 2018), 
patfients wfith IBS should folow as lfiberal a dfiet as possfible over the long run (McKenzfie et 
al. 2016). Therefore knowledge on the beneffits of elfimfinatfing even a very lfimfited number 
of key trfiggers, such as rye bread, mfight be of major practfical relevance to these patfients.  
 
Another strength of the present studfies fis that the loss of partficfipants was relatfively low. 
Al partficfipants fin the wheat study and 85% of partficfipants fin a 4-week rye study were 
retafined throughout the study perfiod.  
 
Generaly, the cross-over desfigns used fin studfies I and IV can be conducted wfith smaler 
numbers of partficfipants whfile stfil detectfing statfistfical sfignfifficant dfiferences between 
treatments because partficfipants serve as thefir own controls. Cross-over studfies also 
mfitfigate some rfisks finherent to paralel group studfies: randomfisatfion may sometfimes fafil 
fin such a way that the treatments groups dfifer already at baselfine. In fact, the 
randomfisatfion could have succeeded better fin study II, fi.e. the only paralel group study 
fincluded fin thfis thesfis work, fi.e. the partficfipants fin the sourdough wheat bread group 
seemed to be slfightly more sensfitfive to wheat than the partficfipants fin the yeast bread 
group. In cross-over studfies, fit fis essentfial to have a long enough wash-out perfiod between 
treatment perfiods fin order to ensure that the efect of the ffirst treatment has been totaly 
elfimfinated before finfitfiatfing any new treatment perfiod. The present wash-out perfiod was at 
least four weeks fin studfies I and IV and thfis can be consfidered long enough. No carry-over 
efect was detected for any end pofints other than fintestfinal cramps.  
 
One lfimfitatfion of the present studfies fis that we were not able to quantfify the FODMAP 
content of the background dfiet. Ffinnfish food databases do not contafin FODMAP data, 
especfialy data on the concentratfions of polyols, GOS, FOS and finulfin fis lackfing. Currently, 
an estfimatfion of FODMAP content of dfiets fin Ffinland fis a practfical chalenge and was 
therefore not performed. There fis a need for database contafinfing FODMAP data here fin 
Ffinland whereas fin Australfia and UK such databases already exfist (Halmos et al. 2014, 
Staudacher et al. 2017). 
 
It fis lfikely that the most sensfitfive persons were excluded from the 4-week rye study 
because a wfilfingness to eat rye for the treatment perfiods was one of the finclusfion crfiterfia. 
Many partficfipants may have thought thfis was too long to expose themselves to symptoms. 
Therefore, our results cannot be extrapolated to those who consfider that they are very 
sensfitfive to rye. In addfitfion, persons wfith constfipatfion predomfinant IBS (IS-C) were 
excluded and consequently the results of the 4-week rye study cannot be extrapolated to 
persons wfith IBS-C. The patfient populatfion was overwhelmfingly female domfinant, and 
therefore the results cannot be certafinly extrapolated to males suferfing from IBS. 
Depressfion or anxfiety were not exclusfion crfiterfia and therefore the results are lfikely to be 






The number of partficfipants was low fin study II, two partficfipants dfiscontfinued the study 
prematurely compoundfing thfis lfimfitatfion. Another pofint to be taken finto account fis that 
hydrogen excretfion tests were performed at home by the partficfipants themselves; thfis may 
possfibly fintroduce some bfias. The power of the study was calculated usfing hydrogen 
excretfion as the prfimary end pofint. In retrospect, fit would have been better to use 
symptoms as a basfis for power calculatfion as they are more clfinficaly relevant. The wheat 
study dfid not finclude any power calculatfion, as fit was a pfilot study and no benchmark 
clfinfical studfies on ATIs exfisted. Because the number of patfients fin the wheat study was 
low, al of the emergfing ffindfings need to be finterpreted wfith cautfion. 
 
The wheat study had a duratfion of seven days and fit fis possfible that thfis fis not enough for 
trfiggerfing finflammatfion or attenuatfing a nocebo efect. However, fit fis extremely dfifficult to 
expose people fin long-term studfies to foods that they thfink may be trfiggerfing symptoms. 
Adherence to treatment commonly sufers as the exposure tfime fincreases. Balancfing the 
requfirements of a long enough treatment perfiod and ensurfing adherence fin dfietary 
finterventfions remafins a chalenge fin IBS studfies.  
 
It was not possfible to analyse the bfioactfivfity of ATIs present fin sourdough/yeast bread and 
thfis should be done fin the future. Furthermore, the amfino acfid sequences of the ATIs 
present fin the breads were not analysed, and therefore one cannot be 100% sure to whfich 
ATI groups the compounds present fin the sourdough and yeast bread belong. More studfies 
on dfiferent methods wfil be needed to verfify the actual ATI content fin wheat breads. 
6.3 Perspectfives for future research 
The present studfies and the lfiterature search conducted fin thfis doctoral dfissertatfion 
provfide gufidance for new ways of conductfing research finto IBS and non-coelfiac wheat 
sensfitfivfity. Ffirst, the studfies should be long enough (fi.e. three months or more) whenever 
possfible. Nocebo and placebo efects fintroduce background nofise finto the studfies that only 
dfimfinfish wfith tfime; they may also mask true but more subtle benefficfial efects.  
 
It would be finterestfing to finvestfigate the efect of a low FODMAP rye bread as a part of a 
holfistfic low FODMAP dfiet sfince here fits efects were measured fin fisolatfion, and the 
habfitual background dfiet was contfinued. Gfiven the efects of low FODMAP dfiet on 
mficrobfiota and the restrfictfive nature of the dfiet, fit would be valuable to examfine fif the 
tolerance to FODMAPs and the abundance of benefficfial bacterfia fin fintestfine could be 
fimproved by achfievfing a slow fincremental fincrease fin the levels of fructans/GOS fin 
patfients who are adherfing to a low FODMAP dfiet. Here, the fintake of FODMAPs fincreased 
rapfidly by addfing regular rye bread to the dfiet (control dfiet) but there were no sfigns of a 
reductfion of symptoms as a functfion of tfime (tfime-efect) durfing the four week perfiod 
(results not publfished). It fis possfible that a gradual fincremental fincrease fin the FODMAP 
fintake mfight act dfiferently. Admfinfisterfing GOS wfith fincreasfing doses as a functfion of tfime 
has been clafimed to fimprove fits tolerabfilfity due to colonfic adaptatfion (Mego et al. 2017). In 
paralel, the abundance of bfiffidobacterfia fincreased. Furthermore, Azpfiroz et al. (2017) 





placebo (maltodextrfin, 8 g/d); fit was found that exposure to finulfin for four weeks 
decreased fintestfinal gas retentfion durfing the gas chalenge test by 22%. To conclude, the 
avafilable data suggests that the tolerance to FODMAPs can be fimproved fif fructans or GOS 
are eaten regularly. It fis not known fif the opposfite can also occur; fi.e. fif a low FODMAP 
dfiet further reduces the tolerance of dfietary fructans or GOS due to colonfic adaptatfion.  
 
It would be valuable to elucfidate the dfiferences fin the ATI contents of fermented and non-
fermented grafin products and verfify the results wfith fin vfitro bfio-actfivatfion tests whfich 
were not performed here. DNA sequencfing of ATI molecules are also recommended fin the 
future studfies to conffirm the nature of the ATIs. From an academfic perspectfive, a dfirect 
comparfison between ATIs and FODMAPs, could provfide dfirect answers to one crucfial 
questfion: fis fit ATIs or FODMAPs that are the causal factors fin finducfing symptoms? Such 
studfies mfight be very dfifficult to arrange because fit fis far from strafightforward to extract 
ATIs from grafins, and there are no commercfialy avafilable technfiques. These lfimfitatfions 
make fit dfifficult to determfine the dose that should be used fin such studfies. 
 
An finterestfing area of research would be to determfine the characterfistfics of the 
polyphenols and thefir role fin IBS. Polyphenols seem to be metabolfised by fintestfinal 
mficrobfiota and produce short chafin acfids wfith antfi-finflammatory propertfies (Parkar 
et al. 2013), they may confer benefficfial efects on the mficrobfiota (Dueñas et al. 2015) 
and findeed they have been clafimed to decrease fintestfinal finflammatfion fin 
experfimental studfies (González et al. 2011). As dfiscussed prevfiously, the current 
lfiterature demonstrates that a low-grade finflammatfion fis present, at least fin a subset 
of patfients (Sfimrén et al. 2013). These concepts rafise the possfibfilfity that an “antfi-
finflammatory dfiet” fincorporatfing a hfigh fintake of polyphenols mfight reduce symptoms 
fin firrfitable bowel syndrome, but no such studfies currently exfist (Mfinfihane et al. 2015). 
 
Ffinaly, more studfies are warranted that would scrutfinfise the combfined role of dfiferent 
substances present fin grafins. Rather than conductfing dfirect comparfisons wfith one 
substance agafinst another substance, more studfies are needed to evaluate the role of one 
substance class, such as pure fructans vs. mfixtures of substances, such as fructan, ATI, 








On the basfis of the results emergfing from thfis thesfis, the folowfing conclusfions can be 
drawn: 
 
1. Flatulence, rumblfing, fintestfinal cramps and abdomfinal pafin decreased along 
wfith colonfic fermentatfion durfing the consumptfion of low FODMAP rye bread 
compared to the consumptfion of regular rye bread. Nevertheless, no dfiference 
was found fin overal symptom control as measured by IBS-SSS. 
 
2. Sourdough bakfing method cleaves the ATIs present fin wheat flour more 
efectfively than yeast fermentatfion, and produces a bread contafinfing only 
monomerfic ATIs. However, cleavage of ATIs dfid not fimprove the 
gastrofintestfinal tolerance of sourdough wheat bread as compared to regular 
yeast-leavened wheat bread. 
 
3. No dfiference was found fin pH, transfit tfimes or fintracolonfic pressure between 
the low FODMAP and regular rye bread perfiods but the lack of dfiferences mfight 




4. The low FODMAP rye bread reduced the abundance of Klebsfiela fin fecal 
samples fin comparfison to regular rye bread but no other statfistficaly sfignfifficant 
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